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1. Human skin 
1.1 Structure of human skin 
Human skin is composed of two layers: the dermis and the epidermis (figure 1). The underlying 
dermis is populated with fibroblasts which produce collagens and elastins, and supports the 
outermost layer, the epidermis1;2. The epidermis mainly consists of keratinocytes and serves 
as an boundary between the external environment and the internal body. The epidermis 
is composed of four layers (Figure 1). In the innermost layer, the stratum basale (SB), the 
keratinocytes proliferate. Thereafter, the cells escape from this layer and start to migrate and 
differentiate through the stratum spinosum (SS) towards the stratum granulosum (SG)3;4. 
During this process, lamellar bodies are formed in the SS and more extensively in the SG. 
These vesicles contain various molecules involved in the formation of the outermost epidermal 
layer the stratum corneum (SC), including lipids and lipid precursors, various enzymes and 
antimicrobial peptides (AMPs). At the SG-SC interface, when the keratinocytes undergo 
terminal differentiation, the contents of the lamellar bodies is released during a process 
that is called lamellar body extrusion. During terminal differentiation the keratinocytes 
loose their nucleus and their cell membrane is replaced by a cornified envelope, after which 
they are referred to as corneocytes. The corneocytes are surrounded by a hydrophobic 
extracellular lipid matrix and together these form the SC. The structure of the SC is often 
compared to a “brick-and-mortar” structure, in which the corneocytes represent the bricks, 
and the surrounding lipid matrix the mortar5. This lipid matrix mainly consists of three 
lipid classes; ceramides (CERs), free fatty acids (FFAs) and cholesterol6-8. The corneocytes 
are interconnected through “linker”-proteins, the so-called corneodesmosomes. Kallikreins 
degrade these corneodesmosomes in the outer layers of the SC, which allows shedding of the 
outer SC, a process that is refered to as desquamation and is required for proper SC turnover9. 
Besides keratinocytes, the epidermis contains various other cell types including dendritic 
cells (langerhans cells) and melanocytes. 
1.2 The skin barrier and its components 
Human skin is continuously in contact with the external environment and encounters many 
potential pathogens such as bacteria, fungi, viruses and parasites as well as harmful and/or 
toxic substances. To protect against such external influences, the epidermis provides a barrier 
in three different ways. As a physical barrier the SC prevents the penetration of harmfull 
pathogens, allergens and toxic exogenous chemicals or substances into the viable epidermis. 
In addition, the SC prevents dehydration of the body by regulating the transepidermal water 
loss (TEWL). The lipid matrix in the SC is highly organized into lipid layers, which compose 
the lipid lamellea. These lamellae are regularly stacked on top of each other, parallel to the 
corneocytes (Figure 1b)10. In human SC, two coexisting lamellar phases have been identified 
with repeat distances of ~13 nm (for the long periodicity phase, LPP) and ~6 nm (the short 




certain density. The lateral packing in human SC is mainly orthorhomibic (very dense), 
although a subpopulation of lipids are organized into a hexagonal lateral packing (less 
dense, Figure 1b)11. Furthermore, the keratinocytes present in the upper layers of the SG are 
interconnected by tight junctions which provides an additional physical barrier12. 
The epidermis also acts as a chemical barrier, in which various AMPs defend against invading 
pathogens. AMPs exhibit broad-spectrum activity against bacteria, fungi and viruses. 
Synthesis of AMPs primarily occurs in the keratinocytes in the SG, after which there are 
packaged into lamellar bodies and transported to the SC where they are released into the 
intercellular regions13. Finally, there is the immunological barrier, in which the keratinocytes 
are part of the constitutively active innate immune response that provides an immediate but 
fairly nonspecific response, while skin-homing T cells that are part of the adaptive immunity 
provide a specific and long-lasting reponse14-16. The immune response will be discused in 

























Figure 1: schematic overview of human skin and the stratum corneum. (a) Human skin is composed 
of a dermal compartment that consists mainly of collagen fibers, elastins and fibroblasts. The epidermis 
is divided into four layers (strata): the stratum basale, stratum spinosum, stratum granulosum and the 
stratum corneum. The epidermis contains mainly keratinocytes, but also melanocytes and langerhans 
cells are present. (b) The outermost layer of the skin is the stratum corneum, which is composed of 
corneocytes that are surrounded by lipids. These lipids are mainly cholesterol, free fatty acids and 
ceramides. The lipids are organized into stacked lipid lamellea forming two lamellar phases with a repeat 
distance (z) of 13 nm (the LPP) or 6 nm (the SPP). In addition, within the lipid lamellae the lipids are 
organized with a certain densitiy which is referred to as the lateral packing. The lateral packing SC can 
be orthorhombic (very dense), hexagonal (dense) or liquid (loose). 
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2. Atopic dermatitis 
2.1 Clinical features of atopic dermatitis
Atopic dermatitis (AD), also frequently termed atopic eczema, is one of the most common 
inflammatory skin diseases. The first written description of AD dates back to the early 19th 
century17. In 1925 the term “atopy” was introduced by Coca, to signify the tendency to develop 
allergies to food and inhalant substances which subsequently manifested as eczema, asthma 
and hay fever on a hereditary basis. In 1933, Wise and Sulzberger provided the first detailed 
diagnosis of AD18. AD is clinically characterized by a broad spectrum of manifestations19. 
Clinical features that are regularly present are dryness of the skin (xerosis), itch (pruritis), 
redness of the skin (erythema) and chronic or relapsing eczematous lesions. Although AD 
can potentially affect any part of the body, it most commonly affects the flexures and the face 
(Figure 2). 
Over the past three decades, the lifetime prevalence of AD has increased 2-to-3 fold and is 
currently affecting 15-30% in children and 2-10% in adults20. Over 50% of the children with 
AD eventually progress into the development of hay fever (allergic rhinitis) and/or asthma; 
the so-called atopic march21. The physical discomfort from the highly pruritic lesions in 
children with moderate-to-severe AD results in sleep deprivation and subsequently cause 
reduced functioning of the patients and their close relatives, as well as distress, anxiety, 
embarrassment, poor self-esteem and lack of self-confidence22;23.  
Figure 2: an example of the clinical presentation of atopic dermatitis. In general, non-lesional AD skin 
appears normal, whereas lesional skin of AD patients appears as red (erythema) and is very dry (xerosis) 
as well as very itchy (pruritis).   
2.2 What is first, barrier dysfunction or inflammation?
The cause of AD is complex and it is the result of the interaction between susceptibility genes 




characteristics of AD; (1) impaired skin barrier function and (2) immunological abnormalities. 
Which one of these two characteristics is the initiating factor in AD development is still a topic 
of extensive research, but traditionally, two competing hypothesis are presented to explain the 
pathogenesis of AD: 
1) The inside-out hypothesis, which suggests that an intrinsic immunological defect 
predisposes individuals to atopy and that this IgE-mediated sensitization will result in 
AD17;25-28. 
2) The outside-in hypothesis, which suggests that disruption of the skin barrier, either 
resulting from a genetic defect in skin barrier formation or as a result of changes in the 
environment, would lead to sensitization and subsequently to AD29-32. 
Experimental data from literature provides support for both hypothesis. However, 
accumulating evidence shows that there is an interplay between the immune system and the 
skin barrier. Examples of such interactions will be discussed in 2.3.3. 
2.2.1. Epidermal barrier dysfunction in AD 
As one of the principle characteristics of AD, the epidermal barrier (dys-)function has 
been subject to extensive research. Both non-lesional and to a larger extent lesional skin of 
AD patients display several barrier abnormalities, including increased TEWL, reduced SC 
hydration and increased SC permeability for irritants such as SDS33-37. 
2.2.2. The SC lipids and their role in the skin barrier in AD
Based on the observations of delayed and possibly incomplete lamellar body extrusion in the 
skin from AD patients, it was hypothesized that lipid synthesis at the SG-SC interface in AD 
skin was impaired, which could explain the impaired skin barrier function in AD38;39. Since 
then, the SC lipid composition of AD skin has been subject to much additional research. Early 
studies revealed a reduction in total levels of the SC lipids as well as decreased CER levels 
in both non-lesional and lesional skin of AD patients40;41. More detailed analysis revealed 
that a specific CER subclass, CER [EOS], was drastically reduced in AD skin, whereas other 
subclasses, CER[NS], [AS] and [AP] showed a relative increase40;42. The CER nomenclature is 
explained in Figure 3.
Whereas most studies have been focussing on the CER subclass composition in AD skin, a 
recent study has characterized the complete CER profile of AD patients, including the 12 CER 
subclasses and their chain length distribution of each subclass43. Subsequent studies showed a 
relative increase in the levels of short chain CERs and a reduction in the levels of CERs with 
very long acyl chains, so-called acyl-CERs, in non-lesional and more extensively in lesional 
skin44. The changes in CER chain length were reflected in a reduced skin barrier function, 
which was determined through the assessment of the TEWL43. A following study revealed 
that parallel to the changes in CER composition, the FFA composition was also affected, i.e. 
reduced FFA chain length and increased levels of unsaturated FFAs44.
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Figure 3: Ceramide (CER) nomenclature. (a) CERs are composed of a polar head group and two long carbon 
chains: a fatty acid chain (acyl chain, marked in black) which is linked via an amide bond to a sphingoid base 
(marked in red). (b) So far, 12 unique CER subclasses have been indentified in human SC, which are composed of 
four different sphingoid bases and three different fatty acid chains. Of these 12 CERs, the CERs in which the very 
long-chain fatty acid component has a terminal hydroxyl group are termed acyl-CERs. 
Although the enzymatic pathways involved in SC lipid synthesis are still not fully elucidated, 
several enzymes are promising candidates for the changes in SC lipid composition in AD. 
Two enzymes that are involved in CER processing, β-glucocerebrosidase (Gcase) and acid 
sphingomyelinase (aSmase), are reported to be affected in AD45;46. Both these enzymes convert 
precursor-CERs into CERs, and alterations in their expression and/or activity may result in 
changes in SC CER composition and in the total level of CER in the SC. In addition, since 
the levels of acyl-CERs was reduced, ceramide synthase 3 (CerS3), which is involved in the 
synthesis of acyl-CERs, might also be a potential candidate. The discovery of shorter FFA chain 
lengths and increased levels of unsaturated FFAs indicate that other candidate enzymes might 
also play a role. Especially those enzymes that are involved in the elongation and desaturation 
of FFAs, e.g. the elongases (ELOVLs) and Stearyl-CoA desaturase (SCD), respectively, 
might be altered in AD. Using mouse models, two ELOVLs (ELOVL1 and ELOVL4) that 
are involved in the elongation of the very long FFAs, were shown to be important for proper 
barrier formation47;48. Furthermore, in vitro studies have shown that the increased levels 
of unsaturated FFAs in human skin equivalents was accompanied by increased epidermal 
expression of SCD and that increasing levels of unsaturated FFAs negatively affect the SC 




2.2.3. Filaggrin and its role in skin barrier function and AD 
Besides SC lipids, structural proteins such as tight junction proteins, are important contributors 
to the skin barrier and skin barrier function51. Various skin barrier-related proteins are being 
investigated for their role in AD or their contribution to AD. However, the strong association 
between loss-of-function mutations in filaggrin (FLG) and AD is one of the most robust and 
reproducible association that is observed in complex human disorders. Since this discovery, 
FLG has been subject to extensive research52-54. The FLG protein was already discovered in 
1977 as a highly insoluble, histidine-rich protein that was present in epidermal extracts. 
This protein has later been shown to condense and align keratin intermediate filaments in 
vitro, and was therefore named filaggrin (for filament aggregating protein)55;56. Due to the 
repetitive nature of the FLG gene, advanced sequencing technology and some innovative 
polymerase chain reaction (PCR) protocols were necessary for comprehensive analysis of 
the FLG gene prior to the discovery of the first pathogenic FLG mutations. Initially, FLG 
mutations were discovered to be the underlying cause for ichthyosis vulgaris (IV), a skin 
disease that is characterized by a dry and scaly skin and that is often associated with AD 57. 
Within several months after this discovery, two FLG mutations (R501X and 2282del4) were 
found to be a major predisposing factor for development of AD52. Since this breakthrough, 
over 45 FLG mutations have been identified in AD patients, which were shown to have a 
specific distribution between European and Asian populations52;58-67.
The FLG  gene is located on chromosome 1q21 in the so-called epidermal differentiation 
complex (EDC), which is a large chromosomal region that contains over 70 genes encoding 
proteins that are involved in terminal differentiation of keratinocytes. Besides the genes for 
FLG, this region also include genes encoding loricrin, involucrin, late cornified envelop (LCE) 
proteins and many others. The FLG gene encodes a precursor protein, profilaggrin, which 
during keratinocyte differentiation is cleaved into 10-12 nearly identical FLG monomers 
by multiple proteases including caspase 1457;68. In the corneocytes, FLG is finally degraded 
into free amino acids and their derivatives, which are part of the natural moisturizing factor 
(NMF), a process that involves caspase 14 as well as other enzymes69. The FLG degradation 
products include histidine and glutamine, which are further degraded into pyrrolidone 
carboxylic acid (PCA) and urocanic acid (UCA)70. PCA and UCA have been shown to have 
several functions, including water retention, protection against ultraviolet (UV) radiation and 






















Figure 4: overview of filaggrin processing and (hypothetical) function in skin barrier Profilaggrin is 
expressed in the terminally differentiating keratinocytes in the stratum granulosum and is the major 
constituent of the keratohyalin granules. In general, profilaggrin is composed of: a calcium (Ca2+) 
binding N-terminal domain that contains an A and B domain, 10-12 FLG repeats and a unique 
C-terminal domain. Terminal differentiation depends on an increase in the calcium (Ca2+) concentration. 
An increase in Ca2+ results in dephosphorylation of profilaggrin allowing multiple proteases, to cleave 
the FLG monomers. The FLG monomers bind to keratins which assists in the formation of the cornified 
envelope, thereby providing structure rigidity. Subsequently, various enzymes including caspase 14 
degrade FLG into UCA, PCA and free amino acids, which are part of the natural moisturizing factor 
(NMF). The NMF functions in water retention, protection against ultraviolet (UV) radiation, and 
modulation of the immune function. Figure based on McAleer and Irvine73. 
Although it is widely accepted that FLG mutations lead to a barrier defect, the underlying 
mechanisms of how FLG as an intracellular protein affects the paracellular barrier are still 
to be elucidated74. Based on the various functions of (pro)-FLG and the FLG breakdown 
products, FLG loss-of-function mutations might cause skin barrier defects through various 
mechanisms: 
1. FLG is part of the cornified envelope and aggregates keratins, thereby contributing to 
the structure and function of the SC. Absence or reduced FLG might therefore lead to a 
defective SC. 
2. FLG breakdown products PCA and UCA are part of the NMF, which regulates skin 
hydration. Various studies have shown that FLG mutations are major determinants of 
the reduced NMF levels and the level of these breakdown products have been shown to 
be influenced by FLG genotype, as well as by AD severity and might contribute to the 
dryness of the skin in AD75-78. 
3. PCA and UCA regulate the SC pH, which is important for the regulation of the activity of 
various enzymes that are involved in SC barrier homeostasis, including serine proteases 
and enzymes involved in lipid synthesis79. In normal skin, the pH is 5.5 which is required 
for the optimal activity for such enzymes. An increase in pH might affect enzyme activity 
and could therefore result in a defective barrier. However, protein analysis for several 
enzymes involved in FFA and CER synthesis revealed that such enzymes are mainly 
expressed in the SG of the epidermis, making it unlikely that changes in SC pH affect the 




The presence of FLG mutations are undeniably the foremost genetic risk factor for AD 
development. However, up to 50% of the AD patients do not have a FLG mutation or are 
heterozygous52;67;81. In addition, there is currently no convincing data that shows a clear 
relationship between FLG mutations and reduced skin barrier function in AD82-85. A recent 
study with IV patients that were homozygous or compound heterozygous for FLG mutations 
displayed only moderate changes in epidermal permeability function86, demonstrating that 
the high TEWL values observed in AD patients cannot be ascribed to FLG mutations only87.   
2.2.4. External factors that influence skin barrier and AD 
Besides intrinsic factors, such as FLG mutations, which might disturb the skin barrier 
homeostasis in AD, external influences like scratching in response to the itch that is present 
in the skin of AD patients cause skin barrier disruption and therefore plays an important role. 
The itching and the rash in AD can be triggered by various environmental factors. These 
factors include allergens (e.g. house dust mite (HDM), pollen and animal dander), irritants 
(e.g. use of soaps, crèmes, cosmetics or wool), climate (a dry environment or dry cold air 
results in dry skin and thereby cause itch) and bacterial toxins26;88;89. In particular toxins 
secreted by Staphylococcus aureus, an opportunistic pathogen, that frequently colonizes skin 
from AD patients have been shown to influence disease severity90;91. While S. aureus skin 
colonization is found in only 5% of healthy individuals, 76% to 100% of the AD patients show 
S. aureus colonization on non-lesional and lesional skin, respectively92-94. Furthermore, recent 
studies have shown that in lesional AD skin, S. aureus forms biofilms, rendering these bacteria 
less susceptible for treatment and allows worsening of the AD skin lesions95. In addition, S. 
aureus itself can be an important trigger for AD, since S. aureus antigens and superantigens 
were shown to evoke a T cell mediated immune response26. 
2.3 The immune response and immune dysregulation in AD
The immune system can be divided into the innate immune response and the adaptive 
immune response. While the innate immune response with the keratinocytes, langerhans 
cells and various leukocytes such as natural killer (NK) cells, is nonspecific and short-term, 
it provides a quick defence against a broad range of pathogens. Conversely, the adaptive 
immune response with T cells and B cells is highly specific and long-lasting, but rather slow. 
AD is characterized by abnormalities in both the innate and the adaptive immune response.
2.3.1 Innate immunnity abnomalities in AD
As part of the innate immune response, keratinocytes play an important role. They express 
various receptors that are important for detection of pathogens, e.g. Toll-like receptors (TLRs). 
In addition, in response to pathogenic stimuli, keratinocytes produce chemokines and pro-
inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin (IL-)1 and in 
particular thymic stromal lymphopoietin (TSLP). The latter cytokine was shown to be a key 
cytokine for the initiation of AD96-98. TSLP promotes a Th2 response, either directly through 
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the induction of Th2 cytokine-expressing cells or indirectly through polarization of dendritic 
cells99;100. Furthermore, keratinocytes produce anti-microbial molecules including RNases 
and AMPs. These AMPs are chemicals present in the epidermis and have antimicrobial 
activity against various pathogens, such as bacteria, viruses and fungi. These AMPs include 
LL-37 and β-defensins (human β-defensins, hBDs)101. In healthy skin, small amounts of hBD-
2 and hBD-3 are present, but their expression is elevated in lesional AD skin102;103. However, 
compared to psoriasis, another immune-mediated skin disorder in which the expression of 
hBD-2 and hBD-3 is drastically increased, both non-lesional and lesional AD skin showed 
decreased expression of both AMPs104;105. 
2.3.2 Adaptive immunity abnomalities in AD 
Lesional AD skin shows the presence of skin infiltrating T-cells, which are predominantly 
Th2 cells in the acute phase and Th1 cells in the chronic phase. During the acute phase, Th2 
cells produce a large array of cytokines such as IL-4, IL-5, IL-10, IL-13 and IL-31 which are 
important for the cutaneous immune response98. Because of their functional overlap, most 
in vitro studies evaluate the effects of both IL-4 and IL-13.  IL-4 is a key Th2 cytokine and 
is found to be critical for the differentiation of naïve T cells into Th2 cells as well as for IgE 
production, eosinophil recruitment and other functions. IL-13 is mainly secreted by Th2 cells 
and is a central mediator of allergic inflammation. Expression of IL-13 is found in both acute 
and chronic lesions of AD106.  Expression of IL-4 and IL-13 in the epidermis of mice was 
shown to induce dermatitis, indicating their important role in AD107;108. 
IL-31 is a more recently identified cytokine which is primarily produced by Th2 cells109. The 
expression levels of IL-31 have been reported to be higher in lesional AD skin compared to 
non-lesional skin and correlate with the IL-4 and IL-13 levels in the skin of AD patients110. 
Much functional evidence comes from IL-31 transgenic mice, which developed spontaneous 
pruritus and skin lesions, both hallmarks of AD. In addition, in a mouse model that 
spontaneously develops AD, IL-31 levels correlated with scratching behaviour, indicating that 
IL-31 is particularly important for the induction of the itching in the skin111. Mouse models 
and their usage for studying AD pathogenesis will be discussed in 3.1.
2.3.3. So? Which one is first, barrier dysfunction or inflammation?
Although the skin barrier with proteins and SC lipids on one hand, and the immune response 
with T cells and cytokines on the other hand, appear to be two separate defence mechanisms, 
recent studies suggest that there is an interplay between the two. The AD related cytokines 
have been found to affect the skin barrier on various levels. 
The observation that AD patients without FLG mutations showed reduced FLG expression, 
implied a role for other factors. In vitro and in vivo experiments have shown that IL-4 and 




of FLG as well as that of loricrin and involucrin in keratinocytes indicating that these 
cytokines have a broad effect on keratinocyte differentiation112;113. Besides IL-4 and IL-13, 
also IL-31 downregulates FLG expression114. In addition to their effects on keratinocyte 
differentiation, IL-4 and IL-13 were demonstrated to downregulate the expression of caspase 
14, an important enzyme for the degradation of FLG into NMF and thereby plays a role in 
regulation of the skin hydration115. Furthermore, AD related cytokines have been shown to 
affect epidermal adhesion molecules and tight junctions in keratinocytes116-118. Besides their 
effects on the epidermal keratinocytes, Th2 cytokines have also been found to affect the SC 
lipid composition, i.e. IL-4 downregulated Gcase and aSmase expression that consequently 
resulted in reduced SC CER levels in vitro119. These findings add another dimension to the 
discussion which entity is the initiating factor for the AD phenotype.
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3. Models to study AD pathogenesis 
3.1 In vivo models to study AD pathogenesis
Much of our understanding about AD pathogenesis is based on studies using mouse models. 
Since the description of the NC/Nga mouse in 1997 as the first mouse model for AD, a 
growing number of mouse models has been developed120. These can be categorized into 
three groups: (1) mice that spontaneously develop skin lesions that closely resemble AD, (2) 
genetically engineered mice (transgenic mice), and (3) mice in which AD features are induced 
by allergens, haptens or epicutaneous application of sensitizers121;122. 
Examples of mice that develop spontaneous skin lesions include the NC/Nga mouse and the 
flaky tail (ft) mouse120;123. The ft mice have been widely used as a model of heritable skin 
barrier deficiencies and spontaneous dermatitis as well as a model for FLG deficiency that 
was associated with AD pathogenesis in patients124-128. Ft mice have a frameshift mutation in 
the mouse filaggrin (Flg) gene which results in absence of the FLG protein. This mouse model 
has therefore frequently been used as a model to study the role of FLG in skin homeostasis. 
However, recent studies have shown that an additional mutation in Matt (Tmem79) was the 
cause of the barrier defects in these mice rather than the Flg mutation123;129-131. Transgenic 
mouse models for AD are generally mice lacking or overexpressing proteins, in particular 
cytokines involved in AD pathogenesis, e.g. mice with skin-specific overexpression of IL-
4, IL-13 or TSLP, as well as the previously mentioned mice that overexpress IL-31107-109;132. 
AD features in mice can also be induced through skin injury, e.g. repeated tape stripping 
or scratching induced by epicutaneous sensitization, or through multiple challenges with 
so-called haptens, e.g. oxazolone (OXZ) and trinitrochlorobenzene (TNCB). Application of 
such haptens has been shown to result in a Th2-dominated inflammatory response similar to 
human AD133;134. 
All these mouse models display different characteristics of AD, comparable to those seen in 
AD patients and collectively, they have significantly contributed to our understanding of the 
pathogenesis of this complex skin disease. 
3.2 In vitro human skin equivalents 
As illustrated above, mouse models are excellent tools for studying the role of particular genes 
or proteins, such as cytokines, through the generation of transgenic mice or for studying 
the influences of environmental factors on AD pathogenesis in vivo. However, their usage 
for studies that focus on the skin barrier and other epidermal features is limited for several 
reasons, including differences in skin morphology and in barrier function. Mouse skin contains 
many hair follicles, is usually thin (3 viable cell layers, versus 6-10 viable cell layers in human 
skin) provides less of a water barrier and displays higher percutaneous absorption, which 




inflammatory studies using mouse models do not always correlate with human responses136;137. 
Furthermore, both social pressure from animal welfare groups and the public opinion, as well 
as political pressure from the European Union. Since 2009, the European Union wants to ban 
animal testing for cosmetic and chemical means, requires development for alternatives for the 
screening of newly compounds, e.g. for the treatment of AD. 
As an alternative, in vitro human skin equivalents (HSEs) can be used for studying various 
aspects of skin biology. In vitro three-dimensional HSEs recapitulate many features of 
native human skin, such as similarities in morphology, expression of differentiation and 
proliferation markers and various SC barrier properties. The SC from HSEs established with 
primary keratinocytes contain all CER subclasses. Despite the presence of a competent skin 
barrier in terms of the presence of the LPP, SC permeability studies have shown that HSEs 
have a decreased barrier function compared to native skin, as well as a less ordered lateral 
lipid organization when compared to native SC50;138. HSEs are generally established by using 
primary keratinocytes. Seeding of primary keratinocytes onto a fibroblast populated dermal 
substrate, i.e. rat tail collagen or de-epidermized dermis results in a full thickness HSE (FT-
HSE) whereas seeding onto an artificial matrix, i.e. an inert filter, results in an epidermal 
skin equivalent (Figure 5)139-141. These keratinocytes are usually obtained from surplus skin, 
most commonly juvenile foreskin or after mammary or abdominal surgery. In addition to in-
house HSEs, various HSEs that are established with primary keratinocytes are commercially 
available. These have been characterized for their permeability and absorption properties and 
have been shown to be applicable for in vitro permeation studies and toxicity screenings, 
e.g. Episkin (SkinEthic) or Epiderm (MatTek)142-144. Although usage of primary keratinocytes 
results in HSEs that mimic native skin to a large extent, they have several drawbacks, including 
a limited in vitro lifespan, a large donor-to-donor variation and limited availability. 
3.2.1 Cell lines as an alternative to primary keratinocytes to establish human skin 
equivalents
In order to overcome the limitations of primary keratinocytes, immortalized keratinocyte cell 
lines can be used. Such cell lines provide an unlimited source of cells that allow the generation 
of reproducible and consistent HSEs, reducing intra- and inter-laboratory variations. One of 
the most frequently used keratinocyte cell line is the spontaneously immortalized HaCaT, 
which has been shown to remain non-tumorigenic during long- term culture145;146. When 
used for generating HSEs using various dermal substrates, HaCaT cells displayed a disordered 
tissue structure with abnormally shaped nuclei and a limited ability for the generation of an 
organized mature cornified epithelium with a proper SC barrier function147. Advancements 
in culture methods have resulted in HSEs with HaCaT cells that display an fairly organized 
epidermis when cultured on a human fibroblast populated dermal substitute148-150. Despite 
the inability to form a proper and functional SC, reconstructed epidermis with HaCaT cells 
is often considered functional and frequently used as a model for unravelling molecular 
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mechanisms regulating keratinocyte growth and differentiation148-150. Nevertheless, when 
topical application, investigation of underlying biological mechanisms or mimicking skin 
diseases such as AD are the main focus, the inability to generate a proper SC must be 
considered.
More recently, another keratinocyte cell line has been described, the Near-Diploid Immortal 
KeratinocyteS, NIKS®. These NIKS® are spontaneously immortalized keratinocytes which 
were accidently found to proliferate beyond the lifespan of normal primary keratinocytes151. 
These cells have been successfully used for the generation of HSEs, StrataTest®, which are now 
commercially available for toxicity screening152. In addition to spontaneous immortalization, 
keratinocyte cell lines can be obtained by genetic engineering of keratinocytes to bypass 
certain cell cycle checkpoints, thereby preventing growth arrest and cell death. In absence 
of non-pathogenic telomere shortening or DNA damage, bypassing of cell cycle checkpoints 
Native human skin 
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Figure 5: Schematic overview of establishing in vitro human skin equivalents (HSEs) HSEs can be 
established with primary keratinocytes and fibroblasts which are isolated from native human skin, or 
with keratinocytes and fibroblasts obtained from immortalized cell lines. Depending on the aim of the 
study, different HSEs can be generated. Full thickness HSEs can be established by seeding keratinocytes 
(primary or immortalized) onto a fibroblast-populated dermal collagen matrix. By placing a skin biopsy 
onto the dermal matrix an explant HSE can be generated. To establish epidermal skin equivalents, 
keratinocytes can be seeded onto an inert acellular filter. Air exposed culturing of the HSEs allow the 




results in the generation of a non-oncogenic cell line. For example overexpression of a protein 
cyclin-dependent kinase 4 (Cdk4) results in a bypass of telomere dependent replicative 
senescence without losing the ability to differentiate normally153.  
3.3 Modulation of skin models to mimic AD in vitro
Currently, no cure for AD is available. In many cases, the disease manifestations cease or 
improve remarkably by the age of five. However, persisting AD is often found to precede the 
atopic march, a concept to describe the progression of AD into allergic rhi nitis and asthma. 
Treatment of AD is currently focused on suppression of the immune response, restoring 
skin barrier function through (re-)hydration of the skin, suppression of the itch, in order 
to reduce scratching and mechanical injury, and anti-microbial treatment to reduce/prevent 
bacterial, viral and fungal infections. Other measures include avoidance of triggers and usage 
of appropriate anti-infective agents and anti-histamines. Due to their limited efficacy and 
their adverse effects, there is much room for improvement in AD therapy. 
Because of the aforementioned arguments, in particular the difficulties in the translation 
of results obtained with mouse models towards humans, newly developed in vitro three 
dimensional HSEs that mimic AD as closely as possible can be useful for biological and 
pharmacological intervention studies for AD135. To mimic the filaggrin mutations as seen 
in AD patients, RNA interference (RNAi) using small interfering RNA (siRNA) or short 
hairpin RNA (shRNA) can be delivered to keratinocytes in order to reduce filaggrin mRNA 
and protein expression (so-called knockdown). Initial studies have used lipofectamine-based 
transfection in primary keratinocytes with synthetic siRNA to knockdown filaggrin (FLG-
KD) in HSEs. However, studies using these FLG-KD have generated controversial results. One 
study showed a defective barrier function as illustrated by an increased epidermal uptake for 
a fluorescent dye, whereas another showed that there were no changes in the surface pH154;155. 
Cytokine supplementation to the medium of HSEs to mimic the inflammation as seen in 
lesional AD skin, resulted in various morphological and molecular characteristics of AD156.
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Aim and outline of this thesis
The aim of the research described in this thesis was to develop a new in vitro human skin 
equivalent (HSE) for human atopic dermatitis (AD), with the focus on the role of filaggrin. 
The ultimate goal was to establish reproducible HSEs to eventually could be used for screening 
and testing purposes of new therapeutic compounds, which are desired due to the rapid 
increase in prevelance of AD. 
In an attempt to establish reproducible HSEs, we have established and characterized a 
novel full thickness HSE using the N/TERT cell line, so-called N/TERT based human skin 
equivalents (N-HSEs). Of these N-HSEs, the SC lipid properties have been characterized in 
detail, which are described in chapter 2. Using the N/TERT cell line and RNAi technology, 
a secondary cell line was generated in which filaggrin knockdown (FLG-KD) was present. 
These cells were subsequently used for the generation of full thickness HSEs, so-called FLG-
KD HSEs. To unravel the role of FLG in SC barrier properties as seen in AD, these FLG-KD 
HSEs were characterized for their epidermal differentiation and SC barrier lipid properties, 
which are described in chapter 3. 
Because of the limited material that is generally available from diseased skin, an explant 
HSE was used to expand small amounts of starting material, by passaging small fragments 
of the outgrowth area. Chapter 4 describes this method using healthy skin, as well as the 
consequences of subsequent passaging outgrowth on epidermal morphogenesis, SC lipid 
organization and lipid composition. This approach was also used in chapter 5, in which 
primary material from AD patients with or without FLG mutations was used. The possibility 
of this method and the possible role of FLG in epidermal morphogenesis are described in this 
chapter as well. 
In chapter 6, a FLG deficient N/TERT based epidermal skin model (NEM) was used, by 
means of FLG-KD or through IL-31 supplementation, to evaluate the role of FLG in epidermal 
S. aureus colonization. In addition, the subsequent epidermal response was studied as well. 
To evaluate whether we can establish a HSE that mimic features of lesional AD skin, a full 
thickness HSE with primary keratinocytes was established in the presence of a mixture of 
AD related cytokines, which was compared to lesional AD skin. The results of this study are 
described in chapter 7. 
A summary, discussion and the future perspectives of the results described in this thesis is 
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Human skin equivalents (HSEs) can be a valuable tool to study aspects of human skin, 
including the skin barrier, or to perform chemical or toxicological screenings. HSEs are 
three-dimensional skin models that are usually established using primary keratinocytes and 
closely mimic human skin. The use of primary keratinocytes has several drawbacks, including 
a limited in vitro life span and large donor-donor variation. This makes them less favorable for 
in vitro toxicity screenings. Usage of an established keratinocyte cell line circumvents these 
drawbacks and allows the generation of easy-to-generate and reproducible HSEs, which can 
be used for pharmacological and/or toxicological screenings. For such screenings, a proper 
barrier function is required. In this study we investigated the barrier properties of HSEs 
established with the keratinocyte cell line N/TERT (N-HSEs).
N-HSEs showed comparable tissue morphology and expression of several epidermal proteins 
compared to HSEs established with primary keratinocytes. Our results clearly demonstrate 
that N-HSEs contain several stratum corneum barrier properties similar to HSEs, including 
the presence of the long periodicity phase and a comparable SC permeability, but show also 
some differences in lipid composition. Nonetheless, the similarities in barrier properties 
makes N/TERT cells a promising alternative for primary keratinocytes to generate HSEs. 
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Introduction 
The main function of human skin is to act as a barrier, thereby preventing excessive water loss 
and protecting against harmful substances and pathogens. The stratum corneum (SC) is the 
outermost epidermal layer and is the principle site of the skin barrier. The SC is composed 
of corneocytes embedded in a hydrophobic lipid matrix, mainly composed of ceramides 
(CERs), free fatty acids (FFAs) and cholesterol (CHOL). These lipids are organized in stacked 
lipid layers, referred to as a lamellar phase, oriented parallel to the skin surface1-3. SC from 
native human skin contains two lamellar phases, the long periodicity phase (LPP) and the 
short periodicity phase (SPP) with a repeat distance of ~13 nm and ~6 nm, respectively4.4 
Within these lipid lamellae, the lipids are organized in either an orthorhombic (very dense), 
hexagonal (dense) or liquid (loose) packing (Figure S1)5;6. 
To study aspects of skin biology and skin barrier, various model systems, in particular animal 
models, are currently used. However, animal skin displays different epidermal morphology 
compared to human skin, e.g. mouse skin has generally 2-3 viable cell layers, while human skin 
has 7-8 cell layers. In addition, mouse skin displays higher percutaneous absorption compared 
to human skin, thereby limiting its use for topical drug-delivery studies7. Therefore, data 
obtained from animal studies are difficult to extrapolate to in vivo human skin. Furthermore, 
there is an increasing social and political pressure to reduce animal usage and to implement 
alternatives8-11. An attractive alternative is the use of in vitro human skin equivalents (HSEs). 
These HSEs are three-dimensional culture models, which are usually established by seeding 
primary keratinocytes onto a dermal substrate and cultured at the air-liquid interface. These 
HSEs have been shown to have fairly similar morphology, expression of differentiation 
markers and lipid properties compared to native human skin12-15. 
However, usage of primary keratinocytes has several disadvantages, e.g. limited availability 
of fresh skin, limited in vitro lifespan and in particular the large donor-donor variation16. 
By using an established immortalized keratinocyte cell line that can be kept in culture for 
prolonged time, such limitations can be circumvented. This allows the possibility to generate 
a robust and reproducible HSE which is desirable for pharmacological and/or toxicological 
screening purposes. The presence of a competent skin barrier is a prerequisite for HSEs when 
used for topical application studies (e.g. toxicological screening). 
In this study we demonstrate that N/TERT based HSEs (N-HSEs) show normal epidermal 
morphogenesis and the formation of a SC that displays a lamellar and lateral lipid organization 
and permeability comparable to that of HSEs. However, N-HSEs displayed some differences 
in the lipid composition. Our results demonstrate that N/TERT cells can be used in addition 
to primary keratinocytes to generate HSEs, and that these N-HSEs might therefore be a 





Primary human keratinocytes and dermal fibroblasts were obtained from surplus skin from 
adult donors undergoing mammary or abdominal surgery and were established and cultured 
as described earlier17. Skin was handled according to the declaration of Helsinki principles and 
collected after informed written consent. Primary keratinocytes were stored in liquid nitrogen 
until usage for generation of HSEs. For all experiments, primary keratinocytes (passage 1 or 
2) and fibroblasts (passage 2 till 5) from different donors were used for generation of HSEs.
The N/TERT keratinocyte cell line was purchased from Harvard Medical School (USA) and 
cultured under low confluency (<40%) in keratinocyte serum free medium (KSFM medium, 
Invitrogen). The N/TERT cell line was originally generated by overexpression of telomerase in 
primary keratinocytes that lacked expression of cell cycle regulatory protein p16ink4a 18.   
Dermal Equivalents
Dermal equivalents were generated as described earlier19. In short, 1 ml of cell-free collagen 
(1 mg/ml) solution was pipetted into a 6 well-filter insert (Corning Life Sciences). After 
polymerization, 3 ml of fibroblast populated (0.4x105 fibroblasts/ml) collagen (2 mg/ml) 
solution was pipetted onto the previous collagen layer. After polymerization the dermal 
equivalents were submerged in medium consisting of DMEM, 5% FCS and 1% penicillin/
streptomycin. Medium was refreshed twice a week. The dermal equivalents were cultured 
under submerged conditions for 3-4 days prior to seeding of keratinocytes.
Generation of HSEs
HSEs and N-HSEs were generated by seeding 0.5x106 primary keratinocytes (mixture of 2 
donors in a 1:1 ratio) or N/TERT cells onto the dermal equivalent, respectively, as described 
elsewere19;20.  Details are given in Supplementary Material and methods.
Morphological and immunohistochemical analysis
HSEs were fixed in 4% formaldehyde and embedded in paraffin. Morphological analysis was 
performed on 5 µm sections through haematoxylin and eosin staining. Immunohistochemical 
analysis was performed using the streptavidin-biotin-peroxidase system (GE Healthcare, 
Buckinghamshire, UK), according manufacturer’s instructions. Staining’s were visualized 
with 3-amino-9-ethylcarbazole (AEC), counterstained with haematoxylin and sealed with 
Kaiser’s glycerin. Primary and secondary antibodies are given in Table 1 of Supplementary 
Material and methods. For the collagen IV staining, a protease treatment using a 0.025% 
protease solution (Sigma, Zwijndrecht, the Netherlands) was done prior to incubation with 
the primary antibody. 
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Estimation of proliferation index
To estimate the proliferation index, the number of Ki67 positive nuclei in a total number of 
100 basal cells (x100%) was determined on 3 locations per slide for four different experiments. 
An independent researcher performed counting of the Ki67 positive cells. 
Determination of the number of SC layers
To determine the number of SC layers, 5 μm sections from snap frozen HSEs were cut and 
stained with a 1% (w/v) safranin (Sigma, Zwijndrecht, The Netherlands) solution for 1 min. 
To allow corneocyte swelling, sections were incubated for 20 min with a 2% (w/v) KOH 
solution. Images of the sections were taken and the number of layers was counted in at least 
6 locations covering the full length of the N-HSEs or HSEs. This was performed for four 
independent experiments.
SC isolation 
The SC from both HSE types was isolated as described earlier21;22. Briefly, (N-) HSEs were 
incubated overnight on filter paper with 0.1% trypsin in 4 °C. Following a 30 min incubation 
at 37 °C, the SC was mechanically separated from the N-HSEs and HSEs and subsequently 
washed with 1 µg/ml trypsin inhibitor (Sigma, Zwijndrecht, The Netherlands) and 
demineralized water. SC samples were air dried at room temperature and stored under Argon 
gas over silica gel in the dark.  
Fourier transformed infrared spectroscopy and small angle X-ray diffraction 
Fourier transform infrared spectroscopy (FTIR) and small angle X-ray diffraction (SAXD) 
were performed as described earlier22. In short, SC samples were hydrated at room temperature 
for 24 hrs in a 27% (w/v) NaBr solution prior to FTIR and SAXD measurements.  
FTIR spectra were obtained using a Varian 670-IR FTIR spectrometer (Agilent technologies, 
Santa Clara, CA), equipped with a broad-band mercury cadmium telluride (MCT) detector 
which was cooled with liquid nitrogen. 
SAXD measurements were performed at the European Synchrotron Radiation Facility (ESRF, 
Grenoble) at station BM26B. All FTIR and SAXD measurements were performed with three 
SC samples of both HSE types. Details concerning FTIR and SAXD measurements are given 
in Supplementary Material and methods.
HPTLC lipid analysis
The SC lipids were extracted according to a modified Bligh and Dyer procedure as described 
elsewhere23. Details are given in Supplementary Material and methods. Extracted SC lipids 
were quantified using HPTLC. The used solvent system to separate the lipids is described 
elsewhere.22 For quantification, co-chromotography of serial dilutions of each of the standards 
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was done as described before23. The standards consisted of cholesterol, palmitic acid, stearic 
acid, arachidic acid, tricosanoic acid, behenic acid, lignoceric acid, cerotic acid, and CER 
EOS, NS, NP, EOP, AS and AP. CER nomenclature according to terminology of Motta et al. 
and Masukawa et al24;25. Details about CER nomenclature and quantification are provided as 
Supplementary Material and methods. Quantification was performed using of lipid extracts 
from 2 different experiments.
Liquid chromatography mass spectrometry (LC-MS) for FFA lipid analysis
The CERs in the pooled lipid extracts of the HSEs and N-HSEs were analyzed using an Alliance 
2695 HPLC (Waters, Milford, MA) coupled to a TSQ Quantum MS (Thermo Finnigan, San 
Jose, CA) measuring in APCI mode as described elsewere26. The separation of free fatty acids 
was achieved using a LiChroCART Purospher STAR analytical column (55x2 µm i.d. Merck, 
Darmstadt, Germany) under a 0.6 ml/min flow rate with a gradient system from acetonitrile/
H2O to methanol/heptane. The ionization mode and scan range was altered to negative mode 
and 200-600 a.m.u., respectively. The total lipid concentration of all samples was around 1 mg/
ml and for the analysis of free fatty acids the injection volume was set to 10 µl. Quantification 
of FFAs was performed using lipid extracts of SC from two experiments for both HSE types. 
Permeability studies
In vitro permeation studies were performed with butyl para-aminobenzoic acid (butyl-PABA) 
using Permegear in-line diffusion cells (Bethlehem, PA, USA) with a diffusion area of 0.28 
cm2 as described earlier, with small adjustments21. The donor compartment was filled with 
1.5 ml butyl-PABA solution (50 µg/ml butyl-PABA) in acetate buffer (pH 5.0). The acceptor 
compartment consisted of PBS (pH 7.4), which was perfused at a flow rate of 1.5 ml/hr. 
Permeability studies were performed with at least 6 SC sheets of HSE and N-HSE type.
Statistical analysis
Statistical significance was determined using the two-tailed Student’s t-test. The permeability 
studies were analysed using one-way ANOVA. 
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Results
N/TERT based HSEs (N-HSEs) and primary keratinocyte HSEs show similar epidermal 
morphogenesis 
To evaluate whether N/TERT cells can be used for the generation of HSEs and whether 
they display similar epidermal morphogenesis compared to HSEs generated with primary 
keratinocytes, we have examined the morphology, expression of differentiation proteins and 
the proliferation in (N-)HSEs that have been cultured for 14 days at the air-liquid interface. 
As shown in Figure 1, N-HSEs display all the epidermal strata, including the SC. A normal 
basement membrane was formed as shown by the expression of collagen type IV at the 
dermal-epidermal junction (Figure 1a). Immunohistochemical analyses for keratin 10 (K10), 
filaggrin and loricrin showed that N-HSEs display expression of these proteins, comparable 
to that of HSEs (Fig. 1A). N-HSEs also expressed the desquamation related proteins kallikrein 
5 (KLK5) and lympho-epithelial Kazal type related inhibitor (Lekti) comparable to HSEs 
generated with primary keratinocytes (Figure 1a). In N-HSEs, generally 4-5 viable epidermal 
cell layers were observed compared to 7-8 cell layers observed in HSEs. The proliferation 
index of N-HSEs was not significantly different compared to HSEs (Figure 1b). Finally, we 
determined the thickness of the SC by using a saffranin red staining. No significant differences 
in the number of SC layers between the N-HSEs and HSEs were found (Figure 1c).  
SC lipid composition of N-HSEs display similarities to HSEs 
After evaluation of the epidermal morphogenesis of N-HSEs, we continued with the evaluation 
of the SC barrier properties. Since the extracellular lipid matrix is regarded to be the main 
route for penetration, we mainly focused on lipid composition, lipid organization and SC 
permeability. 
HPTLC can be used to detect 9 CER subclasses. This method revealed that N-HSEs displayed 
the presence of all 9 CERs, CHOL and FFAs, comparable to HSEs with (Figure 2a). Prior to 
and after lipid extraction, dry SC was weighted from which the percentage of lipids present in 
dry SC was calculated. As shown in figure 2B, the level of lipids in SC from N-HSEs and HSEs 
was comparable (Figure 2b). Quantification revealed that the relative amounts for CERs, 
CHOL and FFA were similar between N-HSEs and HSEs (Figure 2b). The levels of most CER 
subclasses in HSE and N-HSE were similar, however, some differences were also noticed. 
CERs AS/NH was more pronounced in the N-HSEs than in HSEs, while presence of CER AP 
was reduced in N-HSEs compared to HSEs (Figure 2d). Furthermore, the ratio between all 
ω-hydroxy CERs (EO CERs) and the other ceramide subclasses (non EO CERs) was lower 
in the N-HSEs (Figure 2e). Using LC/MS, we observed the presence of all 12 CERs in the SC 
of N-HSEs as observed in the LC/MS profile of HSE (Figure 3a,b). However, we also noticed 
some changes in the CER composition. The peak intensities in the LC/MS chromatogram for 
the polar CERs (e.g. AP, EOP and NP) in the N-HSE were less present compared to the LC/
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MS chromatogram for the HSE, confirming the HPTLC results (Figure 3a,b). The range of the 
CER chain length distribution is similar in both HSEs and N-HSEs (Figure 3a,b). In addition, 
LC/MS was used to quantify the levels of saturated FFAs, mono-unsaturated FFA (MUFAs) 
and hydroxy-FFAs. We observed a comparable level of saturated FFAs between the N-HSEs 
and the HSEs, while in N-HSE the MUFA content was increased at the expense of the OH-
FAs  (Figure 3e). 
Besides the subclass levels, the chain length distribution was also examined. Based on the 
number of carbon (C) atoms, FFAs in the SC can be divided in long-chain fatty acids (LCFA, 
with chain length varying between C16-C21) and very long chain fatty acids (VLCFA, 
chain length between C22-C38). The levels of the LCFAs and VLCFAs did not vary between 
the N-HSEs and HSEs (Figure 3f). Quantification of the individual FFAs is provided in 








































Figure 1: (a) Cross sections of haematoxilin and eosin (HE) and immunohistochemical staining for 
collagen type IV, early (K10) and late (filaggrin, loricrin) differentiation markers and for desquamation 
related proteins KLK 5, Lekti. (b) Graph represents the proliferation index of HSEs and N-HSEs. (c) 
Graph represents the SC thickness in terms of number of SC layers. Data represent the mean + SD of 
four experiments. Scale bars represent 50 µm. 
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Figure 2: SC lipid composition analysis of HSEs generated with primary keratinocytes (HSE) and 
N-HSEs. (a) lipid profiles of HSEs and N-HSEs. (b) Total level of lipids present in dry SC. (c) Relative 
weight % of the different lipid classes, ceramides (CER), cholesterol (CHOL) and free fatty acids (FFA). 
(d) Relative level of CERs in weight % of total CERs. (e) Ratio between the EO CER and non EO CER. 
Data represent mean + SEM from 2 independent experiments. 
N-HSEs and HSEs show similar lateral lipid organization 
Following the evaluation of the lipid composition, we assessed the lipid organization. The 
lateral packing in the SC of the N-HSEs and HSEs was examined using FTIR. The lateral 
packing can be determined by monitoring the CH2 rocking vibrations in the FTIR spectrum. 
When lipids are in a crystalline dense orthorhombic packing, the CH2 rocking band consists 
of two vibrations at 719 and 730 cm-1, whereas a hexagonal less dense lateral packing results in 
a single vibration at 719 cm-1. A detailed explanation of FTIR and its usage for the evaluation 
of the lateral packing in the SC of HSEs is described in detail elsewhere22. As shown in figure 
4, both N-HSEs and HSEs displayed the presence of one peak around 719 cm-1, indicating a 
hexagonal lateral packing (Figure 4).
To evaluate at which temperatures the ordered phase (orthorhombic or hexagonal packing) 
transforms into a liquid phase, the CH2 symmetric stretching vibrations were assessed. This 
provides information about the conformational disorder of the lipids. When organized in an 
ordered packing the carbon chains are fully extended, resulting in CH2 symmetric stretching 
wavenumbers that are below 2850 cm-1. In a liquid phase the conformational disordering is 
high, resulting in CH2 symmetric stretching vibrations of around 2852-2854 cm
-1. The lipids 
in the SC of both HSEs displayed similar conformational disordering illustrated by a CH2 














































































































































































































Figure 3: Three-dimensional multi-mass LC/MS chromatogram showing the presence of the 12 CER 
subclasses in SC from (a) HSEs and (b) N-HSEs. CERs are indicated with a continues line. CERs with 
reduced peak intensity are indicated with a dotted line. Unknown lipid species are indicated with a 
grey line. Three-dimensional multi-mass LC/MS chromatogram showing the saturated FAs, and mono-
unsaturated FA (MUFA) in the SC from (c) HSE and (d) N-HSEs. (e) Distribution of the different FFA 
subclasses in SC of HSE and N-HSE. (F) LCFA/VLCFA distribution in SC of HSEs and N-HSEs. Data 
represent mean + SEM of 2 independent experiments. * Chain lengths based on number of carbon 
atoms.
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FTIR measures the order-disorder transition in a temperature range between 0 and 90 °C, 
therefore, the midpoint temperature of this transition could be determined for both N-HSEs 
and HSEs. The table in figure 4 shows that this midpoint temperature of the steep shift in 
CH2 symmetric stretching frequency of the order–disorder transition occurs at similar 






























































700  704   708  712   716  720   724  728   732  736   740
N-HSE
HSE type  Midpoint Order-Disorder Transition  Symetric stretching (cm -1) at 32°C  
HSE  58 ± 2°C  2850,1 ± 0  
N-HSE  57,3 ± 2,3°C  2850,3 ± 0,2  
  
Figure 4: Representative rocking vibrations over a temperature range from 0-90 °C in the FTIR spectrum 
from SC of HSEs or N-HSEs. Both HSE types form hexagonal lateral packing in the SC illustrated with 
one peak at 719 cm-1. Table: The midpoint order-disorder transition temperature and the symmetric 
stretching for both HSE types. Data represent the mean ±SD of 3 experiments. For a detailed explanation 
about SC lipid organization and FTIR see Thakoersing et al22.
SC of N-HSEs display the presence of the LPP 
The lamellar lipid organization in the SC of HSEs can be determined by SAXD. From the 
position of diffraction peaks, the presence of lamellar phases and their repeat distance can 
be determined. As shown in figure 5, the SAXD profiles display three diffraction peaks, 
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representing the 1st, 2nd, and 3rd order diffraction peaks of a lamellar phase with a repeat distance 
of 12.2 (± 0.08) nm for SC for HSE and 12.1 (± 0.34) nm for SC in N-HSE (Fig. 5A). The peak 
intensity of the N-HSEs was generally lower compared to those of the HSEs. In addition to 
the 1st, 2nd and 3rd order diffraction peaks, an additional peak was sometimes observed in the 
SAXD profile of the HSEs which might indicate the presence of phase separated EO CERs 
(Figure 5a, indicated with an arrow)27. 
SC permeability for butyl-PABA is similar for N-HSEs and HSEs 
To evaluate the barrier function of the SC of N-HSEs and that of HSE an in vitro permeability 
study was performed to determine the flux of butyl-PABA through the SC. As shown in 
Figure 5b, the flux of butyl-PABA through the SC of both HSEs is comparable, indicating that 
the permeability of the SC for butyl-PABA is similar for both HSEs and N-HSEs (Figure 5b). 
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  repeat distance (nm)  
HSE  12.2 (+/ - 0.08)  
12.1 (+/ - 0.36)  N-HSE  
Figure 5: (a) Two representative SAXD profiles for the HSE and N-HSE are shown. The 1st, 2nd and 
3rd order diffraction peaks are indicated by 1, 2 and 3 respectively and the * indicates phase separated 
crystalline cholesterol. Both HSEs and N-HSE display the 1st, 2nd and 3rd order diffraction peaks, 
indicating the presence of the LPP. The arrow indicates an additional peak that was sometimes observed 
in the HSEs. The data represent the mean ± SD of 3 experiments (b) Diffusion profiles for diffusion 
of butyl-PABA through the SC of HSEs and N-HSEs. The data represent the mean ± SEM of at least 6 
measurements.
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Discussion 
For in vitro topical application studies, reproducible HSEs with a competent barrier can be 
used as an alternative for animal studies. To reduce donor-donor variations and to circumvent 
the limited in vitro lifespan of primary keratinocytes, epithelial cell lines can be a useful 
alternative. Unfortunately, not many epithelial cell lines can be used for the generation of 
HSEs28;29. Recently, the commercially available cell line NIKS® has been shown to form a fully 
stratified epidermis when cultured on a fibroblast populated dermal substrate and shown to 
be applicable for toxicological assays (StrataTest, Stratatech, USA).30;31 These skin models have 
been shown to display a barrier function as measured by skin surface electrical impedance. 
To the best of our knowledge, no in depth studies have been performed so far focussing on 
the SC barrier properties of HSEs established with N/TERT cells. In this study we compared 
epidermal morphogenesis and barrier function of our in house full thickness HSEs established 
with primary keratinocytes or with N/TERT cells. 
Morphology and protein expression
Our in-house HSEs established with primary keratinocytes have shown to have features 
comparable to those seen in vivo, in terms of morphology and differentiation22. Furthermore, 
in the most recent publication in which different commercial available HSEs have been 
evaluated, the EpiDerm skin model was shown to have comparable morphology, lipid profiles 
and the presence of the LPP in the SC, similar as our in-house HSEs22;32. N-HSEs showed 
expression and localization of differentiation markers, K10, filaggrin and loricrin, and of 
proteins involved in desquamation, Lekti and KLK5, similar to HSEs established with primary 
keratinocytes. Formation of a proper basement membrane was confirmed by the presence of 
collagen type IV at the dermal-epidermal junction. These results indicate that full thickness 
HSEs established with N/TERT cells have an epidermal morphogenesis comparable to that of 
HSEs generated with primary keratinocytes, and are in line with previously published results 
in which positive staining for K10 and involucrin of differentiating monolayer N/TERT 
immortalized cells was shown18. However, we observed a difference in epidermal thickness 
and in number of viable cell layers. While the HSEs contained 7-8 viable cell layers, the N-HSE 
had 4-5 viable cell layers. This might be caused by the immortalization in the N/TERT cells or 
due to the usage of a mixture of 2 primary keratinocyte donors for the generation of the HSEs. 
Barrier properties
The main focus of this study was the evaluation of the barrier properties of N-HSEs. The 
results presented here indicate that N-HSEs and HSEs display barrier properties that are 
similar to a large extent. Evaluation of the lateral packing showed that the lipid density and the 
conformational ordering of the SC lipids were comparable. More importantly, the SC lipids in 
N-HSEs form the LPP, comparable to the lipid organization in SC of HSEs. Previously it has 
been shown that presence of the LPP is an important factor for a proper barrier function21;33. 
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However, some differences were also observed. A reduced peak intensity that was observed 
in the SAXD profile of N-HSEs, which might be caused by less ordered lipid lamellae. With 
regards to the lipid composition, HPTLC and LC/MS showed that N-HSEs and HSEs display 
the presence of all 12 CER subclasses, although the presence of some CERs, in particular CER 
AP, were reduced in the N-HSEs. In addition, saturated FFAs, MUFAs and hydroxy FFAs 
were present in both the N-HSEs and HSEs. However, differences were observed in the level 
of MUFA’s and hydroxy FFAs. The range of the FFA and CER chain length distribution of 
N-HSEs was similar to HSEs. These observed differences in lipid composition in the SC from 
N-HSEs in terms of CER profile did not affect the permeation of N-HSEs for the lipophilic 
compound butyl-PABA, which has previously been described for its usage in SC permeability 
studies21.
Conclusion
In this study we demonstrate that the N/TERT cell line is able to form a proper epidermal 
skin barrier when used for the generation of human skin equivalents. The differences that 
were found in the SC lipid composition did not affect the barrier function in terms of SC 
permeability for butyl-PABA. A full characterization of the SC permeability by using a range 
of compounds with varying lipophilicity, is subject for future research. Despite the discrepancy 
between in vitro HSEs and in vivo skin that were published earlier22, the results presented in 
this study demonstrate that the N/TERT cell line can be used as an alternative to primary 
keratinocytes to generate HSEs. Usage of N/TERT cells results in a reproducible, robust 
and easy-to-establish in vitro skin model. However, their applicability for pharmacological, 
chemical and toxicological (safety) testing should be further investigated.  
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Supplementary Material and Methods
Generation of HSEs
HSEs and N-HSEs were generated by seeding 0.5x106 primary keratinocytes (mixture of 2 
donors in a 1:1 ratio), or N/TERT cells onto the dermal equivalent, respectively, as described 
elsewere1;2. Briefly, after 2 days of submerged culturing in medium containing 5% FCS, the 
FCS concentration was reduced to 1% for one additional day. Subsequently, HSEs were lifted 
to the air-liquid interface and cultured for 14 days with FCS-free medium supplemented with 
2µM L-serine, 10 µM L-carnitine, 1 µM DL-α- tocopherol-acetate, 50 µM ascorbic acid, a free 
fatty acid supplement which contained 25 µM palmitic acid, 30 µM linoleic acid and 7 µM 
arachidonic acid and 2.4x10-5 M bovine serum albumin. Culture medium was refreshed twice 
a week.
Immunohistochemical analysis
Table 1: Primary and secondary antibodies for immunohistochemical analysis
Primary antibody* Clone Dilution Manufacturer 
Filaggrin (R) Polyclonal 1:1000 Covance, Rotterdam, the Netherlands
Loricrin (R) AF62 1:1000 Covance, Rotterdam, the Netherlands 
Ki67 (M) MIB1 1:100 DAKO, Glostrup, Germany
Keratin 10 (M) DE-K10 1:100 Labvision / Neomarkers, Fremont CA, USA
Collagen type IV (M) MAB1430 1:75 Chemicon, Melbourne, Vic Australia
Lekti (M) 1C11G6 1:20 Invitrogen, Breda, the Netherlands
KLK 5 (R) Polyclonal 1:400 Santa Cruz, Heidelberg, Germany
Secondary antibody Dilution Manufacturer 
Biotinylated Swine anti-rabbit 1:200 DAKO, Glostrup, Germany
Biotinylated Goat anti-Mouse 1:200 Southern Biotechnology
* R= rabbit, M=mouse
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Fourier transformed infrared spectroscopy and small angle X-ray diffraction 
Fourier transform infrared spectroscopy (FTIR) and small angle X-ray diffraction (SAXD) 
were performed as described earlier3. Prior to FTIR and SAXD measurements, SC samples 
were hydrated at room temperature for 24 hrs in a 27% (w/v) NaBr solution. 
The SC sample was sandwiched between AgBr windows after which FTIR spectra in the 
frequency range of 600-4000 cm−1 were obtained using a Varian 670-IR FTIR spectrometer 
(Agilent technologies, Santa Clara, CA), equipped with a broad-band mercury cadmium 
telluride (MCT) detector which was cooled with liquid nitrogen. Each spectrum was collected 
for 4 minutes at a 1°C interval within a temperature range of 0-90°C. Each spectrum was 
derived from the co-addition of 256 scans at a resolution of 1 cm−1. The spectra were processed 
using Bio-Rad Win-IR Pro 3.0 software from Biorad (Biorad laboratories, Cambridge, 
Massachusetts).
Small angle X-ray diffraction (SAXD) measurements were performed at the European 
Synchrotron Radiation Facility (ESRF, Grenoble) at station BM26B. A more detailed 
description of this beamline has been described elsewhere4. The SC samples were hydrated 
for 24 hrs at room temperature over a 27% (w/v) NaBr solution before measurements. The 
scattering intensity (I) was measured as a function of the scattering vector q (in nm-1). The 
repeat distance (d) of a lamellar phase was determined from the position of the diffraction 
peaks with the following equation d= 2nπ/qn, in which q= 4πsinθ/λ. In these equations θ 
is the scattering angle, λ is the wavelength and n is the order of the diffraction peak. All 
measurements were performed with three SC samples of both HSE types.
Lipid extraction 
The SC lipids were extracted according to a modified Bligh and Dyer procedure as described 
elsewhere3;5. A sequence of three chloroform:methanol mixtures (1:2, 1:1, and 2:1 v/v) were 
used for lipid extraction. Subsequently the lipid extracts were pooled and 0.25M KCl and 
water were added. The organic phase was collected and evaporated under a stream of nitrogen 
at 40°C. The obtained lipids were dissolved in a suitable volume of chloroform: methanol 
(2:1 v/v) and stored at −20 °C until use. To obtain enough lipids for quantification using high 
performance thin layer chromatography (HPTLC), the lipid extracts of 2-4 HSEs or N-HSEs 
were pooled from the same experiment. 
Ceramide nomenclature and quantification of HPTLC
Extracted SC lipids were quantified using HPTLC. The used solvent system to separate the 
lipids is described elsewhere. For quantification, co-chromotography of serial dilutions of 
each of the standards was done as described before5. The standards consisted of cholesterol 
(CHOL), palmitic acid, stearic acid, arachidic acid, tricosanoic acid, behenic acid, lignoceric 
acid, cerotic acid, and ceramides (CERs) EOS, NS, NP, EOP, and AP. CER nomenclature 
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according to terminology of Motta et al. and Masukawa et al.6;7. Briefly, CERs with a 
sphingosine (S), phytosphingosine (P), a dihydrosphingosine (dS) or 6-hydroxysphingosine 
(H) are linked via an amide to a fatty acid chain, either an estrified ω-hydroxy (EO), α-hydroxy 
(A) or nonhydroxy (N) fatty acid. All other compounds were purchased from Sigma (The 
Netherlands), except for the CERs that were a gift from Evonik (Essen, Germany). After the 
chromatography, samples were stained (copper acetate and copper sulfate in phosphoric acid) 
and charred for 5 mins at 80°C, for cholesterol quantification and 15 mins at 170°C to quantify 
the other lipid classes. Images were obtained with a densitometer (Bio-Rad GS-800 Calibrated 
Densitometer) and analysed with the software (Quantity One software version 4.6.5, Bio-




Figure S1: Human SC lipid organization. The SC lipids are organized into lipid lamellae, the lamellar 
phases, which are stacked on top of each other between the corneocytes. Lipid lamellae in native human 
SC are organized into two lamellar phases, the long periodicity phase (LPP) and the short periodicity 
phase (SPP) with repeat distances (d) of approximately 13 and 6 nm, respectively.
Within the lamellar phases, the lipids are organized in a certain density, which is referred to 
as the lateral packing. The lateral packing can either be liquid (disordered, loosely packed), 
hexagonal (ordered, less densely packed) or orthorhombic (ordered, very densely packed). 
Adapted from Thakoersing et al.8.
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Figure S2: quantification of the SC free fatty acids (FFAs) from human skin equivalents (HSEs) and 
N/TERT based HSEs (N-HSEs). (a-c) Chain length distribution of saturated FFAs, mono-unsaturated 
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Human skin mainly functions as an effective barrier against unwanted environmental 
influences.  The barrier function strongly relies on the outermost layer of the skin, the stratum 
corneum (SC), which is composed of corneocytes embedded in an extracellular lipid matrix. 
The importance of a proper barrier function is shown in various skin disorders such as atopic 
dermatitis (AD), a complex human skin disorder strongly associated with filaggrin (FLG) 
null mutations, but their role in barrier function is yet unclear. To study the role of FLG in 
SC barrier properties in terms of SC lipid organization and lipid composition, we generated 
an N/TERT based 3D-skin equivalent (NSE) after knockdown of FLG with shRNA. In these 
NSEs, we examined epidermal morphogenesis by evaluating the expression of differentiation 
markers keratin 10, FLG, loricrin and the proliferation marker ki67. Furthermore, the SC 
was extensively analysed for lipid organization, lipid composition and SC permeability. Our 
results demonstrate that FLG knockdown (FLG-KD) did not affect epidermal morphogenesis, 
SC lipid organization, lipid composition and SC permeability for a lipophilic compound in 
NSEs. Therefore, our findings indicate that FLG-KD alone does not necessarily affect the 
functionality of a proper barrier function.
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Introduction
The barrier function strongly relies on the outermost layer of the skin, the stratum corneum 
(SC), which is composed of corneocytes embedded in an extracellular lipid matrix. Since the 
extracellular SC lipid matrix forms a continues pathway between the corneocytes, it has been 
suggested to act as an important penetration pathway through the SC1. This lipid matrix is 
composed of ceramides (CERs), cholesterol (CHOL) and free fatty acids (FFAs) which are 
organized into lipid layers referred to as lamellar phases2-4. X-ray diffraction studies revealed 
that human skin contains two lamellar phases, the long periodicity phase (LPP) and the short 
periodicity phase (SPP), with a repeat distance of approximately 13 and 6 nm, respectively5;6. 
Within the lamellar phases, the lipids are organized in a certain density, referred to as the 
lateral packing, either orthorhombic (very dense), hexagonal (dense) or liquid (loose)5-9 
(Figure S1). Atopic dermatitis (AD) is a common inflammatory skin disorder characterized 
by impaired skin barrier function that affects over 15% of Caucasian children and 2-10% 
adults10. AD skin is characterized by increased transepidermal water loss (TEWL), decreased 
hydration  and increased permeability for compounds such as sodium lauryl sulphate10-13 . To 
date, the strong association between filaggrin (FLG) null mutations and AD is one of the most 
robust genotype linkage observed in complex human genetic disorders, but the effect of such 
FLG mutations on skin barrier is not yet fully understood14-18. Recently, it was demonstrated 
that SC lipid organization and CER composition correlated with the impaired skin barrier 
function in AD19.  
The clinical phenotype of AD is the result of complex interactions between environmental 
and genetic factors that results in an inflammatory response and impaired skin barrier 
function. Therefore the single contribution of reduced FLG expression due to FLG null 
mutations on skin barrier (dys-)function is difficult to assess in vivo. The discovery that Th2 
cytokines such as IL-4, IL-13 and IL-31 affect FLG expression, add further complexity for 
studying the role of FLG in the barrier function of AD patients in vivo20;21. In the present 
study we therefore generated a reproducible full thickness model using the N/TERT cell line 
after shRNA mediated knockdown of FLG. This approach allows us to elucidate the single 
contribution of FLG on epidermal morphogenesis and SC barrier properties in vitro. We 
chose for reconstructed human skin equivalents as these models reproduce many features that 
are present in ex vivo skin concerning the lipid properties and most of the barrier proteins22. 
In a previous study, Mildner and colleagues showed that siRNA mediated knockdown of 
FLG in human skin equivalents (HSEs) results in increased epidermal uptake of a fluorescent 
dye23. However, whether FLG deficiency affects permeation across the SC and whether FLG 
deficiency affects SC lipid organization and SC lipid composition was not studied. Using an 
N/TERT based human skin equivalent (NSE), we extensively analyzed various SC barrier 




Material and Methods 
Cell culture
Primary human fibroblasts were obtained from surplus skin from adult donors undergoing 
mammary or abdominal surgery and were established as described earlier23;24. For all 
experiments, fibroblasts cultured at 37°C and 5% CO2 from passage 2-5 were used for 
generation of NSEs. The N/TERT keratinocyte cell line was purchased from Harvard Medical 
School (USA) and cultured in keratinocyte serum free medium (KSFM medium, Invitrogen), 
supplemented with 25 µg/ml BPE, 0.4 mM CaCl2 0.2ng/ml hEGF, 100 U/ml penicillin and 100 
µg/ml Streptomycin (Invitrogen).  
Generation of stable N/TERT cell lines
N/TERT cells were transfected with pLKO.1-puro plasmid containing shRNA against filaggrin 
using the Amaxa human keratinocyte nucleofector kit (Lonza, Breda, the Netherlands) 
according manufacturer’s protocol using program T-07. Plasmids containing shRNA against 
filaggrin (TRCN0000083680) obtained from the Mission library from Sigma-Aldrich was 
used. As a control we used cells transfected with empty pLKO.1-puro plasmid (Mock, TRC1.5-
SHC001) and untransfected N/TERT. Transfected cells were cultured similar to N/TERT cells 
except for the addition of puromycin to the KSFM medium (1 ug/ml). 
Dermal Equivalents
Dermal equivalents were generated as described earlier25. Briefly, 1 ml of cell-free collagen 
(1mg/ml) was pipetted into a 6 well-filter insert (Corning Life Sciences). After polymerization, 
3 ml of fibroblast populated (0.4x105 fibroblasts/ml) collagen (2 mg/ml) was pipetted onto 
the polymerized collagen layer. After polymerization the dermal equivalents were submerged 
in medium consisting of DMEM, 5% FCS and 1% penicillin/streptomycin. Medium was 
refreshed twice a week.
Generation of NSEs
NSEs were generated by seeding 5x105 N/TERT cells onto a dermal equivalent. These NSEs 
were cultured in medium containing 5% FCS for 2 days, after which the FCS concentration 
was reduced to 1% for an additional day. Next, NSEs were lifted to the air-liquid interface 
and cultured for 2 weeks with FCS-free medium supplemented with 2M L-serine, 10 mM 
L-carnitine, 1 µM DL-α- tocopherol-acetate, 50 µM ascorbic acid, a free fatty acid supplement 
which contained 25 µM palmitic acid, 30 µM linoleic acid and 7 µM arachidonic acid and 
2.4x10-5 M bovine serum albumin. Culture medium was refreshed twice a week.
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Morphology and immunohistochemistry
NSEs were fixed in 4% formaldehyde and embedded in paraffin. Morphological analysis was 
performed on 5 µm sections through haematoxylin and eosin staining. Immunohistochemical 
analyses was performed using the streptavidin-biotin-peroxidase system (GE Healthcare, 
Buckinghamshire, UK), according manufacturer’s instructions. Staining’s were visualized 
with 3-amino-9-ethylcarbazole (AEC), counterstained with haematoxylin and sealed with 
Kaisers glycerin. The primary and secondary antibodies are given in supplementary Material 
and Methods. 
Estimation of proliferation index
To estimate the proliferation index, the number of Ki67 positive nuclei in a total number of 100 
basal cells (x100%) was determined on 3 locations per slide for three different experiments. 
Data represent mean and standard deviation.
Determination of the number of stratum corneum layers
The layers of the stratum corneum were counted as described previously26. For details see 
supplementary Material and Methods. Data represent mean and standard deviation.
RNA isolation, cDNA synthesis and qPCR
RNA was isolated from the epidermis of NSEs using the RNeasy kit (Qiagen) according 
manufacturer’s instructions. Prior to RNA isolation, the samples underwent a proteinase K 
treatment. cDNA was generated using the iScript cDNA synthesis kit (BioRad, Veenendaal, 
The Netherlands) according manufacturer’s instructions. PCR reactions were based on the 
SYBR Green method (BioRad) using the CFX384 system (BioRad). Expression analysis 
was performed using CFX software using the ΔΔCt method using the reference gene 
β-2-microglobulin. Data represent mean and standard deviation of 3 different experiments.
Protein isolation and Western blot
Proteins were isolated from the epidermis using Tissue Protein Extraction Reagent (T-PER) 
supplemented with protease inhibitor cocktail and HALTTM phosphatase inhibitors (Thermo 
Scientific, Etten-Leur, the Netherlands). For western blot details see supplementary Material 
and Methods. 
Stratum corneum isolation 
The SC from NSEs was isolated as described earlier27. Briefly, NSEs were incubated overnight 
on filter paper with 0.1% trypsin in 4˚C. After 30 minutes incubation at 37˚C, SC was 
mechanically separated from the NSEs and subsequently washed with 1 ug/ml trypsin 
inhibitor (Sigma, Zwijndrecht, The Netherlands) and demineralized water. SC samples were 
air dried at room temperature and stored under Argon gas over silica gel in the dark.  
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Fourier transformed infrared spectroscopy and small angle X-ray diffraction 
Fourier transform infrared spectroscopy (FTIR) and small angle X-ray diffraction (SAXD) 
were performed as described earlier22. For details see supplementary Material and Methods. 
All measurements were performed using three SC samples of all NSE types. Data represent 
mean and standard deviation.
Lipid extraction 
SC lipids were extracted according to a modified Bligh and Dyer procedure as described in 
the supplementary Material and Methods and elsewhere22;28. To obtain sufficient lipids for 
quantification, lipid extracts from 2-4 NSEs from each donor were pooled. 
HPTLC lipid analysis
Extracted SC lipids were quantified using HPTLC. The solvent system to separate the lipids 
is described elsewhere29. Co-chromatography of serial dilutions of a standard mixture was 
used to identify and quantify each lipid class. HPTLC details and ceramide nomenclature is 
given in supplementary Material and Methods according to terminology of Motta et al., and 
Masukawa et al.30;31. Data represent mean and standard deviation of 2 different experiments.
LC/MS lipid analysis
The CERs and FFAs in pooled lipid extracts of the NSEs were analyzed by LC/MS according 
to the method described in the supplementary Material and Methods and elsewhere (van 
Smeden et al., submitted). Quantification of FFAs was performed using lipid extracts of SC 
from two experiments for each NSE type. Data represent mean and standard deviation.
Permeability studies
In vitro permeation studies were performed with butyl para-aminobenzoic acid (butyl-PABA) 
as described earlier with small adjustments32. The donor compartment was filled with 1.5 
ml butyl-PABA solution (50 µg/ml butyl-PABA) in acetate buffer (pH 5.0). The acceptor 
compartment consisted of PBS (pH 7.4), perfused at a flow rate of 1.5 ml/hr. Permeability 
studies were performed with at least 6 SC sheets of all NSE types. Data represent mean and 
standard deviation.
Statistical analysis
Statistical significance was determined using the two-tailed Student’s t-test. The permeability 
studies were analyzed using ANOVA. 
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Results
Filaggrin knockdown does not affect epidermal morphogenesis of NSEs
Stable knockdown of filaggrin (FLG-KD) was obtained through electroporation of FLG 
specific shRNA in N/TERT cells selected by puromycin, which were subsequently used for the 
generation of NSEs. After culturing the NSEs for 14 days air-exposed, a significant reduction 
of approximately 85% of FLG mRNA expression was present in FLG-KD NSEs, when 
compared to the control (Mock) (Figure 1a). Both western blot and immunohistochemical 
analysis show a strong decrease in FLG protein expression and reduced expression in the 
stratum granulosum, respectively (Figure 1b, c). All NSE types showed a fully developed 
epidermis consisting of all epidermal layers (Figure 1c). Additionally, the expression of the 
early differentiation marker K10 in the suprabasal layers and the late differentiation marker 
loricrin in the stratum granulosum indicated a normal differentiation program, irrespective 
of FLG-KD (Figure 1c). Determination of the proliferation index by Ki67 showed that FLG-
KD did not affect basal cell proliferation (Figure 1d). To evaluate whether FLG-KD affected 
SC thickness, a saffranin red staining was used which revealed that the number of layers in the 
SC was not affected by FLG-KD (Figure 1e). 
SC lamellar lipid organization is not altered after FLG-KD in NSEs
After evaluation of epidermal development in NSEs, we determined whether FLG-KD affected 
SC lipid organization. Since presence of the LPP is an important determinant in skin barrier 
function, SAXD was used to evaluate the lamellar organization. FLG-KD NSEs displayed the 
presence of the 1st, 2nd, and 3rd order diffraction peaks, indicated the presence of the LPP 
(Figure 2a). The average repeat distance of the LPP for the N/TERT, Mock and FLG-KD NSEs 
was 12.1 nm (± 0.4 nm), 12.3 nm (± 0.7 nm) and 12.1 (± 0.4 nm) respectively (Figure 2a), 
indicating that FLG-KD did not affect the presence of the LPP nor its repeat distance. In 
addition to the 1st, 2nd, and 3rd order diffraction peaks, occasionally a small extra peak was 
observed in the NSE curves.
FLG-KD in NSEs did not affect the lateral packing of the SC lipids
The lateral packing in the SC of the NSEs was examined by monitoring the CH2 rocking band 
vibrations in a FTIR spectrum. When lipids are in an orthorhombic packing the CH2 rocking 
band consists of two vibrations at 719 and 730 cm-1, whereas a hexagonal lateral packing results 
in a single vibration at 719 cm-1. A detailed explanation of FTIR and its usage for evaluation 
of the lateral packing in the SC of HSEs is described elsewhere22. Only a vibration at 719 cm-1 
was observed for all three NSEs, demonstrating that FLG-KD NSEs show a hexagonal lateral 







































































Figure 1: Filaggrin knockdown in 14 days air-exposed NSEs. (a) qPCR analysis after FLG-KD. FLG 
mRNA expression in NSEs was reduced with approximately 85% after nucleofection with FLG-
specific shRNA, compared to the control (Mock). Data represent the mean + SD of three independent 
experiments. (b) Western blot analysis for filaggrin. FLG-KD NSEs show reduced FLG protein expression 
after culturing at the air-liquid interface for 14 days. (c) Immunohistochemical staining for FLG, keratin 
10 and loricrin. Reduced FLG expression was present in the stratum granulosum of FLG-KD NSEs, but 
did not affect the expression of keratin 10 and loricrin. Scale bars: 50 µm. (d) proliferation index after 
Ki67 revealed that FLG-KD did not affect epidermal  proliferation. Data represent the mean + SD of 
three independent experiments. (e) Saffranin red staining for the evaluation of the number of SC layers 
showed that FLG-KD did not affect the number of SC layers of NSEs after 14 days air exposed culturing. 
Data represent mean + SD of 5 independent experiments.
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To evaluate at which temperatures the lipid domains transform into a liquid phase, the 
CH2 symmetric stretching was assessed (Figure S2b). This provides information about 
the conformational ordering of the lipids. Lipids in a crystalline phase (orthorhombic or 
hexagonal packing) display a CH2 symmetric stretching below 2850 cm
-1. In a liquid phase 
the conformational disordering is high, resulting in symmetric stretching vibrations between 
2852 - 2854 cm-1. At 32°C, FLG-KD NSEs displayed a CH2 stretching frequency of 2850.8 ± 
0.8 cm-1 comparable to the CH2 stretching frequency of the Mock (2850.7 ± 0.6 cm
-1) and 
N/TERT (2850.3 ± 0.2 cm-1) (Figure S1c). Since the order-disorder transition occurs over 
a temperature range between 0 and 90°C, the midpoint temperature of this transition was 
determined. This midpoint order-disorder transition of the FLG-KD NSEs was comparable 
to the Mock and N/TERT NSEs (Figure S2c)
FLG-KD did not alter SC lipid composition in NSEs
We quantified the SC lipid composition of the NSEs by HPTLC, which revealed a similar 
SC lipid profile for the N/TERT, Mock and FLG-KD NSEs (Figure 2b). The amount of lipids 
as a percentage of total SC weight was determined by weighing SC before and after lipid 
extraction. FLG-KD did not affect the percentage weight of lipids in the SC (Figure 2c) and 
quantification of the different lipid classes showed similar levels of CHOL, CER and FFA 
present in SC of all NSEs (Figure 2d, e)). FLG-KD did not affect the presence of the different 
CER subclasses, as the relative level of each CER subclass was not significantly different for all 
three NSEs (Figure 2e). Additionally, FLG-KD did not significantly affect the ratio between 
the total EO ceramides (EO CERs, acylceramides) and non EO ceramides (non EO CERs, 
a-hydroxy and non-hydroxy ceramides)  (Figure 2f). Subsequently, SC lipid composition was 
evaluated in more detail using liquid chromatography/mass spectrometry (LC/MS). HPTLC 
can be used to separate 9 CER subclasses, while with LC/MS 12 CER subclasses and their 
chain length distribution can be detected33. LC/MS showed that FLG-KD did not affect the 
presence of the 12 CER subclasses and their chain length distribution by FLD-KD (Figure S3). 
Since FFA chain length is important for CER chain length and for SC lipid organization, 
LC/MS was performed to evaluate whether the FFA composition was affected by FLG-KD. 
All NSEs displayed the presence of saturated FFAs and monounsaturated FFAs (MUFAs) 
(Figure 3a-c). FFA chain length distribution varied between C16:0 and C28:0 and C16:1 and 
C32:1 for the saturated FFAs and MUFAs respectively in all NSEs, indicating that FLG-KD 
did not affect FFA saturation nor chain length distribution. In addition, hydroxy FFAs were 
detected, but due to their low abundance could not be visualised in the plot. Quantification 
of the relative amounts of the various FFA classes revealed that FLG-KD did not affect the 
distribution of the FFAs (Figure 3d and S4). Also the ratio of the long chain fatty acids (LCFA, 
C16-C21) and very long chain fatty acids (VLCFAs, C22-C38) was not affected by FLG-KD 


















































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3: Liquid chromatography/mass spectrometry (LC/MS) chromatograms. Three-dimensional 
multi-mass LC/MS chromatogram of the FFAs present in SC lipid extracts from (a) N/TERT, (b) Mock 
and (c) FLG-KD NSEs. All NSEs display the presence of saturated and monounsaturated FFAs with 
similar chain length distribution ranging between C16:0 and C28:0 and C16:1 and C32:1 indicating 
that FLG-KD did not affect the FFA  saturation nor chain length distribution. (d) relative distribution 
of the different FFA subclasses. The distribution of the FFA subclasses was not affected by FLG-KD. (e) 
relative distribution of the long chain fatty acids (LCFAs) and the very long chain fatty acids (VLCFAs). 
FLG-KD NSEs showed similar distribution of the LCFAs and VLCFAs. Total amount of all FFAs was set 
at 100%. Data represent mean + SD of 2 independent experiments. 
SC permeability was not increased after FLG-KD in NSEs
After investigation of the SC lipid organization and composition, we examined the SC barrier 
function after FLG-KD. Therefore, diffusion of a lipophilic model compound, butyl-PABA, 
through the SC was evaluated. The flux of butyl-PABA through the SC of the three NSEs is 
similar and not affected by FLG-KD (Figure 4), clearly demonstrating that FLG-KD did not 























Figure 4: SC permeability for butyl-PABA after FLG-KD. To investigate the SC permeability, we used 
butyl-PABA as a model drug. The diffusion profiles for butyl-PABA were similar for the untreated 
N/TERT, Mock and FLG-KD NSEs, indicating that FLG-KD did not affect the permeability for this 
compound. Data represent the mean ± SEM of at least 6 measurements from three different experiments.
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Discussion
FLG null mutations are a well-known predisposing factor for development of AD, an 
inflammatory skin disorder characterized by a defective skin barrier function. Since AD is 
the result of complex interactions between genetic and environmental factors that result in 
inflammation, the single contribution of FLG null mutations on skin barrier (dys-)function 
is difficult to assess in vivo. Especially the discovery that cytokines, e.g. Il-4 and IL-13, have 
been shown to reduce FLG expression and that such cytokines affect SC lipid composition, 
add further complexity for studying the role of FLG in barrier function in AD in vivo20;21;34. 
To study the effect of FLG deficiency on epidermal development and SC barrier properties, 
we generated NSEs after shRNA-mediated knockdown of filaggrin. These FLG-KD NSEs 
were studied extensively for their barrier properties, including SC lipid organization, lipid 
composition and permeability. 
FLG-KD did not affect epidermal development in our NSEs. Differentiation was not affected 
by FLG-KD, in line with previous studies that used siRNA oligonucleotides or lentiviral 
transduction for FLG-KD23;34. In addition, FLG-KD did not affect epidermal proliferation 
in NSEs. Earlier reports on the role of FLG on epidermal proliferation are contradicting. 
A recent study showed no effect on epidermal thickening using a raft culture system after 
FLG-KD through adenoviral transfection, while others showed epidermal hyperproliferation 
in primary keratinocytes using lentiviral miR constructs to target pro-FLG34;35. Such 
differences might be explained by differences in the established skin models, cell origin and/
or experimental set-up. 
Since the SC is the principle layer for skin barrier function and FLG is an important barrier 
protein, we mainly focused on this layer to evaluate the effect of FLG-KD on various barrier 
properties. Reduced expression of FLG has been suggested to result in an increase in pH and 
thereby affect the activity of various enzymes involved in lipid metabolism36. Thereby FLG-
KD in an NSE might result in alterations in SC lipid composition as seen in AD patients. 
Our analysis concerning the SC lipid composition using quantitative HPTLC and LC/MS 
show that there is no effect of FLG-KD on the SC lipid composition of NSEs. This indicates 
that FLG-KD alone is not sufficient to affect the SC lipid composition and that other factors 
then FLG, e.g. inflammation, might be involved. This is in agreement with in vivo studies that 
showed that there is no relation between FLG null mutations and the SC lipid composition 
and organization19;37. 
Studies using the flaky tail mouse model containing a homozygous frameshift mutation in 
the FLG gene, have shown an enhanced percutaneous allergen priming and an increased 
sensitivity to epicutanous application of ovalbumin38;39. However, whether these results are   
due to an increased penetration or increased response in the viable skin is not yet known. 
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Furthermore, the stratum corneum barrier properties of these mice have not yet been 
investigated., in addition, a  recent study showed that the development of skin lesions in flaky 
tail mice was dependent on the adaptive immunity rather than the FLG mutations since these 
mice without T and B cells did not develop lesions40.
In agreement with the SC lipid composition, SAXD results showed that FLG-KD did not 
affect the lamellar organisation in SC. The LPP was prominently present and no effect on 
the repeat distance of the LPP was observed. FTIR results showed that the lateral packing 
and the conformational ordering were also not affected by FLG-KD. As reported earlier for 
HSEs generated with primary keratinocytes, SC from NSEs mainly show a hexagonal lateral 
packing and was not affected by FLG-KD22. 
Since the extracellular lipid matrix forms a continuous pathway between the impermeable 
corneocytes, it has been suggested to act as an important penetration pathway through the SC. 
We therefore used a lipophilic compound, butyl-PABA, which has previously been described 
for its usage in in vitro permeability studies32. Our findings clearly show that FLG-KD did 
not affect SC permeability of NSEs for this compound. These studies are different from those 
reported by Mildner et al. who showed an increased epidermal uptake for the fluorescent dye 
Luciferase yellow after FLG-KD23. While these studies provide information about the effect of 
FLG-KD on amount of fluorescent dye present in the epidermis after a predetermined time 
interval, our studies show that FLG-KD did not affect the permeation of butyl-PABA across 
the SC as function of time. Furthermore, the observed differences may also be explained 
by the compound properties (e.g. lipophilic versus hydrophilic) and/or by differences in 
protocols to establish knockdown of filaggrin and the subsequent generation of HSEs. 
In conclusion, we here show that FLG-KD does not affect epidermal morphogenesis, SC 
lipid organization, lipid composition and SC permeability in NSEs. The role of FLG in AD 
pathology remains unclear but our results indicate that FLG does not play a role in the 
SC lipid organization and composition, in line with recent publications for AD patients19. 
Other recent studies have shown that complete FLG deficiency in ichtyosis vulgaris (IV) 
was associated with only moderate changes in epidermal permeability barrier function in 
terms of TEWL, skin hydration and surface pH, changes that were absent in IV patients that 
were heterozygous for FLG null mutations41;42. While these studies focussed on other barrier 
parameters, they underline the findings presented in this study that FLG deficiency alone 
does not result in barrier dysfunction as seen in AD. Altogether, based on our in vitro results 
and these two in vivo studies one might speculate that other yet unidentified factors, such as 
inflammation, cause the barrier dysfunction as seen in AD.
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Supplementary Material and Methods
Primary and secondary antibodies used for immunohistochemistry
The primary antibodies used were Rabbit Filaggrin (1:1000; Covance, Rotterdam, the 
Netherlands), Rabbit Loricrin (1:1000; Covance, Rotterdam, the Netherlands), Mouse Ki67 
(1:100; DAKO, Glostrup, Germany), Mouse Keratin 10 (1:100; Labvision / Neomarkers, 
Fremont CA, USA). The secondary antibodies used were biotinylated Swine anti-rabbit 
(1:200, DAKO), biotinylated Goat anti-Mouse (1:200, Southern Biotechnology).
Determination of the number of stratum corneum layers
Five μm sections from snap frozen NSEs were cut and stained with a 1% (w/v) safranin (Sigma) 
solution for 1 minute followed by 20 minutes incubation with a 2% (w/v) KOH solution to 
allow corneocyte swelling. Images of the sections were taken using a digital camera (Axiocam, 
Zeiss). The number of layers was counted in at least 6 locations covering the full length of the 
NSEs. This was performed for 5 different experiments.
PCR program and primers for qPCR  
The PCR program was: 5 minutes at 95˚C to activate the polymerase followed by 44 cycle 
of 15 seconds at 95˚C, 20 seconds at 60˚C and 20 seconds at 72˚C. Afterwards a melt curve 
was generated. The primers used were filaggrin: forward ‘GGGAAGTTATCTTTTCCTGTC’ 
and reverse ‘GATGTGCTAGCCCTGATGTTG’, and β-2-microglobulin: forward 
‘GATGAGTATGCCTGCCGTGTG’ and reverse ‘CAAACCTCGGGTAGCATCAT’. Data 
represent the mean and standard deviation of 3 different experiments.
Western blot analysis
Protein sample was loaded onto a 10% SDS-PAGE gel and proteins were blotted on a 
polyvinylidene difluoride membrane (Thermo Scientific). Blocking was performed with 10% 
Elk Milk (Campina, The Netherlands) in phosphate-buffered saline-T (0,1% Tween). Primary 
antibody was incubated overnight at 4°C after which it was incubated with the appropriate 
secondary antibody, horseradish peroxidase-conjungated anti-rabbit (Thermo Scientific, 
1:2500). Proteins were detected using Supersignal West Femto ECL (Thermo Scientific/
Pierce). 
Fourier transformed infrared spectroscopy and small angle X-ray diffraction 
Prior to FTIR and SAXD measurements, SC was hydrated at room temperature for 24 hours 
in a 27% (w/v) NaBr solution. 
FTIR measurements were performed using a Varian 670-IR FTIR spectrometer (Agilent 
technologies, Santa Clara, CA), equipped with a broad-band mercury cadmium telluride 
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(MCT) detector, cooled with liquid nitrogen. The SC sample was sandwiched between AgBr 
windows and spectra collected in transmission mode and derived from the addition of 256 
scans at 1 cm−1 resolution every 4 minutes (frequency range of 600-4000 cm−1, temperature 
range of 0°C and 90°C at a rate of 0.25°C/min). Bio-Rad Win-IR Pro 3.0 software from Biorad 
(Biorad laboratories, Cambridge, Massachusetts) was used to process the spectra. 
SAXD measurements were performed at the European Synchrotron Radiation Facility (ESRF, 
Grenoble) at station BM26B. A more detailed description of this beamline is described 
elsewhere43. The scattering intensity (I) was measured as a function of the scattering vector 
q (in nm-1) defined as q= 4πsinθ/λ, in which λ is the wavelength of the X-rays and θ the 
scattering angle. In the generated diffraction pattern a lamellar phase is characterized by a 
number of equidistant peaks. The position of these peaks are directly related to the repeat 
distance d, d= 2nπ/qn, in which n is the diffraction order and d is the repeat distance. All 
measurements were performed with three SC samples of all NSE types. Data represent the 
mean and standard deviation.
Lipid extraction 
The SC lipids were extracted according to a slightly adjusted Bligh and Dyer procedure as 
described elsewhere22;28. We used a series of chloroform:methanol mixtures (1:2, 1:1, and 2:1 
v/v) for 1 hour each. The extracts were combined and treated with 0.25M KCl and water. The 
organic phase was collected and evaporated under a stream of nitrogen at 40 °C. The obtained 
lipids were redissolved in a suitable volume of chloroform: methanol (2:1 v/v) and stored at 
−20 °C until use. To obtain enough lipids for quantification, the lipid extracts of 2-4 NSEs 
from each donor were pooled. 
HPTLC lipid analysis and ceramide nomenclature
Ceramides with a sphingosine (S), phytosphingosine (P) or 6-hydroxysphingosine (H) 
are linked via an amide to a fatty acid chain, which can be either an estrified ω-hydroxy 
(EO), α-hydroxy (A) or nonhydroxy (N) fatty acid. The standards for HPTLC consisted of 
cholesterol, palmitic acid, stearic acid, arachidic acid, tricosanoic acid, behenic acid, lignoceric 
acid, cerotic acid, and ceramides EOS, NS, NP, EOH, and AP. All other compounds were 
purchased from Sigma. Lipid fractions were visualized and quantified as described before33. 
Quantification of HPTLC was performed using lipid extracts of SC from two experiments for 
each NSE type. Data represent mean and standard deviation of 2 different experiments.
LC/MS lipid analysis
The CERs in the pooled lipid extracts of the NSEs were analyzed using an Alliance 2695 HPLC 
(Waters, Milford, MA) coupled to a TSQ Quantum MS (Thermo Finnigan, San Jose, CA) 
measuring in APCI mode. Separation of free fatty acids was achieved using a LiChroCART 
Purospher STAR analytical column (55 x 2µm i.d. Merck, Darmstadt, Germany) under a flow 
Chapter 3
74
rate of 0.6 ml/min using a gradient system from acetonitrile/H2O to methanol/heptane. The 
ionization mode and scan range was altered to negative mode and 200-600 a.m.u., respectively. 
The total lipid concentration of all samples was around 1 mg/ml and the injection volume was 
set to 10 µl for the analysis of free fatty acids. Quantification of FFAs was performed using 
lipid extracts of SC from two experiments for each NSE type. Data represent the mean and 
standard deviation.
Permeability studies
In vitro permeation studies were performed with butyl para-aminobenzoic acid (butyl-
PABA) as described earlier32 using Permegear in-line diffusion cells (Bethlehem, PA, USA) 
with a diffusion area of 0.28 cm2. SC was hydrated for 1 hr in PBS (pH 7.4) prior to the 
experiment. The donor compartment was filled with 1,5 ml butyl-PABA solution (50 µg 
ml-1 butyl-PABA) in acetate buffer (pH 5.0). The acceptor compartment consisted of PBS 
(pH 7.4), which was perfused at a flow rate of 1.5 ml hr-1. Each experiment was performed 
under occlusive conditions. The temperature of the SC was maintained at 32°C during the 
experiment. Fractions were collected for a 15 hr time period with fixed time intervals of 1 hr. 
The exact volume per collected fraction was determined by weighing (balans hyperTerminal). 
Subsequently, the concentration of butyl-PABA in the acceptor solution was determined using 
HPLC as described earlier32. From this concentration the flux was calculated. Permeability 
studies were performed with at least 6 SC sheets of all NSE types. Data represent the mean ± 
standard error of the mean.
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Supplementary Figures
Figure S1: SC lipid organization. The SC lipids are organized into lipid lamellae, the lamellar phases. 
Human skin contains two lamellar phases, the long periodicity phase (LPP) and the short periodicity 
phase (SPP), with a repeat distance (d) of approximately 13 and 6 nm, respectively. Within the lamellar 
phases, the lipids are organized in a certain density, referred to as the lateral packing, either orthorhombic 
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N/TERT  57,3 ± 2,3°C  2850,3 ± 0,2  
Mock 54,3 ± 0,6°C  2850,7 ± 0,6  



























Figure S2: Effect of FLG-KD on the lateral packing of SC lipids. (a) Representative  rocking vibrations 
in a temperature range from 0-90°C in N/TERT, Mock and FLG-KD NSEs. All NSEs show hexagonal 
packing indicating that knockdown of filaggrin did not affect the lateral packing. (b) the CH2 symmetric 
stretching wavenumbers are plotted as a function of temperature. In this example the calculation of the 
midpoint temperature of the order-disorder transition. Adapted from22. (c) The midpoint order-disorder 
transition temperature and the symmetric stretching frequencies at 32˚C, which corresponds to the 
in vivo skin temperature. FLG-KD did not affect the midpoint order-disorder transition temperature 
nor the symmetric stretching frequencies compared to Mock HSEs. Data represent mean ± SD of 3 
independent experiments.
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Figure S4: quantification of the SC FFAs. (a-c) Chain length distribution of saturated FFA, mono 
unsaturated FFAs (MUFAs) and hydroxyl FFAs, respectively. The FFA chain length distribution of the 
saturated FFA, MUFAs and hydroxyl FFAs was not affected by FLG-KD. 
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Explant human skin equivalents (Ex-HSEs) can be generated by placing a 4mm skin biopsy onto 
a dermal equivalent. The keratinocytes migrate from the biopsy onto the dermal equivalent, 
differentiate and form the epidermis of 1st generation Ex-HSEs. This is especially suitable for 
the expansion of skin material from which only small fragments of skin can be harvested e.g. 
diseased skin. The aim of this study was to evaluate whether 2nd and 3rd generation Ex-HSEs 
can be generated from a single skin biopsy whilst maintaining the epidermal properties of 1st 
generation Ex-HSEs and native human skin. One important advantage of this approach is that 
with only a small skin biopsy, a large amount of study material can be generated. 2nd generation 
Ex-HSEs were produced by placing a biopsy from the 1st generation Ex-HSE onto a new 
dermal equivalent. Likewise, the 3rd generation Ex-HSEs were generated from a 2nd generation 
Ex-HSE biopsy. The 2nd and 3rd generation Ex-HSEs display similar epidermal morphology 
and expression of differentiation markers as in native human skin and 1st generation Ex-HSEs. 
The stratum corneum (SC) lipid properties in 2nd and 3rd generation Ex-HSEs also show many 
similarities with 1st generation Ex-HSEs. However, some  differences were observed in the 
SC lipid properties between the various Ex-HSE generations and native human skin. We 
conclude that the expansion of skin biopsies to the 2nd and 3rd generation Ex-HSEs could 
be a promising method to expand valuable epidermal tissue to analyze morphological and 
differentiation parameters in the native epidermis. 
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Introduction
Human skin equivalents (HSEs) are useful tools for studying the interplay between biological 
processes in the skin including modeling skin diseases1-3, wound healing4-6, cutaneous 
irritation and toxicity tests7-9. A novel method of generating HSEs involves placing full-
thickness 4mm skin punch biopsies onto a fibroblast populated collagen matrix i.e. dermal 
equivalent, forming the so called 1st generation explant human skin equivalents (Ex-HSE)1;10;11. 
We previously demonstrated that the epidermis of 1st generation Ex-HSEs show comparable 
epidermal stratification and differentiation as the original ex vivo skin although the stratum 
corneum (SC) lipid properties could not be reproduced in Ex-HSEs12. Following this study, the 
next step was to investigate whether the amount of tissue generated from the 1st generation Ex-
HSEs can be further expanded by growing a 2nd generation and even a 3rd generation Ex-HSE. 
It is also important to further analyze the SC lipids chain length, saturation and expression of 
some key enzymes involved in SC lipid synthesis because these factors contribute significantly 
to the quality/property of the SC. 
Expansion of epidermal tissue by producing up to three generations of Ex-HSEs can be 
potentially useful for analysis that require larger amounts of skin, which cannot be harvested 
from patients. These may include quantitative protein analysis or combining different 
techniques to study various aspects of diseased skin. This could substantially aid studying 
diseased skin in which only small biopsies can be harvested from patients. A 2nd generation 
Ex-HSE would expand the total epidermal surface area by 40 times compared to the original 
4mm skin biopsy (supplementary Table S1). The 1st generation Ex-HSE was generated from the 
original biopsy harvested from ex-vivo skin. The 2nd generation was produced by harvesting a 
biopsy from the 1st generation Ex-HSE and implanting this onto a fresh dermal substrate. By 
harvesting a biopsy from the 2nd generation Ex-HSE, this approach can be repeated and a 3rd 
generation Ex-HSE can also be grown. During this organ culture, the keratinocytes migrate 
from the implanted biopsy onto the dermal equivalent, proliferate, differentiate and form an 
epidermis.
In native human skin, the SC, which is the outermost layer of the epidermis, consists of 
corneocytes embedded in a lipid matrix. The structure of the SC with the lipid matrix plays an 
essential role in the skin permeability barrier. The main lipid classes present in native human 
SC include free fatty acids (FFAs), ceramides (CERs) and cholesterol (CHOL). These lipids 
form two lamellar phases with repeat distances of approximately 6nm and 13nm referred to 
as short periodicity phase (SPP) and long periodicity phase (LPP) respectively13. Within the 
lipid lamellae, the lipids in native human SC are mainly organized in a dense orthorhombic 




The SC lipid properties, epidermal stratification and differentiation pattern from the 2nd 
and 3rd generation Ex-HSEs were analyzed in order to investigate whether these properties 
are similar to those in the 1st generation of Ex-HSE. Finally, the differentiation and barrier 
properties were compared to the ultimate control, namely native human skin.
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Materials and Methods
Isolation of human dermal fibroblasts
Adult human breast or abdominal skin tissue was obtained from cosmetic surgery after 
written informed consent, according to the Declaration of Helsinki Principles. Dermal 
fibroblasts were isolated as described earlier16 and cultured in Dulbecco’s Modified Eagle 
Medium (DMEM; Invitrogen, Netherlands) supplemented with 5% fetal bovine serum (FBS; 
Hyclone, UT, USA) and 1% penicillin/streptomycin (Sigma)17. Passages 2-5 were used for the 
experiments. 
Generation of human skin equivalents 
Dermal equivalents were generated as described earlier16;18. Briefly, 1mL of a 1mg/mL collagen 
solution was pipetted into filter inserts (Corning Life sciences, Amsterdam, Netherlands). 
After polymerization, 3mL of fibroblast populated (0.4 x 105 cells/mL) collagen (2mg/mL) 
was pipetted on the polymerized collagen. After polymerization, the collagen was cultured 
submerged (1 week) in DMEM supplemented with 5% FBS, 25mM ascorbic acid (Sigma) and 
1% penicillin/streptomycin. 
The various generations of Ex-HSEs were generated as described in detail in supplementary 
Figure S1. These cultures consist of an explant and its outgrowing area. The explant is defined 
as the skin biopsy placed onto the dermal equivalent and the outgrowth is defined as the 
keratinocytes that after migration, proliferate and differentiate to form the main part of 
the Ex-HSE. After the generation of dermal equivalents, full thickness (FT) 4mm fat free 
biopsies obtained from breast skin (referred to as the 1st generation explants, age 17-49), 
were gently pushed onto the dermal equivalents. Subsequently, the HSEs were cultured at 
the air-liquid interface and cultured for two days with DMEM and Ham’s F12 (Invitrogen, 
The Netherlands) (3:1 v/v), 0.5µg/mL insulin (Sigma), 0.5µM hydrocortisone (Sigma), 1µM 
isoproterenol (Sigma), 1% penicillin/streptomycin, 25mM ascorbic acid and 5% FBS. During 
the next two days, the HSEs were cultured in a similar medium as mentioned above with some 
changes. These included 1% FBS, 0.053µM selenious acid (Johnson Matthey, Maastricht, The 
Netherlands), 10mM L-serine (Sigma), 10µM L-carnitine (Sigma), 1µM α-tocopherol acetate 
(Sigma), 25mM ascorbic acid and a lipid mixture of 3.5µM arachidonic acid (Sigma), 30 µM 
linoleic acid (Sigma) and 25µM palmitic acid (Sigma). For the remaining culture period, the 
HSEs were cultured with the same composition of the medium with two changes: i) 7µM 
arachidonic acid and ii) no FBS. The culture medium was refreshed twice a week and the 
HSEs were cultured for 21 days at 37°C, 90% relative humidity and 7.3% CO2. At the end of 
the culture period, the dermal equivalent was covered with a keratinocyte outgrowth from 
the biopsy (1st generation Ex-HSE). During the harvest of the 1st generation Ex-HSE, a biopsy 
from the 1st generation outgrowth was placed onto a new dermal equivalent. This biopsy on 
the new dermal substrate is referred to as the 2nd generation explant and served as the start of 
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the 2nd generation outgrowth. The Ex-HSE was cultured for another 21 days generating the 
2nd generation outgrowth. During harvest, the 2nd generation outgrowth was further passaged 
to produce the 3rd generation Ex-HSE and cultured for 21 days. The fibroblast donor used to 
generate a series of 1st -3rd generations Ex-HSEs was kept the same. 
Morphology and Immunohistochemistry
Ex-HSEs were fixed in 4% (w/v) paraformaldehyde (Lommerse Pharma, The Netherlands), 
dehydrated and embedded in paraffin. For morphological analysis, 5μm sections were stained 
with haematoxylin (2mg/ml) and eosin (4mg/ml). Immunohistochemical analysis for keratin 
10 (K10), filaggrin, loricrin, involucrin, steroyl-CoA desaturase (SCD) and ceramide synthase 
3 (CerS3, analyzed by immunofluorescence) expression was performed as described in 
supplementary materials and methods.
Lipid extraction/analysis
The SC was isolated from native human epidermis and HSEs as previously described19. The 
lipids were extracted from the SC using a modified Bligh and Dyer procedure20. SC extracts 
from the outgrowth of 2-3 Ex-HSEs of the same skin donor were pooled. The lipid composition 
of the explants could not be determined due to insufficient amount of material. Extracts were 
dried under a stream of nitrogen, reconstituted chloroform: methanol (2:1) and stored at 
-20°C. Lipid analysis by high performance thin layer chromatography (HPTLC) and liquid 
chromatography coupled to mass spectrometry (LC-MS) is described in supplementary 
materials and methods.
Fourier transformed infrared spectroscopy (FTIR) and small angle X-ray diffraction 
(SAXD)
FTIR: Isolated SC sheets were hydrated at room temperature over a 27% NaBr solution for 
24 hours. The SC was sandwiched between AgBr windows and mounted into a customized 
heating/cooling cell. A Varian 670-IR FTIR spectrometer (Agilent technologies, CA, USA), 
equipped with a broad-band mercury cadmium telluride detector and cooled with liquid 
nitrogen was used to acquire spectra. The spectra were collected in transmission mode, as 
a co-addition of 256 scans at 1cm−1 resolution. Each spectrum was collected for 4 minutes 
at a 1°C interval from 0°C - 90°C, with frequency range of 600-4000cm−1 and deconvoluted 
using half-width of 5cm-1 and an enhancement factor of 1.7 Bio-Rad Win-IR Pro 3.0 software 
(Biorad laboratories, MA, USA) was used to analyze the spectra. 
SAXD: All measurements were performed at the European synchrotron radiation facility 
(ESRF, Grenoble) at station BM26B. SAXD patterns were detected with a Frelon 2000 charged-
coupled device detector using a microfocus of 25µm x 25µm. The X-ray wavelength and 
sample-to-detector distance were 0.1033nm and 24cm respectively. The scattering intensity 
(I, arbitrary units) was measured as a function of the scattering vector q (nm-1) defined as 
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q= (4πsinθ)/λ, in which θ is the scattering angle and λ is the wavelength of the x-rays. From 
the positions of a series of equidistant peaks (qn), the periodicity (d) of a lamellar phase was 
calculated using the equation d=2nπ/qn, n being the order of a diffraction peak attributed to 
the lamellar phase.
Statistical analysis
Statistical outcomes were determined using Graphpad Prism 5. Two-way ANOVA tests were 
performed to analyze the FFA chain length distribution and paired student t-tests for mid-




2nd and 3rd generation Ex-HSEs show a viable epidermis executing early and late 
epidermal differentiation programs
To determine the morphology and differentiation of the epidermis of the Ex-HSEs, the middle 
region, representing the main part of the outgrowths, was investigated. The original biopsies 
could always be passaged till the 2nd generation (age: 17-49 years). However, from 2 out of the 
4 skin donors (age: 17 and 18 years), the 3rd generation Ex-HSE could be cultured.
The 2nd and 3rd Ex-HSE generations display a fully stratified epidermis (Figure 1). The 
expression of the early (keratin 10 (K10)), and late (filaggrin, loricrin and involucrin) 
differentiation markers was investigated to examine whether their expression changed 
during passaging. The outgrowths of the 2nd and 3rd generation showed the presence of 
K10, filaggrin and loricrin similar to the 1st generation and native human skin (Figure 1, for 
explants see supplementary Figure S3). Early and late differentiation programs were executed 
as demonstrated by the expression of K10 in all suprabasal epidermal layers and filaggrin 
and loricin in the stratum granulosum (SG). The expression of involucrin differed in the 2nd 
and 3rd generation outgrowths compared to the 1st generation. The 2nd generation outgrowth 
shows an intense involucrin staining in the SG, which extends weakly to the upper and lower 
stratum spinousum (SS) and 3rd generation outgrowths show evenly distributed involucrin 
expression over the entire epidermis. However, in the 1st generation outgrowth, involucrin 
expression is most pronounced in the SG and a weak staining is observed in the upper SS 
(Figure 1).
Orthorhombic lateral packing is gradually lost with increasing generations of Ex-HSEs
Our previous studies showed that the 1st generation Ex-HSEs do not fully maintain SC lipid 
properties as in native human skin12. Therefore, we investigated whether passaging to the 
2nd and 3rd generation results in SC lipid properties similar to the 1st generation. The lateral 
packing was examined in the Ex-HSEs by collecting FTIR spectra from 0°C-90°C, focusing 
on lipid chain CH2 rocking vibrations. A hexagonal lipid organization is depicted by a single 
peak at 719 cm-1 and an orthorhombic lipid organisation by two peaks at 719 cm-1 and 730 
cm-1 in the FTIR spectrum. At 0°C, 2nd generation explants show two contours at 719 cm-1 
and 730 cm-1. The 730 cm-1 peak disappears at 24.6±4.2°C. The lateral organization in the 3rd 
generation explants could not be detected due to a low IR signal. The 2nd and 3rd generation 
outgrowths only show a hexagonal packing (Figure 2), as only the 719 cm-1 contour is present 
in the spectrum. When comparing the lateral packing in the 2nd generation explant with the 
1st generation explant and native skin, the 1st generation explant and human skin also show 
two peaks with the 730 cm-1 peak more intense indicating a higher level of orthorhombic 
packing. The 730 cm-1 peak disappears at 47.3±3.1°C and 35.0±7.1°C for human skin and 
the 1st generation explant, respectively (data not shown for human skin). When focusing on 
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the outgrowth, the FTIR spectrum of the 2nd generation outgrowth exhibits only one peak, 
reflecting only a hexagonal lateral packing, while the 1st generation outgrowth shows a small 
fraction of lipids in an orthorhombic packing which disappears at 30±8.5°C.
We also investigated the CH2 symmetric stretching frequency to determine whether the 
conformational ordering of the lipid chains underwent changes during culture. In a crystalline 
organization, the chains are fully extended and the conformational order is high with CH2 
symmetric stretching frequencies below 2850 cm-1. CH2 symmetric stretching frequencies at 






3rd generationNative human skin 1st generation 2nd generation
Figure 1: Cross sections of the outgrowth of 2nd and 3rd generation Ex-HSEs in comparison with 
the 1st generation Ex-HSEs and native human skin that are stained with haematoxylin/eosin (HE). 
Immunohistochemical staining of keratin 10 (K10), filaggrin (FLG), loricrin (LOR), involucrin (INV). 
20x magnification, scale bar represents 30μm. 
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From the thermotropic response curves the mid-point temperature at which the lipid domains 
change from a crystalline state to a liquid state was determined (for detailed explanation, see 
supplementary Figure S4). This is referred to as “Mid-point transition temperature” (MTT). 
















































































Figure 2: FTIR spectra showing the CH2 rocking vibrations of 1
st, 2nd and 3rd generation explants and 
outgrowths as a function of temperature (0°C-90°C). A hexagonal lipid organization is characterized by 
the presence of one peak at 719cm-1 at the CH2 rocking band and an orthorhombic lipid packing by two 
peaks at 719cm-1 and 730cm-1. Generation (gen)
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human skin (p<0.05 and p<0.01 respectively, supplementary Table S5). The CH2 stretching 
frequency at skin temperature (32°C) was also higher in the 2nd generation outgrowths in 
comparison to native human skin (supplementary Table S5, p<0.05). These results indicate 
an increased conformational disordering in the 2nd generation Ex-HSEs compared to native 
skin. However, the CH2 stretching frequency at 32°C and MTT of the 2
nd generation Ex-HSE 
was similar to the 1st generation. 
LPP is present in 2nd and 3rd generations Ex-HSEs
The lamellar lipid organization was examined in the explants and their corresponding 
outgrowths using SAXD. The diffraction profiles show three diffraction peaks denoted by 1, 
2 and 3, indicating the 1st, 2nd and 3rd order diffraction peak of the LPP (supplementary figure 
S6). In addition, the diffraction profiles show the presence of crystalline CHOL domains 
similar to the phase separated CHOL in all Ex-HSEs and native human skin. No statistical 
significance in repeat distance of the LPP was observed between the 2nd and 3rd generation 
explants and outgrowths in comparison to the 1st generation (supplementary Table S6). 
2nd and 3rd generation Ex-HSEs contain the main SC lipid classes in native human skin 
Since we observed changes in the lipid organization of the outgrowth, we examined the 
lipid composition since changes in the lipid composition are causative for changes in lipid 
organization. Firstly, we focused on the three main lipid classes, CERs, CHOL and FFAs 
(Figure 3a). The main SC lipid classes were present in the 2nd and 3rd generation outgrowths 
and no significant changes were observed in the band intensity of CERs and CHOL in the 2nd 
and 3rd generation compared to the 1st generation outgrowth and human skin. Compared to 
native skin, the intensity of the FFAs was reduced in the 2nd and 3rd generation outgrowths as 
was also observed in the 1st generation outgrowth (Figure 3b, p<0.05). Secondly, the 2nd and 3rd 
generation show all CERs present in human SC as detected by HPTLC. The relative intensities 
of the ester linked ω-hydroxy (EO) CERs, CER EOS and CER EOP in the 2nd generation were 
similar to the 1st generation. However, CER EOS and CER EOP relative intensities in the 
2nd generation were significantly higher than in native human skin (EOS: p<0.01 and EOP: 
p<0.05, Figure 3c). No significant differences were observed in the relative intensity of the 
other CER subclasses when comparing the 2nd generation Ex-HSEs with the 1st generation 
and native human skin. Since CerS3 is involved in the synthesis of EO CERs (linking the 
sphingoid base to the ω-hydroxy fatty acid), its expression in the epidermis was analyzed by 
immunofluorescence. CerS3 is expressed weakly in supra-basal layers and intensely in the SG 
in native human skin (Figure 3d). However, all Ex-HSE generations show an intense staining 
of CerS3 in all suprabasal layers.
2nd generation Ex-HSEs show a substantial level of unsaturated FFAs 
HPTLC results revealed that the total FFA level was lower in the 2nd generation Ex-HSE 
compared to native human skin. To analyze the FFA composition in more detail, we examined 
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the chain length distribution and saturation of the FFAs using LC-MS. The FFA chain lengths 
with C16-C18 were excluded from the analysis to avoid false positive results from sebaceous 
lipids and subcutaneous fat from native human skin. 
Analysis of saturated FFAs (SFAs) and mono-unsaturated FFAs (MUFAs) showed that the 
2nd generation contains relatively more MUFAs than SFA in contrast to native human skin 
(significance p<0.05, Figure 4a, b) where the SFAs are always highly abundant compared to 
MUFAs. The abundance of MUFAs in the 2nd generation was not significantly different to that 
in the 1st generation. 
The SFAs chain length in the 2nd generation outgrowths displays a normal distribution. The 
even chain length FFAs are more abundant than the odd chain lengths with FFA C24:0 and FFA 
C26:0 as the most predominant chain lengths. The relative level of long chain (C19:0-C22:0) 
SFAs was significantly higher in the 2nd generation than in native human skin (figure 4c; 
p<0.05). Furthermore, the consistent reduction in very long chain SFAs (C24:0-C28:0) in the 
2nd generation was significant compared with native human skin (Figure 4c; p<0.01). The chain 
length distribution of 2nd generation SFAs was similar to the 1st generation with the exception 
of ultra-long chain FFAs (≥C30:0). These were significantly reduced in the 2nd generation 
compared with the 1st generation (Figure 4c). The chain length distribution of MUFAs in the 
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Figure 3: SC barrier lipids and ceramide synthase 3 (CerS3) expression in 1st, 2nd and 3rd generation 
outgrowths and native human skin. (a) Lipid profiles from human skin and outgrowths of Ex-HSEs. 
Lane 1: Native human skin, Lane 2: 1st generation outgrowth, Lane 3: 2nd generation outgrowth, Lane 
4: 3rd generation outgrowth. (b) Relative intensity of the lipid bands of the main SC lipid classes. (c) 
Relative distribution of the various CER subclasses. (d) CerS3 expression in Ex-HSEs and native human 
skin. 20x magnification, scale bar 50µm. Cholesterol (CHOL), free fatty acids (FFA), ceramides (CER). 
CERs are named according to the nomenclature by Motta et al. and Masukawa et al.21, 22 (see Table S4, 
paired student t-test, *p<0.05, **p<0.01). The data is presented as the mean ± standard deviation from 
four independent experiments. 
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with FFA C20:1 and FFA C24:1 as the most abundant. The relative level of MUFAs with chain 
lengths C19:1 till ≥C30:1 was significantly higher in the 2nd generation than in native human 
skin (Figure 4d; p<0.001). No significant difference was observed in the MUFA chain length 
distribution between the 1st and 2nd generation. 
The expression of stearoyl-CoA desaturase (SCD), a key enzyme in FFA unsaturation was 
analyzed. SCD is expressed in the stratum basale (SB) in native human skin. The 1st and 
2nd generation outgrowths show SCD expression in the SB and SS while the 3rd generation 
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Figure 4: The relative level of (a) saturated FFAs (SFAs) and (b) mono-unsaturated FFAs (MUFAs) 
and the chain length distribution of (c) SFAs and (d) MUFAs in the native human skin, 1st generation 
outgrowths and 2nd generation outgrowths. (e) expression of stearoyl-CoA desaturase (SCD) in Ex-HSEs 
and native human skin. In a and b the SFAs and MUFAs are displayed as a percentage of the total FFAs. c 
and d show the variations in the relative levels of the various SFAs chain lengths and MUFAs respectively 
in relation to the total FFA level (i.e. Total FFAs = SFAs+MUFAs = 100%). *p<0.05, **p<0.01, ***p<0.001. 
The data represented is shown as the mean ± standard deviation of four independent experiments. 20x 




In this study, we investigated whether the tissue generated from the 1st generation Ex-HSEs 
can be further expanded by growing a 2nd generation and even a 3rd generation Ex-HSE. This 
method of generating epidermal tissue can be potentially useful for analysis that require 
larger amounts of skin. For example, in studies that involve skin diseases, the expansion of 
skin tissue eliminates the need to harvest several skin biopsies and provides a means to study 
the progression of skin diseases in vitro which cannot be performed in vivo e.g. investigating 
the invasive behavior of skin cancers. 
The results show that it is possible to passage outgrowth from the 1st generation Ex-HSEs to 
establish 2nd and 3rd generations, which maintain morphology, differentiation process and 
lamellar lipid organization similar to the 1st generation. However, only 50% of human skin 
biopsies could be used to establish the 3rd generation. This may be attributed to differences 
between donors influencing keratinocyte proliferation and differentiation, including age, 
genetic factors and lifestyle. Due to donor confidentiality, information regarding lifestyle and 
genetics could not be obtained. However, skin donors aged 17-18 years could be passaged to 
the 3rd generation and other skin donors ranging from 33-49 years could not. This is in line 
with previous studies in which age was associated with proliferation ability of keratinocytes 
in vitro 21;22. We observed that the expression of K10, filaggrin and loricrin were maintained 
in the 2nd and 3rd generation. However, involucrin expression gradually shifts to the SS and 
finally to the SB in the 3rd generation. This finding may result from changes in the STAT5a/
PPAR-γ pathway as this pathway regulates involucrin expression in differentiating human 
keratinocytes23. Suprabasal expression of involucrin in the epidermis has also been reported 
in other HSEs suggesting that culture conditions may influence the expression of involucrin 
in vitro24;25.
The studies presented here indicate that orthorhombic lipid organization is reduced when 
increasing the number of generations. Therefore the orthorhombic packing cannot be 
reproduced in vitro under conditions described in this study. Only a hexagonal lateral packing 
was observed in the 2nd and 3rd generation outgrowths, similar to other epidermal and full 
thickness HSEs12;25-27. The abundant formation of a hexagonal packing in culture may be 
explained by: a reduction in SC FFAs levels and in their chain lengths or by an increase in 
the relative levels of MUFAs. In addition, studies using model membrane systems show that 
increased MUFA content results in a more hexagonal lipid organization28. 
The 2nd generation outgrowth showed a normal SFA chain length distribution although the 
relative level of SFAs was lower, and MUFAs higher than in native human skin. Furthermore 
the ultra-long chain SFAs (≥C30:0) were lower in the 2nd generation than the 1st generation 
outgrowths and human skin. This may contribute to the absence of the orthorhombic lateral 
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packing in the 2nd generation outgrowths. In contrast to the lateral packing, the LPP repeat 
distance can be maintained in all three Ex-HSE generations. Studies using model lipid 
systems also suggest that increased levels of MUFA mainly affects the lateral packing while 
the lamellar phases are not changed28.
The increase in MUFAs content in the 2nd generation Ex-HSE and other HSEs29 in relation 
to native human skin might be related to the increased expression of SCD. In 2nd generation 
Ex-HSEs, the level of MUFAs is increased, especially the long chain MUFAs (C24:1-C28:1), 
whereas long chain SFAs levels (C24:0-C28:0) are decreased in comparison with native human 
skin. This suggests that FFA processing in the Ex-HSEs is skewed towards unsaturation 
probably due to increased SCD expression and/or activity29. SCD-1 generates C16:1 and 
C18:1 from C16:0 and C18:0, after which most probably the unsaturated FFAs are elongated30. 
We therefore hypothesize that in Ex-HSEs, most FFAs are first unsaturated and thereafter 
elongated. In the absence of measuring the abundance of C16:0 and 18:0 FFAs, the average 
chain length of the FFA is similar between the native human skin and the Ex-HSEs (data not 
shown), which suggests that the main difference in FFA profile is unsaturation.
The relative intensities of EO CERs in the HPTLC plates were increased in 1st until 3rd Ex-
HSE generations and in other HSEs compared to native human skin29. The formation of 
CERs in keratinocytes is partly dependent on ceramide synthases (CerS) which n-acylate 
FFAs to a sphingoid base. An increase in CerS activity or expression, especially, CerS3 (which 
synthesizes very long chain CERs) may contribute to the increased EO CER levels31. PPARβ/δ 
and PPARγ may also play a role in the increased EO CERs in the outgrowths, because PPARβ/δ 
and PPARγ activation stimulates CerS3 expression in human keratinocytes and increases 
EO CERs in the hairless mouse 32;33. Furthermore, increased ω-acyl transferase (generates 
EO CERs from acid condensation of linoleic acid to ultra-long CERs) expression and the 
availability of very long chain FFAs could influence the levels of EO CERs in the outgrowths34. 
The 2nd and 3rd generation Ex-HSEs presented in this study maintain expression of epidermal 
differentiation proteins similar to native skin, except for involucrin. Native human SC lipid 
properties cannot be fully reproduced in Ex-HSEs, however, most lipid properties are similar 
between HSE generations. In addition to the presented Ex-HSEs, we also examined outgrowth 
cultures derived from isolated human epidermal sheets. Before culturing, the epidermis 
of the native human skin was separated by dispase treatment and the epidermal sheet was 
placed onto the dermal equivalent. 2nd and 3rd generation HSEs were also generated and with 
similar epidermal differentiation as in Ex-HSEs (supplementary Figure S5) as well as the lipid 
properties (data not shown).
We conclude from this study that expansion of 4mm skin biopsies on a dermal equivalent 
to the 2nd or 3rd generation, depending on the skin donor, can serve as a method to expand 
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valuable skin material in order to analyze morphological and differentiation parameters as 
in the native epidermis. The lipid organization and composition of native human skin is not 
reproduced in 2nd and 3rd generation Ex-HSEs, which should be considered when performing 
barrier function studies. 
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Figure S1: Generation of Ex-HSEs. A 4mm full thickness biopsy from native human skin is placed onto 
a fibroblast populated collagen matrix. This allows the epidermal cells to migrate and cover the surface 
of the collagen matrix and establish the 1st generation Ex-HSE (a). A small fragment of the 1st generation 
Ex-HSE is placed onto a new fibroblast populated collagen matrix to generate the 2nd generation Ex-HSE 
(b). A similar procedure is repeated with the 2nd generation Ex-HSE to generate the 3rd generation Ex-
HSE (c). Generation (gen), explant (exp), outgrowth (out).
Figure S2: Lipid organization in human stratum corneum. The stratum corneum (SC), the outermost 
part of the epidermis consists of corneocytes which are surrounded by an organized intercellular lipid 
matrix. The lipids are organized in two lamellar phases: the long periodicity phase (LPP) and the 
short periodicity (SPP) phase with a repeat distance of 12nm and 6nm respectively. The lipids are also 
organized in the plane perpendicular to the lamellar organization which is referred to as lateral lipid 
organization. The lipids can be arranged in a liquid (disordered), hexagonal (less dense and ordered) 










Figure S3: Immunohistochemical staining of the explants from 1st, 2nd and 3rd generation Ex-HSEs that 
are stained for keratin 10 (K10), filaggrin (FLG), loricrin (LOR), involucrin (INV) and stearoyl-CoA 
desaturase (SCD). Scale bar represents 30μm, 20x magnification. 
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Figure S4: a) The stretching vibrations of the FTIR spectra from a representative Ex-HSE explant 
is shown as a function of temperature. In a crystalline packing, the chains are fully extended, the 
conformational order of the chains are high and this reflected by low CH2 stretching frequencies less 
than 2850cm-1 (peak centre). Disordered chains, which is characteristic for a liquid phase have CH2 
symmetric stretching frequencies of 2852cm-1 and higher. b) Illustrates the procedure used to calculate 
the midpoint of the crystalline to liquid transition using the CH2 stretching vibrations of the lipids. 
The midpoint transition temperature (MTT) is calculated as the mean of the last wavenumber at the 
beginning (WNstart) of the transition and the first wave number at the end of the transition (WNend). The 
wavenumbers at the beginning and the end of the transition are determined by linear regression. The 
temperature at this calculated wavenumber is referred to as the MTT.
Chapter 4
100






Figure S5: Immunohistochemical staining of the outgrowth of 1st, 2nd and 3rd generation epidermal sheet 
outgrowth HSEs for keratin 10 (K10), filaggrin (FLG), loricrin (LOR), involucrin (INV) and stearoyl-
CoA desaturase (SCD). Scale bar represents 30μm, 20x magnification. 
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Figure S6: Representative diffraction pattern of SC from 1st , 2nd and 3rd generation explants and 
outgrowth. The 1st, 2nd and 3rd order of the LPP are indicated as 1, 2 and 3 respectively. The peak denoted 
by 2 in the diffraction pattern of native human SC is not only based on the 2nd order of the LPP, but also 
the 1st order SPP demonstrated by the increased width of this peak (2). Consequently, the repeat distance 
of the LPP and SPP in native human SC cannot be calculated directly from this diffraction profile. 




Table S1: Epidermal outgrowth in Ex-HSEs 
Ex-HSE Average outgrowth area (cm2)
Increase in epidermal material 
(compared to 4mm biopsy)
Original biopsy 0.127 0
1st generation 2.543 20x
2nd generation 2.543 40x
3rd generation 2.543 60x
Table S2: Primary and secondary antibodies for immunohistochemical staining
Antibodies Clone Dilution Company
Primary antibodies 
Mouse cytokeratin 10 Ab-2 DE-K10 1:800 Neomarkers, USA
Mouse filaggrin Ab-1 FLG01 1:800 Neomarkers, USA
Rabbit Loricrin AF62 1:1200 Covance, USA
Mouse involucrin SY5 1:1200 Sanbio, The Netherlands
Rabbit SCD Polyclonal 1:100 Sigma-Aldrich
Rabbit ceramide synthase 3 (IF) Polyclonal 1:75 Sigma Aldrich
Secondary antibody









Table S3: Solvent system used for barrier lipids analysis by thin layer chromatography
Eluent Composition (v/v) Distance (mm)
1 Dichloromethane/Ethylacetate/Acetone/Methanol (88:8:4:1) 40
2 Chloroform/Acetone/Methanol (76:8:16) 10
3 Hexane/Chloroform/Acetone/Methanol (6:80:12:2) 70
4 Hexane/Chloroform/Hexyl acetate/Acetone/Methanol (6:80:0.1:10:4) 95
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Dihydrosphingosine (dS) NdS AdS EOdS
Sphingosine (S) NS AS EOS
Phytosphingosine (P) NP AP EOP
6-hydroxy sphingosine (H) NH AH EOH
The ceramides in human stratum cornuem contains one of these 4 sphingoid bases 
(dihydrosphingosine (dS), Sphingosine (S), phytosphingosine (P) and 6-hydroxy sphingosine 
(H)) and one of three acyl chains (non-hydroxy fatty acid (N), α-hydroxy fatty acid (A) and 
esterified ω-hydroxy fatty acid (EO)). These result in the 12 ceramide subclasses known to be 
present in human stratum corneum.
Table S5: Midpoint transition temperature and CH2 symmetric stretching at 32°C in Ex-HSEs
Midpoint transition temperature (°C) CH2 symmetric stretching (cm
-1) at 32°C
Ex-HSE Explants Outgrowth Explants Outgrowth
1st generation 60.7 ± 6.4 58.5 ± 7.6 * 2849.8 ± 0.4 2849.8 ± 0.2
2nd generation 58.5 ± 0.7 * 55.4 ± 7.3 ** 2849.9 ± 0.7 2850.0 ± 0.2 *
Native human SC 73.5 ± 1.8 2849.5 ± 0.1
Paired student t-test was performed to determine significance between the native human SC 
and the Ex-HSEs (**p<0.01, *p<0.05).
Table S6: Repeat distance of the LPP in the 1st – 3rd generation explants and outgrowths.
Explants Outgrowth
Ex-HSE LPP repeat distance (d) LPP repeat distance (d)
1st generation 12.1 ± 0.3nm 12.1 ± 0.4nm
2nd generation 11.9 ± 0.5nm 11.8 ± 0.4nm
3rd generation 11.6 ± 0.6nm 11.4 ± 0.4nm
Note: LPP in native human skin is ~13nm 2
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Supplementary Material and Methods
Morphology and Immunohistochemistry
The primary and secondary antibodies are listed in Supplementary table S2. The sections 
were incubated in sodium citrate buffer (pH 6) at 95°C for antigen retrieval. After cooling, 
the sections were blocked with normal horse serum (Vector laboratories Burlingame, CA) 
and incubated with the primary antibody diluted in 1% PBS/bovine serum albumin (BSA) 
overnight at 4°C. 
Staining procedure with amino-ethylcarbazole: Sections were incubated with the secondary 
antibody (Vector laboratories Burlingame, CA) for 30 minutes and thereafter with the ABC 
reagent (Vector laboratories Burlingame, CA) for 30 minutes. The sections were washed with 
0.1M sodium acetate buffer and subsequently in amino-ethylcarbazole (Sigma) dissolved in 
N,N-dimethylformamide (1g/250mL) (Sigma) with 0.1% hydrogen peroxide. All sections 
were counterstained with haematoxylin. 
Immunofluorescence analyses: Sections were incubated with the secondary antibody for 1 
hour and mounted using DAPI Vectashield (Vector laboratories Burlingame, CA).
Lipid analysis
High performance thin layer chromatography (HPTLC): Extracted lipids were analyzed 
by HPTLC as described previously 3. The solvents and running distances are provided in 
supplementary table S3. Co-chromatography of a standard lipid mixture was performed to 
identify the different lipid classes. The standard mixture contained free fatty acids (cerotic 
acid, tricosanoic acid, behenic acid, arachidonic acid, stearic acid, lignoceric acid, palmitic 
acid), cholesterol (Sigma) and ceramides (EOS, EOP, NS, NP, AS and AP, Cosmoferm, The 
Netherlands). The ceramide nomenclature is according to the terminology of Motta et al., and 
Masukawa et al.,4;5 (Supplementary table S4). 
Reverse-phase liquid chromatography mass spectrometry (LC-MS): LC-MS analysis of FFA 
species was performed according to van Smeden et al., 6. An Alliance 2695 HPLC (Waters 
Corp. Milford, MA) was attached to a TSQ Quantum mass spectrometer (Thermo Finnigan, 
San Jose, CA, USA) which measured in atmospheric-pressure chemical ionization (APCI) 
mode. The analysis was performed in negative ionization mode with a scan range of 200-
600 amu. The source heater temperature was set at 450⁰C, and heated capillary at 250⁰C and 
the discharge current at 5 μA. The total sample lipid concentration was 1mg/mL with an 
injection volume of 10 µL. FFA separation was achieved using a LiChroCART Purospher 
STAR analytical column (55 x 2 mm i.d. Merck, Darmstadt, Germany) under a flow rate of 
0.6 mL/min using a binary gradient solvent system of acetonitrile/H2O (90:10) to methanol/
heptane (90:10). The analysis was performed using Xcalibur software version 2.0. The FFA 
chain lengths with C16-C18 were excluded from the analysis to avoid false positive results 
from sebaceous lipids and subcutaneous fat from native human skin.
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Explant cultures of atopic dermatitis biopsies 
maintain their characteristics in vitro 
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Atopic dermatitis (AD) is a common inflammatory skin disorder characterized by various 
epidermal alterations. Filaggrin (FLG) mutations are a major predisposing factor for AD and 
since this discovery, much research focused on this protein. To increase the understanding 
about FLG in AD and to provide a tool for screening of new therapies aimed at FLG 
replacement, in vitro human skin equivalents (HSEs) can be useful tools. In this study we 
aimed to establish an explant HSE (Ex-HSE) for AD, using non-lesional skin from AD 
patients that were wildtype for FLG or harboured homozygous FLG mutations. These Ex-
HSEs were evaluated on whether they maintain in vivo characteristics in vitro and whether 
FLG mutations affect the expression of various differentiation markers.  
FLG mutations did not affect the outgrowth from the biopsy to establish the Ex-HSEs. FLG 
expression was present in healthy skin and that of AD patients without FLG mutations 
and their Ex-HSEs, but hardly present in biopsies from patients with FLG mutations and 
the corresponding Ex-HSEs. AD Ex-HSEs and AD biopsies shared many similarities, i.e. 
proliferation and keratin 10 and loricrin expression, irrespective of FLG mutations. KLK5 
and Lekti expression was not affected by FLG mutations, but altered in the Ex-HSEs.  
Here we show that Ex-HSEs established with biopsies from AD patients maintain their FLG 
genotype-phenotype in vitro and that expression of most proteins in vivo and in vitro remained 
similar. Therefore, this approach is promising as an alternative to genetic engineering 
approaches to study the role of FLG in AD.
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Introduction
Atopic dermatitis (AD) is one of the most frequent occurring inflammatory skin diseases, 
characterized by various epidermal alterations, including a disrupted skin barrier function. 
Currently, AD affects 15-30% of Caucasian children and 2-10% of adults1. Clinically, the 
skin from AD patients is characterized by dry, red and pruritic skin with possible chronic 
or relapsing eczematous lesions. Since the discovery of filaggrin (FLG) mutations as a major 
predisposing factor for AD, much research has been focused on this protein in the context of 
AD2. The role of FLG in formation of the cornified envelope and as a precursor for the NMF is 
well established3-5. However, there is currently no clear relation between the presence of FLG 
mutations and the skin barrier defects in AD In previous studies, reduced FLG expression 
due to mutations in vivo or filaggrin knockdown (FLG-KD) in vitro did not affect various skin 
barrier properties6-9. 
In order to study AD pathogenesis and the role of FLG in AD development, various model 
systems have been used, including murine models and in vitro three-dimensional human skin 
equivalents (HSEs). These murine models include the flaky tail (ft) mouse, which contains 
a homozygous frameshift mutation in the Flg gene. These ft mice are FLG deficient and are 
therefore frequently used as a model to study the role of FLG in the skin barrier10-13. However, 
recent studies have shown that additional mutations in the Tmem79/matt gene were the cause 
of the barrier defects in the ft mice14;15. Due to the morphological and functional differences 
between mouse and man, in vitro skin equivalents might serve as an useful alternative 16. 
Establishing in vitro HSEs involve FLG-KD in keratinocytes to reduce FLG expression, 
thereby mimicking the FLG mutations as seen in vivo in AD patients17-19. Other approaches 
include supplementation of cytokines to mimic lesional AD skin20;21. Whereas these studies 
have used manipulated keratinocytes, either by genetic engineering or through cytokine 
supplementation, in the current study we aimed to establish an explant human skin equivalent 
(Ex-HSE) using the primary keratinocyte outgrowth from non-lesional AD biopsies. Such 
a HSE will represent more closely AD compared to genetically engineered keratinocytes. 
With this approach we wanted to recapitulate features of the original AD biopsies. Earlier 
studies have used this explant approach to establish a HSE for Recessive Epidermolysis 
Bullosa Simplex (REBS) or Squamous Cell Carcinoma (SCC). These studies have shown that 
specific characteristics of these skin disorders, e.g. disturbed differentiation in the SCC skin 
equivalents, persist in vitro when used for establishing skin equivalents22;23. Based on these 
findings, we reasoned that AD biopsies, that were wildtype for FLG (FLG+/+) or harboured a 
homozygous FLG mutation (FLG-/-), could be used to establish HSEs. 
Here we present such a HSE, which was characterized for the expression of various epidermal 
markers for epidermal differentiation, proliferation and desquamation. The results presented 
in this study indicate that FLG mutations results in reduced FLG protein expression in vivo 
and in vitro, as well as in vitro maintenance of other features from the original AD biopsy.
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Material and Methods 
Healthy volunteers and AD Patients
The study was conducted in accordance with the Declaration of Helsinki and was approved 
by the Ethical Committee of the Leiden University Medical Center. All subjects (healthy 
volunteers and AD patients) were recruited by public advertisement and have given written 
informed consent. Three Caucasian healthy volunteers without (history of) dermatological 
disorders and six Caucasian AD patients (age range 20-42, 2 male and 7 female) were included. 
Of the AD patients, three were wildtype (AD FLG+/+) and three had a homozygous filaggrin 
mutation (AD FLG-/-) (FLG genotyping analysis is described below). No dermatological 
products were applied onto the forearms for at least one week prior to the study. From all 
individuals, healthy volunteers and AD patients, two biopsies from non-lesional skin from 
the inner forearm were taken.
FLG genotyping
Heparinized blood was drawn from healthy volunteers and AD patients, and peripheral blood 
mononuclear cells (PBMCs) were isolated by Ficoll density centrifugation. Dry cell pellets 
were stored in -80°C until DNA isolation. From the PBMCs, DNA was isolated using the 
DNeasy Blood and Tissue kit according to the manufacturer’s instructions (Qiagen, Venlo, the 
Netherlands). All individuals were genotyped for the four most prevalent mutations found in 
European Caucasians (2282del4, R501X, S3247X, and R2447X), which cover approximately 
93% of the currently known FLG mutations that have been detected in Western Europe24, 
according the method described earlier (Sandilands, 2007). 
Fibroblast culture 
For the isolation of human dermal fibroblasts, dermis was obtained through overnight 
incubation of freshly obtained skin using dispase II (Roche Diagnostics, Almere, The 
Netherlands). To isolate the fibroblasts, the dermis was incubated for 2 hrs with a collagenase 
II (Invitrogen, Breda, The Netherlands) and dispase II (ratio 1:3 and 3 ml/gr dermis) solution 
at 37°C for 2 hrs. The cells were filtered using a 70 µm cell strainer (BD Biosciences, Breda, The 
Netherlands), and cultured in fibroblast medium at 37°C and 5% CO2 until subconfluency. 
Fibroblast medium consisted of Dulbecco’s modified Eagle’s medium (DMEM, Gibco/
Invitrogen) supplemented with 5% foetal bovine serum (FBS, HyClone/Greiner, Nurtingen, 
Germany), 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen). Culture medium 
was refreshed every 3 days. Fibroblast passages two to five have been used for the experiments.
Explant human skin equivalents (Ex-HSEs)
Upon arrival, fresh punch biopsies (4 mm) from the inner forearm from healthy volunteers 
and from AD patients were rinsed three times in sterile phosphate-buffered saline (PBS). 
Thereafter, one biopsy was immediately fixed in 4% paraformaldehyde and one biopsy was 
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placed on dermal equivalents which were constructed as described earlier25-27. In short, rat-tail 
collagen was seeded with 1.25x105 fibroblasts/ml and incubated for at least 1 and maximally 
7 days under submerged conditions. 
All explants were cultured at the air-liquid interface under serum-free conditions for 3 weeks. 
The medium used during this period was composed of DMEM and Ham’s F12 medium (3:1 
ratio) supplemented with, 0.5 µm hydrocortisone, 1 µM isoproterenol, 0.1 µM insulin (Sigma-
Aldrich, Zwijndrecht, The Netherlands), 100 U/ml penicillin and 100 µg/ml streptomycin, 
53 µM selenious acid, 10 mM l-serine, 10 µM l-carnitine, 7 µg/ml, β-dextrin, 1 µM DL-α-
tocopherol-acetate, 100 µg/ml ascorbic acid phosphate and a lipid supplement containing 
2.4x105 M bovine serum albumin (Sigma-Aldrich), 25 µM palmitic acid, 30 µM linoleic acid 
and 7 µM arachidonic acid .
Immunohistochemistry 
After the culture period, Ex-HSEs were fixed in 4% paraformaldehyde, dehydrated and 
paraffin embedded. The morphology of the biopsies and skin equivalents was performed on 5 
µm sections using haematoxylin and eosin (HE) staining. 
Immunohistochemical analysis was performed to detect markers specific for keratinocyte 
proliferation, basement membrane formation and epidermal differentiation. For 
immunohistochemical analysis, 5 µm sections were cut, deparaffinised and rehydrated, 
followed by heat-mediated antigen retrieval. After blocking non-specific binding with PBS 
containing 1% BSA and 2% normal human serum (NHS, Sanquin, Leiden, the Netherlands), 
primary antibodies were incubated overnight at 4°C. The used primary antibodies were: Ki67 
(1:100, clone MIB1, DAKO, Glostrup, Germany), Collagen type IV (1:75, clone MAB1430, 
Chemicon, Melbourne, Vic Australia), Keratin 10 (K10, 1:100, clone DE-K10, Labvision/
Neomarkers, Fremont CA, USA), Loricrin (1:1000, clone AF62, Covance, Rotterdam, the 
Netherlands), Kallikrein-related peptidase 5 (KLK5, 1:400, polyclonal, Santa Cruz, Heidelberg, 
Germany), Lympho-epithelial Kazal-type-related inhibitor (Lekti, 1:20, clone 1C11G6, 
Invitrogen, Breda, the Netherlands). Following incubation with the appropriate secondary 
antibody, the streptavidin-biotin-peroxidase system (GE Healthcare, Buckinghamshire, UK) 
was used according to the manufacturer’s instructions with 3-amino-9-ethylcarbazole (AEC) 
for visualization. The sections were counterstained shortly with haematoxylin and sealed 
with Kaiser’s glycerin. For the collagen type IV staining, a protease treatment using a 0.025% 
protease solution (Sigma, Zwijndrecht, the Netherlands) was performed prior to incubation 
with the primary antibody.
Immunofluorescence
For immunofluorescence analysis, 5 µm sections were cut, deparaffinised and rehydrated, 
followed by heat-mediated antigen retrieval. Hereafter, non-specific binding was blocked by 
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using PBS containing 1% BSA and 2% NHS followed by overnight incubation at 4°C with 
the primary antibody for filaggrin (FLG, 1:1000, Covance, Rotterdam, the Netherlands). 
Subsequently, sections were incubated with the appropriate secondary antibody (Rhodamine 
Red, 1:300, Jackson ImmunoResearch, Amsterdam, The Netherlands). The sections 
were mounted with Vectashield containing DAPI for visualization of the nuclei (Vector 
Laboratories, Amsterdam, the Netherlands).
Proliferation index
The proliferation index was determined by an independent researcher through counting the 
number of Ki67 positive nuclei in a total number of 100 basal cells (×100%) on three locations 
per slide for three different donors and their corresponding skin models. Data represent mean 
+ standard error of the mean.
5
Explant cultures of atopic dermatitis biopsies 
113
Results 
Explant cultures of AD biopsies with filaggrin mutations display normal epidermal 
morphogenesis
To evaluate whether AD biopsies can be used to establish Ex-HSE and whether FLG loss-
of-function mutations affect epidermal regeneration, 4 mm biopsies from non-lesional AD 
skin were placed onto a fibroblast-populated collagen matrix. These AD patients were either 
wildtype (AD FLG+/+) or had homozygous FLG mutations (R501X or 2282del4, AD FLG-/-). 
After culturing for 21 days at the air-liquid interface, keratinocytes have grown out from the 
biopsy in a lateral fashion and covered over 90% of the collagen matrix (Figure 1a). This was 
irrespective of the presence of FLG mutations. The biopsies from healthy volunteers and AD 
patients displayed the presence of all epidermal layers; the stratum basale, stratum spinosum, 
stratum granulosum and stratum corneum, irrespective of the presence of FLG mutations 
(Figure 1b). The Ex-HSEs established with biopsies from healthy volunteers (healthy Ex-HSE), 
AD patients without FLG mutations (AD Ex-HSE(+/+)) or with FLG mutations (AD Ex-
HSE(-/-)) displayed the presence of all the epidermal layers, similar to the original biopsies. 
In addition, the number of viable cell layers was comparable between healthy Ex-HSE, AD 
Ex-HSE(+/+) and AD Ex-HSE(-/-). FLG expression was present in the granular layer of the 
epidermis from healthy volunteers and AD FLG+/+, whereas the AD FLG-/- biopsies showed 
almost complete absence of FLG, as demonstrated by an immunofluorescence staining 
(Figure 1c). More importantly, whereas the healthy Ex-HSE and the AD Ex-HSE(+/+) 
showed pronounced FLG expression in the granular layer, the AD Ex-HSE(-/-) displayed an 
almost complete absence of FLG protein expression, similar to the original biopsies from 
these patients (Figure 1c).
AD Ex-HSEs maintain similar expression of differentiation markers
After evaluation of the morphology and FLG protein expression, the Ex-HSEs were further 
characterized for their expression of various epidermal markers. The presence of the basement 
membrane was assessed by collagen type IV staining. Biopsies from healthy volunteers, AD 
FLG+/+ and AD FLG-/- showed a continuous collagen type IV expression at the dermal-
epidermal junction indicating the presence of a normal basement membrane (Figure 2A). 
Early differentiation was assessed by a keratin 10 staining. Keratin 10 was expressed in all 
suprabasal cell layers of the epidermis from biopsies from healthy volunteers and AD patients, 
irrespective of FLG mutations (Figure 2a). Terminal differentiation was assessed by staining 
for involucrin and loricrin. Involucrin expression was present in the granular layer and in 
the upper spinous layers of all biopsies, irrespective of FLG mutations  (Figure 2a). However, 
whereas the biopsies from healthy volunteers and AD FLG+/+ patients display continuous 
loricrin expression in the upper two granular layers, in the biopsies from the AD FLG-/- 
loricrin expression was strongly reduced in the uppermost granular layer (arrows, Figure 2a). 
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Figure 1: Establishing an Ex-HSE using biopsies from AD patients and healthy volunteers. (a) An 
example of an Ex-HSE established by placing an AD biopsy onto a fibroblast populated collagen matrix. 
Biopsies from both healthy and AD patients (FLG+/+ and FLG-/-) gave similar results, i.e. coverage 
of at least 90% of the collagen matrix. Dotted line indicates the boundaries of the outgrowth, solid line 
indicates the original biopsy. (b) Cross-sections are shown of biopsies and their corresponding Ex-HSEs. 
All epidermal layers were present in all biopsies and their Ex-HSEs, irrespective of FLG mutations, as 
shown by haematoxylin and eosin staining. (c) Immunofluorescent staining for FLG showing reduced 
FLG expression in the granular layer of AD FLG(-/-) and AD Ex-HSE(-/-). Scale bar indicates 50 µm.
a
Healthy AD FLG +/+ AD FLG -/-
Healthy Ex-HSE AD Ex-HSE(+/+) AD Ex-HSE(-/-)
b
c
Healthy Ex-HSE AD Ex-HSE(+/+) AD Ex-HSE(-/-)
Healthy AD FLG +/+ AD FLG -/-
 
a
Healthy AD FLG +/+ AD FLG -/-
Healthy Ex-HSE AD Ex-HSE(+/+) AD Ex-HSE(-/-)
b
c
Healthy Ex-HSE AD Ex-HSE(+/+) AD Ex-HSE(-/-)
Healthy AD FLG +/+ AD FLG -/-
 
a
Healthy AD FLG +/+ AD FLG -/-
Healthy x-HSE AD x-HSE(+/+) AD x HSE(-/-)
b
c
Healthy x-HSE AD x-HSE(+/+) AD x HSE(-/-)
Healthy AD FLG +/+ AD FLG -/-
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Figure 2:  Expression of epidermal markers is maintained in AD explant HSEs. Immunohistochemical 
staining for collagen type IV, Keratin 10 (K10), involucrin and loricrin in (a) biopsies from healthy 
volunteers and AD patients and (b) their corresponding Ex-HSEs. Collagen type IV expression was 
continuously expressed at the dermal-epidermal junction in all specimens. K10 expression was present 
in all suprabasal cell layers of the biopsies and their corresponding Ex-HSEs. Involucrin was expressed 
in the granular layer of the biopsies but the expression was increased in their corresponding Ex-HSEs. 
Loricrin expression was present in the granular layer of healthy volunteers and AD FLG+/+ biopsies and 
their corresponding Ex-HSEs, but the expression was reduced in the AD FLG-/- biopsies and reduced 
and rather patchy in the AD Ex-HSE(-/-). Scale bar indicates 50 µm, arrows indicate residual loricrin 
expression. (c) Shown is a graph representing the proliferation index of the initial biopsies (white bars) 
and Ex-HSEs (black bars) was similar and not affected by the presence of FLG mutations. Data represent 








































All Ex-HSEs showed the formation of a basement membrane as assessed by a collagen type IV 
staining, similar to their original biopsies (Figure 2b). In all Ex-HSEs, keratin 10 expression 
was present in all suprabasal layers indicating that early differentiation was similar in the 
Ex-HSEs compared to the original biopsies. Involucrin expression was present in almost 
all suprabasal layers of all Ex-HSEs, irrespective of presence of FLG mutations. This earlier 
expression of involucrin was different in the Ex-HSEs compared to the original biopsies. 
Expression of loricrin in the Ex-HSEs was present in the granular layer of healthy Ex-HSE and 
AD Ex-HSE(+/+), similar to their original biopsies. However, the AD Ex-HSE(-/-) displayed 
a reduced and rather patchy loricrin expression in the granular layer (arrows, Figure 2b). 
To evaluate whether proliferation was affected in the AD Ex-HSEs and/or is influenced by 
FLG mutations, a staining for the proliferation marker Ki67 was performed. The proliferation 
index in biopsies from healthy volunteers (24.7±0.7), AD FLG+/+ patients (23.7±4.9) and 
AD FLG-/- patients (21.7±6.2) was not different, whereas the Ex-HSEs showed a proliferation 
index of 27.5±0.5 (healthy Ex-HSE), 23.7±1.7 (AD Ex-HSE(+/+)) and 28.3±3.5 (AD Ex-
HSE(-/-)) (Figure 2c).   
5
Explant cultures of atopic dermatitis biopsies 
117
AD Ex-HSEs show alterations in the expression of desquamation-related enzymes
To evaluate whether the expression of enzymes involved in the desquamation process were 
affected in AD biopsies and in Ex-HSEs, immunohistochemical analyses for Kallikrein-
related peptidase 5 (KLK5) and Lympho-epithelial Kazal-type-related inhibitor (Lekti) 
were performed. In the biopsies, both enzymes are expressed in the granular layer of the 
epidermis and unaffected by the presence of FLG mutations (Figure 3a). In the Ex-HSEs, 
KLK5 expression is continuously present in the granular layer of the healthy Ex-HSE and AD 
Ex-HSE(+/+). However, in the AD Ex-HSEs(-/-), KLK 5 expression was reduced and patchy 
(Figure 3b). In one case, KLK5 expression was barely present in the granular layer of the AD 
Ex-HSE(-/-) (data not shown). Compared to the biopsies, Lekti showed a different expression 
pattern in all Ex-HSEs. In the biopsies, Lekti is expressed in the uppermost 2 granular layers, 
while in all Ex-HSEs the expression is present in the granular layer as well as in the upper layer 
of the stratum spinosum  (Figure 3b).
Kallikrein 5
Lekti
Healthy AD FLG +/+ AD FLG -/-
Kallikrein 5
Lekti
Healthy Ex-HSE AD Ex-HSE(+/+) AD Ex-HSE(-/-)
a
b
Figure 3: Expression of desquamation related enzymes in Ex-HSEs. Shown are cross sections of the 
initial biopsies (A) and explant-HSE cultures (B). Immunohistochemical staining for Kallikrein-related 
peptidase 5 (KLK5) and Lympho-epithelial Kazal-type-related inhibitor (Lekti) in (a) biopsies from 
healthy volunteers and AD patients and (b) their corresponding Ex-HSEs. Both KLK5 and Lekti are 
expressed in the granular layer of the biopsies, irrespective of FLG mutations. In healthy Ex-HSE and 
AD Ex-HSE(+/+), KLK5 expression is present in the granular layer, but reduced in the AD Ex-HSE(-/-). 
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The objective of the current study was to establish an in vitro explant human skin equivalent 
(Ex-HSE) for AD. Previous studies have used FLG-KD in keratinocytes or cytokine 
supplementation to mimic AD in vitro. In the current study we have used biopsies from non-
lesional skin from AD patients, wildtype for FLG (FLG+/+) or harboured a homozygous FLG 
loss-of-function mutation (FLG-/-, R501X or 2282del4), which were placed onto a fibroblast-
populated collagen matrix. The main objective was to evaluate whether we can maintain 
characteristics from the original biopsy in vitro and to evaluate whether FLG mutations 
play a role in the epidermal morphogenesis of the Ex-HSEs. FLG mutations did not affect 
the ability to form an Ex-HSE. Earlier studies showed that reduced profilaggrin expression 
eliminate the granular cell layer by abolishing keratohyalin granules and FLG monomers from 
the epidermis28. In the current study, AD-biopsies and the generated Ex-HSEs display the 
presence of all epidermal layers, including the granular layer. More importantly, the presence 
of FLG mutations resulted in reduced FLG protein expression in the biopsies as well as in the 
outgrowth areas of the corresponding Ex-HSEs. 
To the best of our knowledge, so far no studies have been conducted in which the effect of 
FLG mutations on the expression of various epidermal proteins in vivo and in vitro within the 
same patient has been evaluated. The role of FLG monomers in aggregating keratin filaments, 
as a component of cornified cell envelope, and as a source of free amino acids for the natural 
moisturizing factor has been well established29. Furthermore, FLG was found to be associated 
with particularly keratin 1 and 105. In the current study we show that the expression of keratin 
10 was similar in all biopsies and Ex-HSEs, irrespective of FLG mutations. These findings are 
similar to those in which HSEs were generated after FLG-KD in keratinocytes. In these FLG-
KD HSEs no effect on keratin 10 expression was observed17;18. 
Since the FLG gene is located in the epidermal differentiation complex, mutations in FLG 
might affect the expression of other genes and proteins located in this complex, e.g. involucrin 
and loricrin. The expression of involucrin in the biopsies was not affected by the presence 
of FLG mutations. However, in all Ex-HSE, involucrin was expressed earlier, irrespective 
of FLG mutations. These observations are in line with earlier studies which characterized 
various in vitro HSEs27. Loricrin expression was reduced in AD FLG-/- biopsies as well as 
in their corresponding Ex-HSEs, which implies that the reduction of FLG expression is not 
compensated by loricrin. A relation between loricrin and filaggrin expression was shown 
in a recent study, in which one of the terminal domains of profilaggrin was associated with 
loricrin30. The underlying mechanism of how the FLG mutations affect loricrin expression was 
beyond the scope of this research. Lentiviral-mediated knockdown of profilaggrin in primary 
keratinocytes was shown to result in a hyperproliferative epidermis in HSEs31. However, in 
the Ex-HSEs established with FLG-/- biopsies, we did not observe an effect of FLG mutations 
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on epidermal proliferation. The observation that FLG mutations, i.e. R501X and 2282del4, 
do not affect proliferation might indicate that such mutations do not affect the presence of (a 
partly) functional profilaggrin. Other studies showed the presence of a truncated profilaggrin 
in the epidermis of human Ichthyosis vulgaris patients, as well as in the flaky tail mouse10;32-34. 
Processing of profilaggrin is controlled by a complex network of serine proteases, including 
KLK5 and Lekti35-38. Although we didn’t observe an effect of FLG mutations on KLK5 
expression in vivo, in the AD Ex-HSEs(-/-) a reduced KLK5 expression was observed. Since 
desquamation is absent in HSEs, the underlying mechanisms as well as the consequences of 
this reduced KLK5 in the AD Ex-HSEs(-/-) are difficult to address. Lekti loss-of-function 
mutations are the underlying cause of Netherton syndrome, a rare skin disorder that shares 
many similarities with AD. Lack of Lekti has been shown to result in premature profilaggrin 
processing39, due to uncontrolled activity of proteases during formation of the cornified 
envelope. However, here we show that lack of FLG does not affect Lekti expression. The 
increased Lekti expression in the Ex-HSEs might result in increased Lekti activation and a 
subsequent increased inhibition of KLK5 activity, which was observed in various HSEs40. 
Such a change in Lekti expression in HSEs might therefore (partially) explain the absence of 
desquamation in vitro. 
In conclusion, we present a novel AD-HSE that is established with biopsies from non-lesional 
AD skin that was wildtype for FLG or harbour a homozygous FLG loss-of-function mutation. 
We have shown that most of the in vivo AD characteristics, including FLG genotype-
phenotype, are maintained in vitro. Therefore, we believe that this approach is a promising 
alternative to FLG-KD in keratinocytes to mimic this in vivo feature of AD in vitro, in order 
to better study and understand the role of FLG in AD. Furthermore, this Ex-HSE model 
might aid to the development and evaluation of therapies aimed at FLG protein replacement 
therapy41;42.  
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Background Atopic dermatitis is an inflammatory skin disease that is characterized by a 
reduced skin barrier function, reduced filaggrin (FLG) expression as well as increased 
colonization by Staphylococcus aureus.
Objective The current study focused on the possible involvement of FLG in epidermal 
colonization by S. aureus and/or whether it affects the epidermal defence mechanisms, 
including the expression of antimicrobial peptides (AMPs) and enzymes involved in stratum 
corneum barrier lipid synthesis. Furthermore, IL-31 has been shown to reduce FLG expression, 
but its effects on bacterial colonization and on the expression of AMPs and enzymes involved 
in the barrier lipid synthesis are not known. 
Material and Methods We established N/TERT-based epidermal models (NEMs), after FLG 
knockdown (FLG-KD) and/or cultured with IL-31, that were colonized with S. aureus for 24 
hrs.
Results Both FLG-KD and IL-31 supplementation resulted in significantly increased epidermal 
S. aureus colonization, as well as in an upregulation of S. aureus-induced IL-8 expression. 
IL-31, but not FLG-KD, prevented S. aureus-induced upregulation of mRNA expression for 
the AMPs humanβ-defensin 2 and -3 and RNAse7, whereas psoriasin expression remained 
unchanged. Furthermore, the S. aureus colonization induced changes in mRNA expression 
of ELOVL4 was not affected by FLG-KD, but was blocked by IL-31. Expression of SCD-1 and 
Gcase mRNA was reduced by IL-31, but not by FLG-KD. 
Conclusion This study shows that NEMs, with FLG-KD and/or cultured in the presence of 
IL-31, mimics the skin of atopic dermatitis patients in several aspects, including enhanced 
bacterial colonization, increased inflammatory and reduced protective responses.  
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Introduction
Atopic dermatitis (AD) is a frequently occurring chronic inflammatory skin disease 
characterized by a reduced skin barrier function. Whereas over 90% of the AD patients show 
skin colonization by Staphylococcus aureus, only 5% of the healthy individuals is colonized by 
this bacterium1(Roll et al., 2004). The mechanism underlying this increased host susceptibility 
in AD patients is less understood. To survive on human skin, bacteria have to overcome 
various barriers, including acidic conditions, fatty acids and antimicrobial peptides (AMPs). 
S. aureus colonization of healthy skin is usually transient. However in case of a dysfunctional 
skin barrier as seen in AD patients, S. aureus produces factors that promote adhesion, e.g. 
fibronectin binding proteins, which result in an increased colonization and the subsequent 
inflammatory response2. In addition, S. aureus might play a role in the alterations in the 
stratum corneum (SC) lipid composition as seen in AD, through their suggested ability to 
alter the expression of enzymes involved in SC lipid synthesis3. 
To date, the association between AD and filaggrin (FLG) mutations is one of the strongest 
genotype linkage observed in complex human genetic disorders4;5. FLG is initially transcribed 
as profilaggrin, which during epidermal differentiation, is cleaved into 10-12 FLG monomers 
that bind to keratin filaments to ensure corneocyte rigidity. Subsequently, FLG is broken 
down by various enzymes, including caspase-14, into small peptides and free amino acids, 
i.e. urocanic acid (UCA) and pyrrolidonic carboxylic acid (PCA), which are components of 
the natural moisturizing factor6. In addition to their contribution to skin hydration, UCA and 
PCA may also be involved in regulation of SC pH and reduced UCA and PCA levels were 
found to be associated with FLG null mutations as well as with disease severity7-9. 
Lesional AD skin is characterized by increased levels of Th2 cytokines of which IL-31 has 
been shown to play an important role10. IL-31 overexpressing transgenic mice display skin 
inflammation, pruritus and severe dermatitis11;12. Furthermore, IL-31 has been shown to 
reduce FLG expression in organotypic human skin models13. While the Th2 cytokines IL-4 
and IL-13 have been shown to reduce the expression of the antimicrobial peptides (AMPs) 
human β-defensin 2 and 3 (hBD-2 and hBD-3) in vitro, the effect of IL-31 on AMP expression 
and the innate immune response is still unknown14;15. Furthermore, IL-8 is known to play 
an important role in skin inflammation, both after injury and infection, through attracting 
various immune cells,  e.g. neutrophils and dendritic cells, and increased IL-8 expression was 
observed in AD which was associated with the presence of S. aureus16. 
The aim of the current study was to evaluate whether reduced FLG expression contributes to 
epidermal S. aureus colonization. Therefore, we established a novel N/TERT-based epidermal 
model (NEM) after knockdown of filaggrin (FLG-KD) and/or IL-31 supplementation. These 
NEMs allowed us to study whether these two factors affect epidermal colonization with S. 
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aureus. Moreover, we could study their effects on the expression of inflammatory mediators, 
AMPs and enzymes involved in SC barrier lipid synthesis.  
Here we demonstrate for the first time that both FLG-KD and IL-31 supplementation resulted 
in enhanced epidermal S. aureus colonization of NEMs. This S. aureus colonized in vitro 
epidermal model could therefore be a promising tool for testing novel antibacterial agents for 
the treatment of the infectious complications of AD.
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Material and Methods 
N/TERT keratinocyte cell line
The N/TERT keratinocyte cell line was purchased from Harvard Medical School (USA) and 
cultured under low confluency (<40%) at 37°C and 7.3% CO2 in keratinocyte-serum free 
medium (K-SFM, Invitrogen, Breda, the Netherlands) supplemented with the following 
final concentrations; 25 µg/ml BPE, 0.4 mM CaCl2, 0.2 ng/ml hEGF, 100 U/ml penicillin and 
100 μg/ml streptomycin (Invitrogen, Bleiswijk, the Netherlands). The culture medium was 
refreshed every three days.
Transfection 
Knockdown of filaggrin in N/TERT cells was performed as described earlier17(van, V et al., 
2013). In short, N/TERT cells were transfected with pLKO.1-puro plasmid containing shRNA 
against filaggrin (TRCN0000083680) or control (Mock, TRC1.5-SHC001) using the Amaxa 
human keratinocyte nucleofector kit (Lonza, Breda, the Netherlands). After transfection, the 
cells were cultured similar to the N/TERT cells, except for the addition of puromycin to the 
KSFM medium (1 µg/ml). 
N/TERT-based epidermal model (NEM) 
The NEMs were constructed by seeding 2x105 cells on insert filters (ThinCert 12 well, 
Greiner bio-one, Alphen aan den Rijn, the Netherlands) in Dermalife K medium including 
lifefactors (Lifeline Cell Technology, Walkersville, MD) till confluency. Dermalife medium 
was supplemented with 10 μM ι-carnitine (Sigma, Zwijndrecht, the Netherlands), 10 mM 
ι-serine (Sigma), 1 μM hydrocortisone, 1 μM isoproterenol, 0.1 μM insulin, 53 μM selenious 
acid (Sigma), 100 U/ml penicillin and 100 μg/ml streptomycin (Invitrogen). Thereafter, 
they were cultured in CNT medium (basal medium plus supplement kit, CellnTec, Bern, 
Switserland), supplemented with 24 µM bovine serum albumin, 25 μM palmitic acid, 15 μM 
linoleic acid and 7 μM arachidonic acid (all from Sigma). Next, cultures were lifted to the 
air/liquid interface and after one day the linoleic acid concentration was increased to 30 μM. 
Medium was refreshed every 2 days. NEMs were cultured at the air/liquid interface for 10 
days at 37 °C and 7.3% CO2 prior to infection. For IL-31 supplementation, IL-31 (30 ng/ml, 
R&D Systems, Minneapolis, USA) was added to the medium once 5 days prior to inoculation 
and once on the day of inoculation. 
Colonization of NEMs
Methicillin resistant S. aureus  (MRSA) strain LUH14616, a clinical isolate that was kindly 
provided by S. Croes18, was used in this study. Bacteria were preserved for prolonged periods 
in nutrient broth supplemented with 20% (vol/vol) glycerol at -80°C. Inocula from frozen 
cultures were grown overnight at 37°C on sheep blood agar plates (bioMérieux, Zaltbommel, 
the Netherlands). To create a log-phase growth culture, LUH14616 was cultured for 2.5 hrs 
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at 37°C in Tryptic Soy Broth (TSB) (Oxoid, badhoevedorp, the Netherlands) at 200 rpm. 
This suspension was centrifuged for 10 min at 1200 rpm and resuspended in phosphate-
buffered saline (PBS; pH 7.4) to a concentration of 3.3x105 CFU/ml, calculated from the 
absorbance of the suspension at 600 nm.  Next, NEMs were inoculated with 300 µl of the 
bacterial suspension at 37°C in 7.3% CO2. After 1 hr, the bacterial suspension was aspirated to 
remove the non-adherent bacteria. After 24 hrs the non-adherent bacteria were removed by 
washing the NEMs with 1 ml of PBS. This bacterial suspension was serial diluted and plated 
onto diagnostic sensitivity test agar (DST) (Oxiod). These plates were incubated for 24 hrs 
at 37°C, after which the colony forming units (CFU) were counted. Lower limit of detection 
was 20 CFU/ml. To determine the number of adherent bacteria, the NEMs were mechanically 
homogenized using a glass Potter-Elvehjem tissue homogenizer and resuspended in 1 ml PBS, 
then serial diluted and plated onto DST plates and the number of CFUs was determined as 
above and is described previously19. 
Immunohistochemistry
Morphological and immunofluorescent analysis was performed on 5 µm paraffin-embedded 
NEM sections. For analysis of morphology sections were cut, deparaffinized, rehydrated, 
and stained with haematoxylin and eosin (HE). For analysis of filaggrin expression, sections 
were cut, deparaffinised and rehydrated, followed by heat-mediated antigen retrieval. After 
blocking non-specific binding using PBS containing 1% bovine serum albumin (BSA, Sigma) 
and 2% normal human serum (NHS, Sanquin, Leiden, the Netherlands), the sections were 
incubated overnight at 4°C with primary antibody for filaggrin (1:1000; Covance, Rotterdam, 
the Netherlands). After washing with PBS sections were incubated with secondary antibody 
Goat anti-Rabbit (Rhodamine Red, 1:300, Jackson ImmunoResearch, Amsterdam, the 
Netherlands). The sections were mounted with Vectashield containing DAPI for visualization 
of the nuclei (Vector Laboratories, Amsterdam, the Netherlands). 
RNA isolation, cDNA synthesis and qPCR analysis
RNA isolation was performed using the Qiagen RNeasy mini kit (Qiagen, Venlo, the 
Netherlands) according to the manufacturer’s instructions. Prior to RNA isolation, NEMs 
were incubated in 500 µl of RLT buffer (Qiagen) and homogenized using a fine syringe. To 
remove  bacterial residues, the samples were spun down at 10.000 rpm for 5 min after which 
350 µl of RLT buffer was aspirated.  
cDNA was synthesized with 1 µg RNA using the iScript cDNA synthesis kit (BioRad, 
Veenendaal, The Netherlands) according to the manufacturer’s instructions. PCR reactions 
were based on the SYBR Green method (BioRad) using the CFX384 system (BioRad) and 
the primers listed in Table 1. Expression analysis was performed using the CFX software with 
the ΔΔCt method and the reference genes β-2-microglobulin (B2M) and β glucuronidase 
(GUSB).
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Table 1: primer sequences 




Rnase 7 GGAGTCACAGCACGAAGACCA CATGGCTGAGTTGCATGCTTGA 
Psoriasin AGACGTGATGACAAGATTGAC TGTCCTTTTTCTCAAAGACGTC
Elovl 1 GGAGCTCCAGGTATTGCCAAGG AGCCGTGGTCCCTGTAGAGCA
Elovl 4 GGGTTGCAGGAGGACAAGCATT GAGACAGTGCCGTGTGCCCAA






Enzyme-linked immunosorbent assays  
Protein content of culture media was determined by enzyme-linked immunosorbent assays 
(ELISA). Measured were the levels of interleukin-8 (IL-8) (Biosource, Invitrogen), and human 
beta defensin-2 (hBD-2) (Phoenix Pharmaceuticals, Karlsruhe, Germany). All measurements 
were performed according to the manufacturer’s instructions. 
Statistical analysis
Statistical analysis was conducted using Graph Pad Prism, version 5.04. The effect of IL-31 on 
FLG mRNA expression was analysed using a paired t-test. CFU data and IL-8 ELISA data was 
analysed using one-way ANOVA. qPCR data was analyzed by two-way ANOVA. P values of 




Reduced filaggrin expression after knockdown and/or IL-31 supplementation in NEMs
To study the role of FLG in epidermal S. aureus colonization, we established a NEM after FLG-
KD. In addition, since the Th2 cytokine IL-31 was shown to reduce FLG expression in human 
organotypic skin models and is associated with AD, IL-31 (30 ng/ml) was supplemented 
to the culture medium of both Mock and FLG-KD NEMs 13. After 10 days of air-exposed 
culturing, the NEMs were evaluated for their morphology. NEMs that were generated after 
FLG-KD displayed an epidermal morphology similar to native human skin, i.e. all epidermal 
layers, including the SC, were present (Figure 1a). FLG-KD resulted in 70% reduction in 
FLG mRNA expression compared to the control, Mock (P<0.01, Figure 1b). Reduced FLG 
Fig. 1. FLG-KD and IL-31 supplementation reduce filaggrin mRNA and protein expression in NEMs. 
(a) HE staining of the NEMs. Both the Mock and the FLG-KD NEMs show a normal differentiated 
epidermis with the presence of all epidermal layers. Supplementation of IL-31 (30 ng/ml) for five days 
did not affect epidermal morphology, scale bar indicates 50 µm. (b) Reduced FLG mRNA expression 
after FLG-KD and/or IL-31 supplementation. mRNA data represents mean +SEM of 3 independent 
experiments. White bars indicate Mock NEMs, black bars indicate FLG-KD NEMs. * indicates P<0.05, 
** indicates P<0.01. (c) Reduced immunofluorescent staining for FLG after FLG-KD and IL-31 
supplementation. Scale bar indicates 50 µm
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expression was confirmed at protein level by immunofluorescent staining for FLG (Figure 
1c). Supplementation of the NEMs with IL-31 for five days prior to termination of the 
cultures did not affect epidermal morphology (Figure 1a). IL-31 supplementation resulted 
in a reduction of FLG mRNA expression of approximately 50% compared to control NEMs 
(Figure 1b). The IL-31 induced reduction of FLG expression was confirmed on protein levels 
by immunofluorescent staining (Figure 1c). 
 
FLG-KD and IL-31 increase S. aureus colonization of NEMs
Next, we evaluated the effect of FLG-KD and/or presence of IL-31 on epidermal S. aureus 
colonization. For this purpose we used the clinical relevant methicillin resistant S. aureus 
(MRSA) strain LUH14616. After inoculating 1x105 bacteria onto the skin model for 1 hr, the 
suspensions were aspirated from the skin models to remove the non-adherent bacteria. After 
24 hrs, the number of detachable and adherent bacteria were determined by CFU counting. 
As shown in Figure 2a, 24 hrs post inoculation S. aureus colonies were present on the SC 
of the NEMs (Figure 2a, right panel). No effects of bacterial colonization on the epidermal 
morphology were observed. 
We did not observe significant differences in the number of detachable bacteria between the 
different models (Figure 2b). However, compared to the control (inoculated Mock NEMs) 
the number of adherent bacteria after IL-31 supplementation or FLG-KD was increased by 
2.3 fold (P<0.05) and 2.4 fold (P<0.05), respectively (Figure 2c). Supplementation of IL-31 
to FLG-KD NEMs resulted in a 3.3 fold increase (P<0.01) in adherent bacteria compared to 
control NEMs. After IL-31 supplementation, the number of adherent bacteria on FLG-KD 
NEMs was 1.4 fold higher (P<0.05) compared to IL-31 supplemented Mock NEMs, indicating 
an additional effect of FLG-KD in presence of IL-31. Supplementation of IL-31 to FLG-KD 
NEMs did not result in a significant increase in the number of adherent bacteria compared to 
FLG-KD alone (Figure 2c).  
Effect of FLG-KD and/or IL-31 on IL-8 release by NEMs after S. aureus colonization  
Next, we wanted to know whether the epidermal inflammatory response of NEMs was 
affected by S. aureus, by FLG-KD and/or by IL-31. Therefore, we assessed the levels of secreted 
IL-8 in the culture medium after 24 hrs of S. aureus colonization. Our results show that S. 
aureus colonization on both the Mock and the FLG-KD NEMs resulted in a significant two 
fold increase of IL-8 (P<0.001) (Figure 2d). Although we observed higher levels of IL-8 in the 
FLG-KD NEM medium before and after S. aureus colonization compared to Mock NEMs, 
these differences were not significantly different (Figure 2d). Supplementation of IL-31 did 
not affect IL-8 secretion by NEMs. However, subsequent S. aureus colonization resulted 
in 4.5-6.5 fold increase (P<0.001) in IL-8 release from the NEMs, irrespective of FLG-KD 
when compared to non-supplemented or to IL-31 supplementation alone (Figure 2d). No 
significant additional effect of FLG-KD on the IL-8 release after IL-31 supplementation was 




























































Figure 2. FLG-KD and/or IL-31 supplementation results in increased S. aureus colonization of NEMs. 
(a) S. aureus on the SC of NEMs is indicated with an arrow. The right panel shows a close-up of adherent 
S. aureus on the SC of a Mock and FLG-KD NEM.  Scale bars indicate 50 µm. (b) The number of 
detachable bacteria 24 hrs after inoculation of the NEMs was not affected by FLG-KD and/or IL-
31 supplementation. (c) The number of adherent S. aureus 24 hrs after inoculation of NEMs with S. 
aureus was increased on FLG-KD NEMs and NEMs cultured with IL-31 respectively, compared to the 
inoculated Mock NEMs. FLG-KD with IL-31 supplementation resulted  increased number of adherent 
S. aureus compared to the inoculated Mock NEMs. Data represents mean + SEM of 4 independent 
experiments (d) IL-8 levels in culture media of FLG-KD and/or IL-31 cultured NEMs colonized for 
24 hrs by S. aureus or without S. aureus colonization were measured by ELISA. Data represents mean 
+ SEM of 3 independent experiments. White bars indicate Mock NEMs, black bars indicate FLG-KD 
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IL-31 prevents upregulation of AMPs after S. aureus colonization
AMPs are associated with local antimicrobial activity, immunomodulation and wound 
healing. Furthermore, it is known that AMP expression is altered in AD20-22. Therefore, we 
evaluated the expression of several AMPs, hBD-2 and -3, RNAse7 and psoriasin after S. 
aureus colonization on the FLG-KD and IL-31 supplemented NEMs. The mRNA expression 
for hBD-2, hBD-3 and RNase7 was not affected by FLG-KD or IL-31 (Figure 3). S. aureus 
colonization resulted in a significant increase of hBD-2, hBD-3 and RNase7 mRNA expression, 
irrespective of FLG-KD (Figure 3a, c, d). IL-31 supplementation to the medium followed 
by S. aureus colonization of the NEMs completely prevented upregulation of hBD-2, hBD-3 
and RNase7 mRNA expression (Figure 3a-c). For hBD-2, protein analysis revealed similar 
results, IL-31 blocked the S. aureus-induced increase in hBD-2 expression (Figure 3b). The 
mRNA expression of psoriasin was not affected by either FLG-KD, IL-31 supplementation or 
S. aureus colonization (Figure 3e). 
Effect of FLG-KD and/or IL-31 on expression of enzymes involved in SC lipid synthesis 
after S. aureus colonization  
In addition to their effects on the expression of AMPs, we wondered whether FLG-KD and/or 
IL-31 supplementation to NEMs affects the expression of enzymes that are involved in SC lipid 
synthesis following S. aureus colonization. Free fatty acids (FFA) and ceramides (CERs) are two 
SC lipid classes that are crucial components of the SC, which protects against external factors, 
including bacteria. We evaluated whether S. aureus, FLG-KD and/or IL-31 supplementation 
affected mRNA expression of the elongases ELOVL1, -4 -6, and of Stearly-CoA desaturase 1 
(SCD-1), which are involved in FFA synthesis, and of glucocerebrosidase (Gcase) and acid 
Sphingomyelinase (aSmase), which are involved in CER synthesis were altered by S. aureus 
colonization. The expression of ELOVL1 and ELOVL6 was not significantly altered by S. 
aureus colonization or IL-31 supplementation (Figure 4a and c). However, colonization of 
NEMs by S. aureus resulted in increased ELOVL4 mRNA expression, irrespective of FLG-
KD (Figure 4b). However, IL-31 supplementation prevented the S. aureus-induced increase 
in expression irrespective of FLG-KD (Figure 4b). SCD-1 and Gcase mRNA expression by 
NEMs was not affected by S.aureus colonization alone, however supplementation of IL-31 
prior to S.aureus colonization resulted in significant down-regulation of these enzymes in 
both the Mock and FLG-KD NEMs (Figure 4d). In addition, the mRNA expression of aSmase 






















































































































































Figure 3. Effects of FLG-KD and IL-31 supplementation on AMPs by NEMs after S. aureus colonization. 
(a) hBD-2 mRNA expression, (b) hBD-2 protein expression, (c) hBD-3 mRNA expression, (d) RNase 7 
mRNA expression and (e) psoriasin mRNA expression. White bars represent the Mock NEMs and black 
bars FLG-KD NEMs. Data represents mean + SEM of 3 independent experiments. * indicates P<0.05, ** 
indicates P<0.01, *** indicates P<0.001
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Mock FLG-KD Mock FLG-KD
Mock FLG-KD Mock FLG-KD
Figure 4. Effects of FLG-KD and IL-31 supplementation on the mRNA expression of enzymes involved 
in SC lipid synthesis, following S. aureus colonization.  (a) ELOVL1, (b) ELOVL4, (c) ELOVL6, (d) 
SCD-1, (e) Gcase, and (f) aSmase mRNA expression. White bars represent the Mock NEMs and black 





Skin of AD patients is characterized by a high frequency of S. aureus colonization1. Impaired 
skin barrier function is a hallmark of AD, but the underlying cause of this barrier defect 
are still unknown23;24. Despite the highly reproducible finding that FLG mutations are a 
predisposing factor for AD development, its exact role in AD pathogenesis is not fully 
understood. Previously, we have shown that FLG-KD did not affect the SC lipid properties of 
reconstructed full thickness skin models17. Reduced FLG expression, due to FLG mutations 
or due to the presence of Th2 cytokines, e.g. IL-31, has been proposed to be an important 
contributor to skin barrier defects in AD 13;25. However, whether increased colonization is 
a cause or a consequence of a defective skin barrier or whether the presence of cytokines 
is the initiating cause of AD remains subject to extensive research. In the current study, we 
utilized a NEM with reduced FLG expression, through FLG-KD or IL-31 supplementation, 
to evaluate its role in epidermal colonization by S. aureus. These NEMs were evaluated for 
their epidermal responses to this bacterium, such as the production of the pro-inflammatory 
chemokine IL-8, AMPs and expression of enzymes involved in the SC lipid synthesis. Due to 
their similarities with native human skin, e.g. presence of all epidermal layers including the 
SC, and the expression epidermal markers, e.g. proliferation marker Ki67, early differentiation 
marker K10 and late differentiation marker FLG, NEMs are suitable for studying many aspects 
of epidermal barrier function26. However, such epidermal models lack immune cells such as 
Langerhans cells. 
Most data obtained for studying the effects of staphylococci, including S. aureus, and their 
secreted products on keratinocytes are performed using keratinocytes cultured in monolayer. 
Although keratinocytes cultured in monolayer are able to differentiate under submerged 
culture conditions, these keratinocytes do not form a SC. The SC is the epidermal layer mainly 
responsible for epidermal barrier function and is therefore necessary for studying epidermal 
S. aureus colonization and its consequences. Miajlovic and colleagues have shown that PCA 
and UCA, both FLG breakdown products, can reduce S. aureus growth rate as observed by 
measuring cell densities in vitro, which suggests that the epidermal “acid mantle” functions 
as an additional antimicrobial barrier27. Using NEMs, we found that both FLG-KD and IL-
31 supplementation resulted in increased epidermal colonization by S. aureus, similar to 
what is seen in AD1;28. These findings implicate that FLG is important for protection against 
epidermal S. aureus colonization.   
Using full thickness skin models, S. aureus strain LUH14616 was shown to induce the release 
of the inflammatory chemokine IL-8 by epidermal keratinocytes 29. Although no much is 
known about the role of IL-8 in AD, its upregulation in AD was shown to be associated 
with the presence of S. aureus16. We have found that the S. aureus-induced IL-8 response 
by epidermal models was not affected by FLG-KD, but significantly enhanced following 
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exposure to IL-31, suggesting that enhanced S. aureus colonization alone due to FLG-KD is 
not sufficient to evoke an inflammatory response and requires the presence of (AD related) 
cytokines such as IL-31. 
While the role of AMPs in psoriasis is well established, their role in AD is still not completely 
known. Recent studies have shown that both lesional and non-lesional AD skin showed 
alterations in the expression of various AMPs, including hBD-2, hBD-3, RNase7 and psoriasin 
20;21. In line with a previous study using full thickness skin models29, we found that following 
S. aureus colonization of NEMs, the mRNA expression of hBD-2, hBD-3 and RNase7 was 
increased, whereas psoriasin mRNA expression was not affected. FLG-KD did not affect the 
increase in AMP expression, whereas IL-31 supplementation prior to inoculation prevented 
the increase in AMP expression. The bacterial superantigen, Staphylococcal enterotoxin B , 
has been shown to rapidly induce IL-31 mRNA expression in skin from AD patients, whereas 
other studies using mouse models revealed that IL-31 is important in the induction of 
scratching behaviour 20;30-32. Furthermore, AMPs have been shown to induce IL-31 secretion 
by mast cells 33. These studies clearly show the importance of S. aureus and IL-31 in the 
development of AD. Our results suggest that IL-31 might act as a repressor of upregulation of 
AMP expression by keratinocytes in response to S. aureus.
The SC consists of corneocytes surrounded by an extracellular lipid matrix mainly composed 
of cholesterol, CERs and FFAs. Besides their function in maintaining proper SC barrier 
function, some lipids such as certain FFAs and CERs have roles in host defences against 
potential pathogenic or opportunistic microorganisms such as S. aureus34-36. Furthermore, 
the reduced CER and FFA chain lengths that were found in the SC of AD patients, were 
suggested to be caused by S. aureus- induced changes in expression of enzymes involved 
in SC lipid synthesis3;37. Two enzymes involved in FFA synthesis, ELOVL1 and ELOVL4, 
have been shown to be important for the skin barrier function and absence of one of these 
enzymes resulted in impaired barrier function in mice38;39. Using a NEM we found that 
ELOVL4 expression was upregulated in response to S. aureus colonization, irrespective of 
FLG-KD, but was prevented by IL-31. In addition, we have found downregulation of SCD-1 
and Gcase after S. aureus colonization in the presence of IL-31. These alterations in enzyme 
expression suggest bacterial colonization as an additional factor for alterations in the skin 
barrier function, besides the presence of inflammatory cytokines. However, future research is 
needed to evaluate whether S. aureus indeed contributes to the changes in lipid composition 
and reduced barrier function as seen in AD. 
In conclusion, we have demonstrated that reduced FLG expression resulted in increased 
epidermal S. aureus colonization. However, increased colonization due to FLG-KD alone 
was not sufficient to alter the epidermal responses to these bacteria. On the contrary, IL-
31 shifted a defensive response towards a pro-inflammatory response, by inducing more 
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IL-8 production, as well as repressing AMP upregulation. In addition, we have shown that 
S. aureus colonization of NEMs after IL-31 supplementation resulted in the downregulation 
of Gcase and SCD-1 which are involved in CER and FFA synthesis. The FLG-KD epidermal 
skin model used in this study resembles non-lesional AD skin in terms of increased S. aureus 
colonization and altered AMP expression, whereas supplementation of this model with Th2 
cytokines can be used to mimic features that are seen in lesional AD skin. These human 
skin models might therefore be a useful tool for screening of novel therapeutic antimicrobial 
compounds that targets the infectious complications of S. aureus in AD.   
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Establishment of an in vitro human skin 
equivalent that mimics lesional characteristics of 
Atopic Dermatitis
Vincent van Drongelen, Mogbekeloluwa O. Danso, Jacoba J. Out-Luiting, Aat 





Atopic dermatitis (AD) is a frequent occurring inflammatory skin disease characterized by a 
disrupted skin barrier function and immunological abnormalities. Lesional AD skin displays 
dermal infiltration of Th2 cells, which produce high levels of multiple inflammatory cytokines 
including IL-4, IL-13, and IL-31. Whereas these cytokines have been shown to affect several 
epidermal features individually, not much is known about the effects of a mixture of these 
cytokines on the epidermis. In addition, the possible role of fibroblast on the epidermal 
response to Th2 cytokines is not yet clear. To address these questions, a full thickness human 
skin equivalent (FT-HSE) composed of a fibroblast-populated collagen matrix and an 
epidermis were cultured in the presence of a Th2 cytokine mixture. 
Supplementation of Th2 cytokines affected the epidermis on various levels. Expression of 
early differentiation marker K10 was delayed, while expression of the late differentiation 
markers filaggrin and loricrin was reduced. Furthermore premature expression of Lekti was 
observed after Th2 cytokine supplementation. Supplementation of Th2 cytokines resulted in 
decreased expression of various enzymes involved in stratum corneum lipid synthesis as well 
as a poor lamellar lipid organization in stratum corneum of FT-HSEs. 
In this study we have shown that supplementation of Th2 cytokines to FT-HSEs simultaneously 
affects various epidermal processes, including the expression of differentiation markers, 
expression of enzymes involved in desquamation and stratum corneum lipid synthesis and 
organization. Most of the changes induced by these Th2 cytokines were also present in lesional 
AD skin. 
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Introduction 
Atopic dermatitis (AD) is a frequent occurring inflammatory skin disease characterized 
by a disrupted skin barrier function and immunological abnormalities1;2. The skin barrier 
dysfunction in AD is characterized by increased transepidermal water loss (TEWL) and 
increased susceptibility for penetration of irritants such as sodium dodecyl sulphate 
(SDS) and theophylline3;4. Depending on the disease stage, lesional AD displays various 
histological features, including intraepidermal edema (spongiosis) and dermal infiltration of 
predominantly T-helper 2 (Th2) cells5. These Th2 cells produce high levels of inflammatory 
cytokines including IL-4, IL-13, and IL-312;6. Lesional AD skin contains high levels of IL-4 
and IL-137, as well as the more recently discovered cytokine IL-31, which was shown to be 
correlated with the IL-4 and IL-13 levels in the skin of AD patients8. The highly reproducible 
discovery of filaggrin (FLG) mutations as a strong genetic risk factor for AD9, has drawn 
considerable attention towards the skin barrier in several inflammatory skin disorders. In 
addition to FLG   mutations, additional research showed that Th2 cytokines e.g. IL-4 and IL-13 
reduce FLG expression, as well as the expression of involucrin and loricrin in keratinocytes10;11. 
Furthermore, IL-31 was also shown to reduce FLG expression in organotypic skin models12. 
Most studies so far evaluated the effects of individual cytokines on keratinocytes in 2D and 
3D systems13-17. However, in AD lesions, there is always a mixture of cytokines that might have 
cumulative effects as well as other additional effects18. Previously, IL-4 and IL-13 have been 
shown to induce morphological and molecular features in human skin equivalents (HSEs) 
as seen in lesional AD19;20. In one study, changes in the expression of various differentiation 
related proteins have been observed in skin biopsies from non-lesional and lesional AD skin21. 
The expression of kallikreins (KLKs) and of Lympho-epithelial Kazal-type-related inhibitor 
(Lekti) is well studied in Netherton syndrome, a chronic inflammatory skin disorder that 
shares several similarities with AD22. However, less is known about their expression in lesional 
AD and the effects of Th2 cytokines on their expression. 
In addition to epidermal alterations in lesional AD, changes in lipid composition have been 
shown in lesional AD skin, as well as in other inflammatory skin diseases such as psoriasis 
and Netherton Syndrome23-25. The changes in lipid composition are more extensive in lesional 
AD skin compared to non-lesional AD skin25. These observations suggest that inflammation 
might influence lipid synthesis. In epidermal skin equivalents, IL-4 has been shown to affect 
the expression of acid Sphingomyelinase (aSmase) and β-glucocerebrosidase (Gcase)17. 
Furthermore, in a recent study, we have shown that Th2 cytokines and TNF-α affect the lipid 
composition, i.e. ceramides (CERs) and free fatty acids (FFAs), in the stratum corneum (SC) 
of epidermal skin equivalents19. However, it is not yet known whether presence of fibroblasts 
in a dermal matrix affect the epidermal response to cytokines. 
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Therefore, in the current study we used a full thickness human skin equivalent (FT-HSE) to 
mimic lesional AD. These FT-HSEs are composed of a fibroblast-populated collagen matrix 
and a fully stratified epidermis, which was supplemented with a mixture of AD related 
cytokines (IL-4, IL-13 and IL-31). These HSEs were analysed for the expression of epidermal 
differentiation markers and enzymes involved in desquamation and SC lipid synthesis and 
compared to lesional AD skin. In addition, the effects of the Th2 cytokine mixture on SC lipid 
organization of the FT-HSEs was evaluated as well.
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Material and Methods
Atopic dermatitis (AD) biopsies
The study was conducted in accordance with the Declaration of Helsinki and was approved by 
the Ethical Committee of the Leiden University Medical Center. AD patients were recruited by 
public advertisement and have given written informed consent. No dermatological products 
were applied onto the forearms for at least one week prior to the study. From lesional AD skin, 
a 4mm biopsy was taken which was immediately fixed in 4% formaldehyde. As a control, skin 
from healthy individuals was used. 
Cell culture
Human keratinocytes and human dermal fibroblasts were obtained from surplus skin from 
adult donors undergoing mammary or abdominal surgery and were established as described 
earlier26. The surplus skin was handled according to the declaration of Helsinki principles. 
The skin was collected after written informed consent. Primary keratinocytes were cultured in 
keratinocyte medium consisting of DMEM/Ham’s F12 medium (3:1 ratio, Invitrogen, Breda, 
the Netherlands), supplemented with 5% FBS (HyClone/Greiner, Nurtingen, Germany), 0.5 
µM hydrocortisone, 1 µM isoproterenol, 0.1 µM insulin (Sigma-Aldrich, Zwijndrecht, The 
Netherlands), 100 U/ml penicillin and 100 µg⁄ml streptomycin (Invitrogen) at 37°C and 7.3% 
CO2 until subconfluency (<70%) after which they were stored in liquid nitrogen until usage 
for generation of the human skin equivalents. Fibroblasts were cultured at 37°C and 5% CO2 
until subconfluency (< 70%) in fibroblast medium consisting of DMEM (Invitrogen), 5% 
FCS  and 100 U⁄ml penicillin and 100 µg⁄ml streptomycin (Invitrogen). For all experiments, 
primary keratinocytes from passage one or two and fibroblasts from passage two till five were 
used for generation of HSEs.
Dermal equivalents
Collagen-type I based dermal equivalents were generated as described earlier 27;28. Collagen 
(4 mg/ml, isolated from rat tails) was mixed with Hank’s Buffered Salt Solution (Invitrogen), 
0.1% acetic acid, 1M NaOH and fetal calf serum (FCS, Hyclone) to obtain a final collagen 
concentration of 1 mg/mL. One milliliter of this mixture was pipetted into a filter insert 
(Corning transwell cell culture inserts, membrane diameter 24mm, pore size 3mm; Corning 
Life Sciences) and allowed to polymerize for 15 minutes at 37°C. Subsequently, a 2 mg/mL 
collagen solution was prepared by mixing a 4 mg/mL collagen stock solution with Hank’s 
Buffered Salt Solution, 0.1% acetic acid, 1M NaOH, and a fibroblast containing FCS solution 
(final fibroblast cell density of 0.4x105 cells/mL collagen solution). Three ml of this mixture 
was pipetted onto the polymerized collagen layer. After polymerization the dermal equivalents 
were cultured submerged in fibroblast medium. The medium was refreshed twice a week. The 




Generation of full thickness human skin equivalents (FT-HSEs)
FT-HSEs were established as described earlier29;30. In short, FT-HSEs were generated by seeding 
5x105 primary keratinocytes onto the dermal equivalent. These FT-HSEs were cultured under 
submerged conditions in keratinocyte medium for 2 days, after which it was replaced for 
keratinocyte medium containing 1% FCS  for an additional day. Next, the FT-HSEs were lifted 
to the air-liquid interface with keratinocyte medium omitted from serum and supplemented 
with 2M L-serine, 10 mM L-carnitine, 1 µM DL-α- tocopherol-acetate, 50 µM ascorbic acid, 
a free fatty acid supplement which contained 25 µM palmitic acid, 30 µM linoleic acid and 7 
µM arachidonic acid and 2.4x105 M bovine serum albumin. Culture medium was refreshed 
twice a week. The HSEs were cultured at the air-liquid interface for 14 days. 
Cytokine supplementation
After 7 days of culturing at the air-liquid interface, the medium was refreshed with the same 
medium supplemented with a mixture of the Th2 cytokines IL-4, IL-13 and IL-31 (30 ng/
ml each, R&D systems, Abingdon, United Kingdom). The total duration of culturing with 
cytokine enriched medium was 7 days.
Morphology, immunohistochemistry and immunofluorescence 
After termination of the cultures, FT-HSEs were fixed in 4% paraformaldehyde and 
subsequently dehydrated and embedded in paraffin. As a control for the cytokine-induced 
effect, biopsies from lesional AD skin were used, which were fixed in a similar manner. 
For assessment of the morphology of the biopsies and the FT-HSEs, a haematoxylin and eosin 
(HE) staining was performed on 5 µm sections. 
Expression of the epidermal differentiation markers keratin 10 (K10) and loricrin was assessed 
using immunohistochemical staining, using the following antibodies: Keratin 10 (1:100, 
clone DE-K10, Labvision/Neomarkers, Fremont CA, USA) and Loricrin (1:1000, clone AF62, 
Covance, Rotterdam, the Netherlands). Following incubation with the appropriate secondary 
antibody, the streptavidin-biotin-peroxidase system (GE Healthcare, Buckinghamshire, UK) 
was used according manufacturer’s instructions with 3-amino-9-ethylcarbazole (AEC) for 
the visualization of the sections. The sections were counterstained with haematoxylin and 
sealed with Kaiser’s glycerin. Expression of filaggrin (FLG), KLK5 and Lekti was assessed by 
immunofluorescence stainings using the following antibodies: Filaggrin (1:1000, Covance, 
Rotterdam, the Netherlands), KLK5 (1:400, ployclonal, Santa Cruz, Heidelberg, Germany), 
Lekti (1:20, clone 1C11G6, Invitrogen, Breda, the Netherlands). For immunofluorescence 
analysis, 5 µm sections were cut, deparaffinised and rehydrated, followed by heat-mediated 
antigen retrieval. After blocking non-specific binding using PBS containing 1% bovine 
serum albumin (BSA, Sigma) and 2% normal human serum (NHS, Sanquin, Leiden, the 
Netherlands), sections were incubated overnight with primary antibody at 4°C. After washing 
with PBS sections were incubated with the appropriate secondary antibody Goat anti-Rabbit 
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(Rhodamine Red, 1:300, Jackson ImmunoResearch, Amsterdam, The Netherlands) or Goat 
anti-Mouse (Cy3, 1:1000, Jackson ImmunoResearch). The sections were mounted with 
Vectashield containing DAPI for visualization of the nuclei (Vector Laboratories, Amsterdam, 
the Netherlands).
RNA isolation, cDNA synthesis and qPCR
Total RNA was isolated from the epidermis after mechanical separation from the fibroblast 
populated dermal matrix. The epidermis was cut very finely, stored in RLT buffer containing 
0,01% β-Mercaptoethanol and stored in -80°C until isolation. RNA was isolated using the 
Qiagen RNeasy mini kit (Qiagen) according manufacturer’s instructions. Prior to RNA 
isolation, the samples underwent proteinase K treatment for removal of residual collagen and 
digestion of residual proteins. For cDNA synthesis, 1 μg of total RNA was reverse transcripted 
using the iScript cDNA synthesis kit (BioRad, Veenendaal, The Netherlands) according 
manufacturer’s instructions. PCR reactions were based on the SYBR Green method (BioRad). 
Quantitative RT-PCR was performed using the CFX384 instrument (BioRad). The total 
reaction volume was 7 μl, which included cDNA, Sybr green mix, 10 μM forward primer and 
10 μM reverse primer. The reactions were performed using the following program; 5 minutes 
at 95˚C to activate the polymerase followed by 44 cycles of 15 seconds at 95˚C, 20 seconds at 
60˚C and 20 seconds at 72˚C. Afterwards a melt curve was generated. The primer sequences 
are listed in Table 1. Data analysis was done using CFX software (BioRad) with the ΔΔCt 
method and β2 microglobulin (B2M) and Beta-glucuronidase (GUSB) as reference genes. 
The data represent the mean and + standard error of the mean (SEM) of three independent 
experiments.
Table 1: primer sequences




KLK 5 TCTGCGCCGGTGACAAAGCA TGGGCCGGGCACAAGGGTAA
KLK 7 TCACATCAGATCCTCTCGAGCCCA TGTCGCCCAGCGTATCACTGC
KLK 8 ACTACTCTGTGGCGGTGTCC TGGTCACGCAGTTGAAGAAG














Stratum corneum (SC) isolation 
The SC from the FT-HSEs was isolated as described earlier 28;31. Briefly, the FT-HSEs were 
incubated overnight on filter paper with 0.1% trypsin in 4°C. Following incubation at 37°C for 
30 minutes, the SC was mechanically separated from the FT-HSEs and subsequently washed 
with 1 µg/ml trypsin inhibitor (Sigma, Zwijndrecht, The Netherlands) and demineralized 
water. SC samples were air dried at room temperature and stored under Argon gas over silica 
gel in the dark.  
Fourier transformed infrared spectroscopy and small angle X-ray diffraction 
Fourier transform infrared spectroscopy (FTIR) and small angle X-ray diffraction (SAXD) 
were performed as described earlier28. Prior to FTIR and SAXD measurements, SC samples 
were hydrated at room temperature for 24 hours in a 27% (w/v) NaBr solution.  
The SC sample was placed between AgBr windows after which FTIR spectra in the frequency 
range of 600-4000 cm−1 were obtained using a Varian 670-IR FTIR spectrometer (Agilent 
technologies, Santa Clara, CA), equipped with a broad-band mercury cadmium telluride 
(MCT) detector which was cooled with liquid nitrogen. Each spectrum was collected for 4 
minutes at a 32°C. Each spectrum was derived from the co-addition of 256 scans at a resolution 
of 1 cm−1 with frequency range of 600-4000cm−1 and deconvoluted using half-width of 5 cm-1 
and an enhancement factor of 1.7. The spectra were processed using Bio-Rad Win-IR Pro 3.0 
software from Biorad (Biorad laboratories, Cambridge, Massachusetts). 
Small angle X-ray diffraction (SAXD) measurements were performed at the European 
Synchrotron Radiation Facility (ESRF, Grenoble) at station BM26B. A more detailed 
description of this beamline has been described elsewere32.  Diffraction data were collected 
using a PILATUS IM detector with 1043x981 pixels  and spatial resolution of 172µm. The 
SC samples were hydrated for 24 hours at room temperature over a 27% (w/v) NaBr solution 
before measurements. The scattering intensity (I) was measured as a function of the scattering 
vector q (in nm-1). The repeat distance (d) of a lamellar phase was determined from the position 
of the diffraction peaks with the following equation d=2nπ/qn, in which q=4πsinθ/λ. In these 
equations θ is the scattering angle, λ is the wavelength and n is the order of the diffraction 
peak.  All measurements were performed with three SC samples of both HSE types.
Statistics
Statistical analysis was conducted using GraphPad Prism, version 5.04. The effect of the Th2 
mixture on the expression of all target genes was analysed using 2-way ANOVA followed by a 
Bonferroni-holm post-hoc test. P values of <0.05 were considered significant.
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Results 
Th2 cytokines delay keratin 10 expression and reduce loricrin and filaggrin expression in 
full thickness HSEs (FT-HSEs)
To investigate the effects of Th2 cytokines on the epidermis of FT-HSEs, a mixture of IL-4, 
IL-13 and IL-31 (30 ng/µl each, Th2 mixture) was added to the culture medium for a total of 
7 days. Supplementation of this Th2 mixture resulted in significant downregulation of mRNA 
expression of loricrin and filaggrin, but not for involucrin (although a trend was observed, 
p=0.06) (Figure 1a). 
The FT-HSEs without cytokines (control) showed the presence of all epidermal layers, including 
the SC. Supplementation of the Th2 mixture did not affect the presence of all epidermal layers, 
nor the presence of the SC. We also evaluated the effects of the Th2 mixture on keratinocyte 
proliferation, but no significant differences were observed (data not shown). However the 
epidermal thickness and the number of viable cell layers was increased considerably and 
appeared more disorganized (Figure 1b). In the control FT-HSEs, expression of the early 
differentiation marker keratin 10 (K10) is present in all suprabasal layers of the epidermis, 
but in the Th2 mixture FT-HSEs, K10 expression was negative in the basal layer as well as in 
the lower 2-3 spinal layers of the epidermis (figure 1B). Expression of the late differentiation 
markers loricrin and filaggrin was present in the upper granular layer of the control FT-HSEs. 
Supplementation of the Th2 mixture resulted in discontinuous or patchy expression of both 
markers (Figure 1b). 
Although lesional AD skin contains all viable epidermal layers similar to normal skin, it 
generally displays an increased number of cell layers and appears thicker compared to normal 
skin (Figure 1c). Whereas K10 expression in normal skin is present in all suprabasal cell 
layers, in lesional AD skin K10 expression was clearly negative in the lower 2-3 layers of the 
epidermis (Figure 1c). Normal skin displays a continuous expression of loricrin and filaggrin 
in the granular layer, which is strongly reduced in the granular layer of lesional AD skin 
(Figure 1c). These findings indicate that  differentiation is altered in lesional AD skin.
Th2 cytokines affect the expression of KLK5 and SPINK5/Lekti in full thickness HSEs 
(FT-HSEs)
In addition to the effects on epidermal morphology and differentiation, we wanted to 
know whether the Th2 mixture affects the expression of epidermal kallikreins (KLKs) and/
or of Lympho-epithelial Kazal-type-related inhibitor (Lekti). KLK7 mRNA expression was 
significantly increased after supplementation of the Th2 mixture, whereas the expression of 
KLK8 was significantly decreased. No significant effects on the expression of KLK5 and KLK14 
were found, although for KLK5, we observed a trend (p= 0.07, Figure 2a). The expression of 
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SPINK5, the gene encoding Lekti, was not affected by supplementation of the Th2 mixture 
(Figure 2a).
Immunofluorescent staining revealed that KLK5 and Lekti expression was present in the upper 
2-3 layers of the epidermis of the control FT-HSEs (Figure 2b). However, supplementation 
of the Th2 mixture resulted in reduced KLK5 expression, which was only present in the 
uppermost granular layer. Lekti expression was increased and present in the uppermost 4-5 
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*** *** p = 0.06
Figure 1: Effect of Th2 cytokines on epidermal morphogenesis of FT-HSEs and the comparison to 
lesional AD skin. (a) Epidermal mRNA expression for loricrin, filaggrin and involucrin in the control 
and Th2 mixture FT-HSEs. Data represents mean +SEM of three independent experiments, *** indicates 
P<0.001. Representative cross sections after a haematoxylin and eosin (HE) staining for morphology, 
immunohistochemical stainings for keratin 10 (K10) and loricrin and immunofluorescent staining for 
filaggrin of control and Th2 mixture FT-HSEs (b) and of normal skin and AD lesional skin (c). Dotted 
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Figure 2: Effect of Th2 cytokines on enzymes involved in desquamation in FT-HSEs and the comparison 
to lesional AD skin. (a) Epidermal mRNA expression for KLK5, KLK7, KLK8, KLK14 and SPINK5. 
Data represents mean +SEM of three independent experiments, * indicates P<0.05, ** indicates P<0.01
Representative cross sections after immunofluorescent staining for KLK5 and Lekti of control and Th2 
mixture FT-HSEs (b) and of normal skin and lesional AD skin (c). Scale bar indicates 50 µm.
skin, the expression of KLK5 and of Lekti was present in the upper granular layer, but in AD 
lesional skin the expression of both enzymes was increased and present in the upper 3-5 layers 
of the epidermis (Figure 2c). 
Th2 cytokines affect the expression of enzymes involved in lipid synthesis in FT-HSEs
In addition to their effects on the expression of differentiation and desquamation related 
genes, we wanted to know whether the Th2 mixture affect the expression of enzymes that 
are involved in lipid synthesis. Therefore we performed qPCR with RNA samples from the 
whole epidermis. In particular enzymes involved in the synthesis of free fatty acids (FFA) 
































































































































Supplementation of the Th2 mixture resulted in downregulation of enzymes involved the 
CER synthesis, aSmase, Gcase and acid-ceramidase (aCdase) (Figure 3a). The expression of 
Ceramide Synthase 3 (CerS3) did not changes following supplementation (Figure 3a).
In addition to the downregulation of enzymes involved in CER synthesis, supplementation of 
the Th2 mixture resulted in downregulation of members of the Elongase family, the ELOVLs. 
As shown in Figure 3b, the expression of ELOVL1, ELOVL4 and ELOVL6 was downregulated 
(Figure 3b). The expression of Stearoyl-CoA desaturase-1 (SCD-1) was not affected by the 
Th2 mixture (Figure 3b).
Th2 cytokines affect the SC lipid organisation of FT-HSEs
Besides the effects on the expression of enzymes that are involved in lipid synthesis, we 
wanted to know whether the Th2 mixture affects the SC lipid organization of FT-HSEs. In the 
SC of normal skin, the lipids are organized into lipid lamellae, with a repeat distance of 13nm 
(long periodicity phase, LPP) or 6nm (short periodicity phase, SPP)33. Besides the lamellar 
organization, the lateral lipid organization provides information about the lipid density 
within the lipid lamellae. 
To evaluate the effects of the Th2 mixture on the lamellar lipid organisation, SAXD 
measurements were performed. In the SC of the control FT-HSEs, the LPP was present 
as shown by the presence of three peaks in the SAXD profiles, indicated by I, II and III in 
the profiles, which are attributed to the lamellar phase with a repeat distances of 12.03 (± 
0.07) (Figure 4a). Supplementation of the Th2 mixture resulted in absence of all the peaks, 
indicating that there was no lamellar organization in the SC of FT-HSEs in these HSE (Figure 
4a). The lateral lipid organization in SC from the controls was assessed by FTIR, focusing on 
the CH2 rocking vibrations. We observed an hexagonal lipid organisation characterised by a 
single peak at 719cm-1 in the spectrum of both the control HSEs and after supplementation 
with the Th2 mixture (data not shown). By assessing the CH2 symmetric stretching at 32°C, 
the conformational ordering of the lipids at in vivo skin temperature was determined. As 
shown in Figure 4b, the CH2 symmetric stretching frequency in the spectrum of the control 
HSEs and the HSEs supplemented with the Th2 mixture were comparable and were 2850.4 
(± 0.19) and 2850.7 (± 0.06), respectively, indicating that the conformational ordering of the 
lipid chains in FT-HSEs was not affected by the Th2 mixture (figure 4b). 
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Figure 3: Effect of a Th2 mixture on the mRNA expression of enzymes involved in SC lipid synthesis. 
(a) Epidermal mRNA expression for enzymes involved in CER synthesis: aSmase, Gcase, aCdase and 
CerS3. (b) Epidermal mRNA expression for enzymes involved in FFA synthesis: ELOVL1, ELOVL4, 
ELOVL6 and SCD-1. Data represents mean +SEM of three independent experiments, * indicates 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4: Effect of a Th2 mixture on the SC lipid organization of FT-HSEs. (a) Representative SAXD 
profiles of 2 independent experiments. The control FT-HSEs show the presence of first, second and third 
order diffraction peaks of the LPP, indicated by I, II, III respectively, corresponding to a repeat distance 
of 12.03 (± 0.07). Presence of phase separated cholesterol is indicated by *, arrows indicate unknown/
unidentified peaks observed in the spectra. No peaks could be observed after supplementation of the 
Th2 mixture. (b) Graph representing the CH2 symmetric stretching at 32°C. Data represents mean + 
SEM of three independent experiments. 
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Discussion
Lesional skin of AD patients is characterized by the dermal infiltration of Th2 cells that 
produce various Th2 cytokines, including IL-4, IL-13, and IL-312;5;6. Much research on the 
effects of cytokines has been performed using cytokines individually13;15-17;34. However, in 
AD lesions, there is always a combination of cytokines that have been proposed to have 
simultaneous effects which might alter the overall effect18. In addition, most research on 
the effects of cytokines has been performed using 2D-monolayer keratinocyte cultures. In 
a previous study we have used a 3D- epidermal skin equivalent to evaluate the effects of a 
mixture of various Th2 cytokines on the SC lipid composition19. To increase the complexity 
of the HSEs, in the current study fibroblasts were added to establish a FT-HSE which was 
compared to lesional AD skin. In other skin diseases, e.g. recessive epidermolysis bullosa 
simplex (REBS) and squamous cell carcinoma (SCC), the fibroblast have been shown to play 
an important role29;35. However, whether fibroblasts affect the epidermal response to cytokines 
is not yet known. To evaluate the effects of a Th2 cytokine mixture on the epidermis in the 
presence of fibroblasts, we have established a FT-HSE, cultured in the presence of a mixture 
of IL-4, IL-13 and IL-31 to (partly) mimic the cytokine environment as seen in lesional AD. 
These FT-HSEs were evaluated for their differentiation, expression of enzymes involved in 
desquamation and compared to lesional AD. In addition, the expression of enzymes involved 
in lipid synthesis and the SC lipid organization of these FT-HSEs were assessed as well.
The Th2 cytokine mixture induced an increased epidermal thickness in the FT-HSE, similar 
to the increased epidermal thickness as seen in lesional AD skin. In a recent study using an 
epidermal skin equivalent, Th2 cytokines did not affect epidermal thickness19. These results 
implicate that presence of fibroblasts is necessary for the increase in epidermal thickness as 
seen in lesional AD, without affecting the epidermal proliferation. Supplementation of Th2 
cytokines resulted in delayed K10 expression and reduced the expression of filaggrin and 
loricrin in FT-HSE. These features were also seen in lesional AD skin, indicating that these 
FT-HSE closely resemble lesional AD skin with regards to the epidermal differentiation. In 
the epidermal skin equivalents from our previous study, these changes in expression were also 
observed19, indicating that the presence of the fibroblasts did not interfere with the cytokine-
induced effects on epidermal differentiation. 
In addition to alterations in epidermal differentiation, enhanced desquamation has been 
proposed to play a role in deterioration of the barrier function in AD16;36. Several studies 
on desquamation-related enzymes have been performed using patients with Netherton 
Syndrome. The skin of these patients displays increased protease activity caused by absence 
of the protease inhibitor Lekti due to mutations in its gene, SPINK537. However, not much 
is known about the effects of Th2 cytokines on the expression of KLKs and Lekti in the 
viable epidermis. One study has shown increased KLK7 mRNA expression after IL-4 and 
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IL-13 stimulation of keratinocytes similar to our results with a Th2 cytokine stimulated FT-
HSE. Increased KLK7 protein expression in lesional AD has been shown in the same study16. 
Whereas we found reduced KLK5 protein expression in the epidermis of the FT-HSEs after 
supplementation of Th2 cytokines, in lesional AD skin we observed premature expression of 
KLK5 and Lekti. Due to the absence of desquamation in vitro, results obtained with FT-HSEs 
are difficult to translate to the in vivo desquamation process. Nevertheless, the alterations in 
expression of KLK5 and Lekti in lesional AD skin might suggest a disturbed desquamation. 
In addition to their effects on differentiation and desquamation, supplementation of Th2 
cytokines resulted in a poor SC lipid organization of the FT-HSEs, illustrated by the absence 
of a lamellar ordering. Little is known of the lamellar lipid organization in lesional AD. 
SC from non-lesional skin from AD patients display alterations in the lipid organization 
that were correlated with the changes in lipid composition38. Since the changes in lipid 
composition in lesional skin are more drastic, alterations in lipid organization in lesional 
AD skin are more extensive25. However, absence of the lamellar organization peaks as seen 
in the FT-HSE after supplementation of Th2 cytokines is not expected in lesional AD, based 
on the lipids that are still present. A mixture of Th2 cytokine did not affect the lamellar lipid 
organization of epidermal skin equivalents 19. Earlier studies have shown that HSEs with a 
fibroblast-containing dermal compartment had more variation in the repeat distances from 
the LPP compared to epidermal HSEs, suggesting a possible role of fibroblasts in modulation 
of the lamellar lipid organization28. Furthermore, fibroblasts have been shown to be involved 
in regulation of epidermal differentiation39 and might therefore also possibly involved in the 
SC lipid organization. Nonetheless, these differences might also be explained by differences in 
experimental set-up, i.e. the total concentration of cytokines initially added to the medium. 
Lesional skin from AD patients was shown to have alterations in the CER- and FFA chain 
length25. In the present study, the Th2 mixture resulted in reduced expression of the elongases 
ELOVL1 and ELOVL4, enzymes involved in the elongation of the very long free fatty acids 
and have been shown to be important for the skin barrier function. Knockout mice for 
one of these enzymes displayed severely impaired barrier function resulting in neonatal or 
perinatal death40;41. Furthermore, supplementation of the Th2 cytokines altered the expression 
of aSmase, Gcase and aCdase, enzymes involved in CER synthesis. Whether the expression 
of these enzymes is altered in lesional AD is not yet known but changes in expression and/
or activity of these enzymes might explain the alterations in SC lipid composition that were 
observed in lesional AD, i.e. shorter CER- and FFA chain lengths and an alterations in the 
CER composition25;42. 
In conclusion, in the present study we have shown that a mixture of AD related Th2 cytokines 
affect epidermal homeostasis of FT-HSEs at multiple levels; differentiation, expression 
of enzymes involved in desquamation and lipid synthesis as well as the lamellar lipid 
organization in the SC. Whereas some Th2 cytokine induced changes in the FT-HSEs were 
7
An human skin equivalent that mimics lesional atopic dermatitis characteristics
157
similar in epidermal models, the FT-HSE displayed alteration in epidermal morphology, i.e. 
increased thickness, as well as poor lamellar organization, features that were not observed 
in the epidermal model. This model might therefore provide a possible starting point for 
evaluation of the efficacy of newly developed anti-inflammatory therapies targeting the 
epidermis. Additionally, this FT-HSE might be an useful asset in unrevealing the role of 
fibroblasts in AD.
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Atopic dermatitis (AD) is a common inflammatory skin disease that is clinically characterized 
by a broad spectrum of manifestations. Clinically, AD skin is generally characterized by 
dryness (xerosis), itch (pruritis) and redness (erythema) and frequently present eczematous 
lesions1;2. It is in particular the highly pruritic lesions that have a severe impact on the quality 
of life of the patients3;4. In addition to the skin problems, a large group of the AD patients 
progresses into a secondary disease, such as allergic asthma and hay fever5. AD is the result of 
interaction between susceptibility genes and the host environment. Important characteristics 
are an impaired skin barrier function and both local as well as systemic immunological 
abnormalities. An impaired barrier function is present in both lesional (affected) and non-
lesional (less affected and normal appearing) skin of AD patients, and is illustrated by increased 
transepidermal water loss (TEWL), reduced stratum corneum (SC) hydration and increased 
SC permeability6-11. The immunological abnormalities comprises changes in the innate 
immune response, e.g. increased expression of pro-inflammatory cytokines such as TSLP, 
and in the adaptive response, e.g. increased presence of T-helper 2 (Th2) cells. Initially, barrier 
dysfunction and the immunological abnormalities were proposed to be separate mechanisms 
of which either one was the initiating cause for AD. However, recent studies imply that there 
is interaction between these two mechanisms, e.g. cytokines have been shown to affect the SC 
lipid composition12-14. 
Increased prevalence of AD in industrialized countries and the likelihood of progression 
of AD into allergic rhi nitis and asthma are becoming an emerging problem1;5. The current 
treatments for AD are mainly aimed at skin inflammation and barrier restoration and/or 
consist of anti-microbial approaches. 
Anti-inflammatory therapy targets the cutaneous inflammation in AD, which is crucial since 
inflammation is one of the major contributors to the symptoms and complications of AD. 
Barrier restoration includes application of moisturizers, to reduce the transepidermal water 
loss15, or lipid enriched creams to restore the lipid deficiencies in AD and thereby improve the 
skin barrier function16. Anti-microbial treatments are in particular aimed at S. aureus, since 
almost all AD patients have an increased susceptibility to S. aureus colonization and recurrent 
infections by this bacterium17. Whereas most of the available anti-inflammatory treatments 
are aimed at reduction of the inflammation in a systemic manner, less therapies are present 
that aim directly at restoration of the epidermis. Due to the limited efficacy as well as the 
adverse effects of the current treatments, there is much room for improvement. In particular 
novel treatments targeting S. aureus are desired, since increased bacterial colonization is a 





Whereas much of our understanding about AD and its pathogenesis is obtained using 
various mouse models18;19, their applicability for screening of newly developed compounds is 
limited due to the large differences in both skin morphology as well as skin barrier function 
between mouse and human skin20;21. These differences have often resulted in difficulties in the 
translation of the obtained results towards humans and patients22;23. As an alternative, in vitro 
three-dimensional human skin equivalents (HSEs) for AD (AD-HSEs) can be useful tools for 
increasing our understanding of AD pathogenesis, as well as for screening of new therapeutic 
compounds and pharmacological studies. Therefore, as an initial step, the primary aim of the 
studies described in this thesis was to develop reproducible novel HSEs that mimic important 
characteristics of AD. In the future, these HSEs might serve as a potential tool to screen newly 
developed compounds or formulations for the treatment of patients. 
Filaggrin mutations and their role in AD
The discovery of the strong association between filaggrin (FLG) mutations and AD was a 
breakthrough in AD research, and resulted in an increased focus on the epidermal skin barrier 
and the role of FLG therein24-26. Moreover, currently attempts are made in which FLG is used 
as a target for protein replacement therapy27. However, the precise role of FLG in AD and 
why FLG mutations are a predisposing factor for AD are currently still not fully understood. 
The frequently used flaky tail (ft) mouse model contains a homozygous mutation in Flg and 
mimics AD in this regard28. However its translation towards humans remains rather difficult, 
due to aforementioned differences between mice and man as well as the presence of other 
mutations, which were recently shown to be the cause for the barrier defects in these mice29;30. 
To study the role of FLG in various aspects of AD in vitro, several HSEs have been developed 
in the research that is described in this thesis, which were used to address the following 
questions: 
- Does reduced FLG expression result in a defective skin barrier? 
- What is the effect of reduced FLG expression on epidermal S.aureus colonization? 
- Does an explant HSE recapitulate all characteristics of the original AD biopsy in the 
presence or absence of FLG mutations? 
- Does cytokine supplementation mimic lesional AD in a human skin equivalent?
The different HSEs and their application to address these questions are described in this thesis 
and are summarized below.
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Establishing a reproducible HSE using a keratinocyte cell line
HSEs are usually established using primary keratinocytes that are obtained from surplus skin. 
These HSEs mimic human skin in many aspects including morphology, expression of various 
differentiation markers and several important aspects of the skin barrier31. However, primary 
keratinocytes have several drawbacks, including a limited in vitro lifespan, large donor-to-
donor variation and their limited availability. To overcome these limitations, immortalized 
cell lines can be an attractive alternative. Such cell lines provide a homogeneous and unlimited 
source of cells. However, their suitability to establish a functional HSE is not always evaluated. 
Many studies use the spontaneously immortalized HaCaT cell line to study epidermal 
biology, but HSEs established with these cells display a disturbed differentiation which 
probably resulted in poorer stratum corneum barrier properties32. Although improved culture 
conditions have resulted in an improved epidermal organization of HaCaT-based HSEs, the 
SC barrier properties of these improved HaCaT-based HSEs have not been evaluated33. In 
addition to HaCaT cells, another spontaneous keratinocyte cell line, NIKS®, is currently 
available. These cells have been shown to be applicable for establishing reproducible HSEs34. 
Nonetheless, these HSEs have not been evaluated for their SC properties. 
Besides spontaneous immortalization, genetic engineering of keratinocytes can be used to 
generate cell lines. An example of such a genetically engineered cell line is the N/TERT cell line, 
which expresses hTERT to prevent telomere shortening and lack the p16INK4a cell cycle control 
mechanism35. In the studies described in this thesis, N/TERT cells were used to establish 
N/TERT based skin equivalents (NSEs), in order to establish a novel and reproducible skin 
equivalent. These NSEs were studied in great detail for their SC barrier properties. 
The results described in chapter 2 indicate that these NSEs display many similarities to full-
thickness (FT)-HSEs that are established with primary keratinocytes. NSEs have a comparable 
epidermal morphology and the expression of collagen IV, keratin 10, loricrin and filaggrin in 
NSEs was comparable to that of FT-HSE established with primary keratinocytes. In addition, 
NSEs display a comparable SC lipid organization and contain all 12 CER subclasses and a 
comparable distribution of ceramides, free fatty acids and cholesterol. Furthermore, the SC 
permeability for the lipophilic compound butyl para-aminobenzoic acid (butyl-PABA) was 
similar between both skin equivalents. However, some differences in the composition of 
one of the three main SC lipid classes, the ceramides, were observed, which may affect the 
outcome of topical application studies.
Besides N/TERT cells, genetic engineering of keratinocytes might provide novel and unlimited 
sources of keratinocytes, which can be used to establish improved HSEs that mimic features 
of native human skin even more closely. Additionally, the uniformity of keratinocyte cell lines 
allows a specific investigation of the role of different fibroblasts on epidermal morphogenesis 




Establishing a reproducible AD-HSE through FLG-knockdown 
In addition to its reproducibility when used for generation of HSEs, cell lines are also 
convenient for transfection experiments. Transfection of immortalized cells results in novel 
genetically engineered cell lines that can be used for the generation of reproducible HSEs that 
mimic genetic features of skin diseases. To establish a FT-HSE that mimics the FLG mutations 
as seen in a large group of AD patients, N/TERT cells were transfected with shRNA to induce 
filaggrin knockdown (FLG-KD). This approach resulted in reduced FLG expression in these 
cells, which were subsequently used to establish the FT-HSEs that are described in chapter 3. 
This study revealed that this approach resulted in reduced FLG mRNA and protein expression 
in FT-HSEs after 14 days of air-exposed culturing. The reduction in FLG expression due to 
FLG-KD did not affect epidermal morphology, i.e. all four epidermal strata were present after 
FLG-KD. Furthermore, FLG-KD did not affect the expression of the early differentiation 
marker keratin 10, and the expression of the late differentiation marker loricrin. Evaluation 
of the SC barrier properties indicated that FLG-KD did not affect various SC lipid properties, 
i.e. the SC lipid composition, lipid organization and the SC permeability for a lipophilic 
compound were not affected. Based on these observations, the conclusion was drawn that 
FLG alone cannot be the sole contributing factor for the impaired barrier function as seen in 
AD. 
An AD-HSE established by outgrowth of biopsies from AD patients 
Besides using isolated primary keratinocytes or a keratinocyte cell line to establish HSEs, 
biopsies can be used as an alternative source. By placing small biopsies onto a fibroblast 
populated collagen matrix, keratinocytes from the biopsy are able to grow out and form an 
epidermis and thereby establish an explant HSE (Ex-HSE). In chapter 4, a study is described 
in biopsies from healthy skin are used to establish such a HSE. After establishing the Ex-HSE, 
a small piece of the outgrowth was taken and placed onto a secondary collagen matrix in 
order to establish a secondary Ex-HSE (2nd generation). This procedure was repeated again to 
establish a tertiary Ex-HSE (3rd generation). The results described in this chapter indicate that 
the expression of the differentiation markers, e.g. keratin 10, FLG and loricrin, was present 
in the Ex-HSE and in the 2nd and 3rd generation. Furthermore, the 2nd and 3rd generation Ex-
HSEs displayed the presence of the three main SC lipid classes. Whereas the density of the 
lipid packing the SC of the 2nd and 3rd generation gradually reduced, the lamellar organization 
in the SC of these HSEs remained similar. However in comparison to human skin, all Ex-
HSEs displayed alterations in the SC lipid properties.
Following the usage of healthy skin biopsies, in the following study we wanted to know whether 
biopsies of diseased skin could also be used to establish an Ex-HSE that maintain their in vivo 
characteristics. Chapter 5 describes this study in which biopsies from AD patients were used 
to establish an AD Ex-HSE. In addition, in this study the effect of FLG mutations on epidermal 
morphogenesis was evaluated, by using biopsies from AD patients with a homozygous FLG 
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mutation that were compared to wildtype AD patients. To examine whether the AD Ex-HSE 
recapitulate features of AD skin as well as the effects of FLG mutations on the outgrowth 
of the AD Ex-HSEs, we evaluated the expression of differentiation markers in vivo and in 
vitro, i.e. within the biopsy and the corresponding Ex-HSE from the same patient. The results 
from this study showed that FLG mutations resulted in reduced FLG protein expression in 
the biopsies, which was also present in their corresponding Ex-HSEs. FLG mutations did 
not affect the expression of keratin 10, involucrin, kallikrein 5 and Lekti. However, in the 
presence of FLG mutations reduced loricrin expression was observed in AD biopsies, which 
was also maintained in their corresponding Ex-HSEs. The observations from this study show 
that AD biopsies, with and without FLG mutations, maintain many characteristics in vitro 
when used for establishing an Ex-HSE. This study also revealed that loss of FLG expression 
due to mutations is not rescued by the increase in the expression of other proteins from 
the epidermal differentiation complex, i.e. involucrin and loricrin. These findings show the 
possibility of establishing an AD-HSE with primary cells from AD patients. Such an AD Ex-
HSE might be a suitable tool in the later stages of development of FLG restoring therapies.   
Reduced FLG expression as a risk factor for S. aureus colonization
In addition to intrinsic factors, such as the presence of FLG mutations, external factors play an 
important role in the development of AD. These external factors include bacterial colonization 
with Staphylococcus aureus. Almost all AD patients show increased and persistent S. aureus 
colonization, which secrets toxins that negatively affect disease severity17;36-38. Furthermore, 
these bacteria form biofilms, which makes their treatment more difficult39. 
Since FLG breakdown products have been shown to affect bacterial growth in vitro40, an N/
TERT based epidermal HSE (NEM) was developed to address the possible involvement of 
FLG in epidermal colonization with S. aureus. Therefore, FLG expression in this epidermal 
HSE was reduced through FLG-KD or through supplementation the culture medium with 
IL-31. The results from this study, which are described in chapter 6, show that both FLG-
KD and IL-31 supplementation resulted in decreased FLG expression accompanied by an 
increased epidermal S. aureus colonization. The presence of S. aureus resulted in increased 
IL-8 secretion and increased expression of various anti-microbial peptides (AMPs), including 
human β defensin (hBD-) 2, hBD-3 and RNase 7. However, the presence of IL-31 shifted 
the epidermal response towards S. aureus from protective - towards inflammatory. This was 
illustrated by increased expression of IL-8 and prevention in the increased expression of 
AMPs. Furthermore, both S. aureus and IL-31 were able to affect the expression of various 
enzymes that are involved in stratum corneum lipid synthesis.  
Mimicking lesional AD skin by supplementation of Th2 cytokines 
Besides FLG mutations and skin barrier dysfunction, AD is characterized by various 




established in the presence of a Th2 cytokine mixture, to mimic a lesional AD environment 
as closely as possible. The effects of this cytokine mixture on the epidermis were compared 
to lesional AD skin to evaluate whether supplementation of this cytokine mixture resulted 
in a HSE that mimics lesional AD skin. The results from this study indicate that a mixture 
of Th2 cytokines induced simultaneously alterations on various levels in the epidermis of 
HSEs; differentiation, expression of enzymes involved in the desquamation process and 
stratum corneum lipid synthesis as well as in the stratum corneum lipid organization. 
Supplementation of the Th2 cytokine mixture resulted in increased epidermal thickness that 
is also present in lesional AD skin. The marked changes in expression of keratin 10, loricrin 
and filaggrin indicate a delay in early differentiation as well as incomplete late differentiation. 
The expression of Lekti was increased by Th2 cytokines similar to what is seen in lesional AD 
skin. In the FT-HSE, the expression of various enzymes that are involved in SC lipid synthesis 
was reduced by supplementation of the Th2 cytokine mixture. Furthermore, presence of the 
Th2 cytokine mixture resulted in alterations in the SC lipid organization. 
In conclusion 
As a multifactorial inflammatory skin disease, AD is difficult to recapitulate into one HSE. 
The AD-HSEs that are described in this thesis all mimic various aspects of AD. These include 
reduced FLG expression, increased epidermal colonization with S. aureus and various features 
that can be observed in lesional AD skin. Depending on the research question these HSEs 
can be applied for various purposes. However several aspects of in vitro AD-HSEs can be 
further improved. The application of the currently available AD-HSEs and the opportunities 
for improvement of AD HSEs will be discussed below.  
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Future perspectives on in vitro AD human skin equivalents
AD-HSE 2.0: application and improvements of AD-HSEs 
The currently developed AD-HSEs, including those described in this thesis mimic some of 
the features of AD, e.g. reduced FLG expression. However, as described above, these AD-
HSEs have several limitations. In particular the generation of a lesional AD-HSE remains a 
challenge. Despite their limitations, the current AD-HSEs can be applied for various purposes, 
but to mimic AD more closely in vitro, several aspects could be improved. The applications of 
the current AD HSEs and the possible improvements are described below.
Evaluation of the role of FLG in AD 
The discovery of FLG mutations as an important predisposing factor for AD allows the 
study of the role of FLG in epidermal homeostasis and in the skin barrier function in vitro. 
Such approaches include application of RNAi to knockdown FLG (FLG-KD) expression and 
thereby mimic FLG mutations. 
Reduced FLG expression due to FLG-KD or due to FLG mutations did not affect the epidermal 
morphogenesis, expression of keratin 10, nor the SC thickness and SC lipid properties of 
HSEs, as shown in chapter 3 and 5 and in other FLG deficient HSEs41. These in vitro studies 
are in line with in vivo studies with AD patients in which no correlation was found between 
presence of FLG mutations and SC barrier properties42;43. However, some studies have shown 
that various SC lipid properties of HSEs are different from those observed in SC from native 
skin31. Therefore, optimization of the SC lipid properties of the current HSEs allows the 
generation of FLG-KD HSEs that can be used to examine the role of FLG in the skin barrier 
even more accurately. 
The consequences of reduced FLG, reduced levels of the FLG breakdown products PCA 
and UCA, were shown to affect epidermal S. aureus colonization (chapter 6), and to provide 
protection against UV41. In addition, FLG mutations were found to be a cause for reduced 
NMF levels in the SC in vivo44. Taken these observations together, it appears that in particular 
the FLG breakdown products are an important factor in the skin barrier, rather than the 
FLG protein itself. Therefore, FLG deficient HSEs might be useful for the development and 
screening of compounds for rehydration therapies, e.g. FLG protein replacement based 
therapies as has been described recently27, rather than for the evaluation of the role of the FLG 
protein in the skin barrier function. However, usage of HSEs to evaluate FLG degradation 
products might require several improvements. A previous study has shown that the levels of 
PCA are depending on the environmental humidity45. This study implies that environmental 
factors are important for the regulation of FLG degradation is different and that it is possibly 





The finding of increased colonization of S. aureus on FLG deficient HSEs provides an 
important answer to the question concerning the contribution of FLG as an initiating factor in 
AD development. Increased presence of S. aureus, as well as the presence of an itch, caused by 
S. aureus toxins or other factors, induces a mechanical barrier disruption through scratching 
that results in an infection. This might trigger the cycle of barrier disruption – inflammation 
– worsening of barrier disruption. 
Mimicking the inflammatory environment in vitro
Currently, only supplementation of Th2 cytokines has been used successfully to mimic 
epidermal features of lesional AD in FT-HSEs, as described in chapter 7 and in epidermal 
HSEs12. Using this approach, the effects of other AD related cytokines on the epidermis could 
be investigated, e.g. IL-17 and/or IL-22. Recently, these two cytokines were suggested to be 
involved in tissue repair and remodelling in AD46. Supplementation of these cytokines to the 
medium during generation of FT-HSEs might provide additional insight in their contribution 
to the epidermal changes as seen in AD. Although this approach can be used to study the 
biological mechanisms underlying these features of lesional AD in vitro, it surely has several 
disadvantages. In particular when such HSEs are used for screening anti-inflammatory 
compounds. In general, the concentration of cytokine(s) added to the medium is arbitrarily 
selected, since little is known about the concentration of various cytokines in lesional AD 
skin. Furthermore, the cytokine concentration in lesional AD skin is also subject to many 
variables, including disease severity but also treatment history. Although HSEs generated in 
the presence of cytokines can provide significant insight in the effects of a compound on 
reducing the inflammatory effects on the epidermis, translation to the in vivo situation should 
be done with precaution. Furthermore, currently, cytokines are relatively expensive which 
makes it unsuitable for high throughput screenings. 
As an alternative, integration of immune cells, obtained from healthy individuals or from AD 
patients, is an attractive approach, since these immune cells can easily be collected from blood 
and can be cultured and modified in vitro. Whereas a previous attempt to incorporate Th2 cells 
in HSEs did not result in an AD phenotype47, optimization of the protocol for polarization 
of the T-cells might result in Th2 cells that induce an AD phenotype after introducing them 
into HSEs. In addition, T cells from AD patients might be an interesting alternative to in vitro 
polarized T cells. Next to Th2 cells, various other immune cells have been shown to be present 
in lesional AD skin, including eosinophils, mast cells and dendritic cells (DCs). 
Eosinophils have immunoregulatory role by secretion of a large number of cytokines and 
chemokines. Whereas eosinophils are absent in normal skin, they can be found in lesional 
AD skin48. However, not much is known about the contribution of these cells to the AD 
phenotype, but they are thought to be involved in the switch from acute to chronic AD49. 
Introducing these immune cells in the HSE might provide insight in the contribution of these 
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cells to the epidermal abnormalities as seen in AD. Furthermore, investigation of these cells, 
in a 3D environment and their interaction with fibroblasts and keratinocytes might provide 
new targets for interfering in AD progression. 
Mast cells are present in chronic AD lesions50 and have been shown to affect keratinocytes 
through the release of histamine. Furthermore, a recent publication has shown the applicability 
of HSEs to evaluate histamine-induced effects51. Introduction of (activated) mast cells in the 
HSE might therefore result in a relevant HSE to screen antihistamine therapies for AD.  
Dendritic cells (DCs) are professional antigen-presenting cells that are present in an immature 
stage in various epithelia, including the skin, where they are called Langerhans cells (LCs). 
Upon activation, LCs migrate from the epidermis to the draining lymph nodes, which is 
essential for the initiation of an adequate immune response. A recent study showed that LCs 
can successfully be introduced in a HSE 52. Introducing these cells might aid in discovering 
initiating factors for AD development, as well as its contribution in e.g. S. aureus colonization 
and host defences in vitro. Furthermore, DCs/LCs from AD patients or healthy patients might 
behave differently in HSEs. Whereas previous studies have shown that LCs and T cells can be 
successfully introduced in HSEs, the introduction of multiple cells into a single HSE might be 
difficult and requires optimization of various culturing protocols. Furthermore, incorporation 
of various cell types into a single HSE increases the variability, which might cause difficulties 
in the interpretation of the results.
Studies on the AD bacterial environment in vitro 
The increased colonization of S. aureus on FLG-KD HSEs provides new opportunities to study 
the role of S. aureus in AD in vitro, using HSEs. Moreover, the role of FLG in colonization 
of other bacteria/pathogens, e.g. the commensal bacteria S. epidermidis, and possibly in the 
alteration in the skin microbiome as seen in AD can be investigated53;54. Using a FLG deficient 
HSE, the role of FLG in establishing a host environment favourable for pathogenic or less 
favourable for commensal bacteria, can be investigated. Besides increased colonization, S. 
aureus was found to form biofilms in lesional AD39, which renders this bacterium harder to 
treat. S. epidermidis has been shown to secret proteases, including Esp55, which inhibits S. 
aureus biofilm formation and therefore this protease might provide new peptides that can 
be used to combat the S. aureus biofilm formation in AD. The epidermal FLG-KD HSEs as 
described in chapter 6 might provide a valuable tool in screening such commensal-bacterial-
derived peptides. 
Furthermore, the presence of the SC on the HSEs allows the investigation of the interactions 
between bacteria and the epidermis. Currently, this epidermal FLG-KD HSE is being used 
for screening of AMP-derived peptides, for their ability to effectively kill S. aureus in vitro. If 




and moderate-to-severe AD. Besides screening of peptides that are potential new treatments 
for AD, S. aureus colonization was found to induce alterations in the expression of enzymes 
that are involved in SC lipid synthesis.  These findings imply that S. aureus might be an 
additional cause for the disrupted barrier in AD. Evaluation of the SC lipid composition of a 
(FLG deficient) HSE after inoculation with S. aureus might reveal an additional role of this 
bacterium in AD, and therefore create new possibilities for intervention in AD. 
The role of fibroblasts in AD
Whereas much research for AD is focused on the role of the keratinocytes, the epidermis 
and the SC, little research has been performed to investigate the role of the fibroblasts. 
However, several studies suggest that these cells might also play an important role in the 
AD microenvironment. Cytokine stimulated dermal fibroblasts were shown to promote 
the migration of dendritic cells and to attract various immune cells by secretion of soluble 
compounds such as eotaxin and metalloproteinase-1356-58. In addition fibroblasts were shown 
to be involved in regulation of the pro-inflammatory response of the keratinocytes 59. The 
fibroblasts might play an additional role in regulating other epidermal alterations in AD, 
including in the modulation of the SC properties. In chapter 7 it was shown that addition of 
fibroblasts to a skin equivalent resulted in some changes in the epidermal response to Th2 
cytokines that were absent in epidermal HSEs12. 
Participation of fibroblasts has been shown in other skin diseases. In recessive epidermolysis 
bullosa simplex (REBS), the fibroblasts have been shown to play an important regulatory role 
in establishing the REBS phenotype in vitro60. In squamous cell carcinoma (SCC), the cancer-
associated-fibroblasts (CAFs) have been shown to play an important role in SCC development61. 
An initial study using fibroblasts from AD patients showed that such fibroblasts in HSEs affect 
epidermal homeostasis62. Therefore, incorporation of dermal fibroblasts from AD patients 
(with or without FLG mutations) can be used to examine their role in keratinocyte-fibroblast 
interaction, in epidermal morphogenesis and in epidermal barrier properties. 
Furthermore, whereas some studies have shown that monolayer fibroblasts respond to IL-4 
and/or IL-13 by secretion of various molecules/proteins56;57, it would be interesting to evaluate 
how fibroblasts respond to inflammatory mediators in a 3D environment, and whether 
fibroblasts from AD patients display increased or decreased sensitivity to cytokines. 
Concluding remarks 
In this thesis, research is presented that describes several new HSEs for AD. These HSEs mimic 
various aspects of AD and have been applied to address the role of FLG in this skin disease. 
Whereas the findings in this research suggests a more indirect role of FLG in AD, through the 
FLG degradation products that appears to prevent increased bacterial colonization, the exact 
role of FLG as a predisposing factor for AD remains a subject for future research. As most 
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models, HSEs have some limitations, such as the lack of systemic aspects e.g. a closed system 
for vascularization and absence of the nerve system for the sensitization of itch. Studies that 
address these aspects, e.g. screenings of anti-pruritic compounds, will therefore, for the time 
being, require mouse models.
The HSEs that are presented in this thesis have shown their applicability and they belong to the 
first generation of AD-HSEs. Thereby they provide a solid starting point for the development 
of improved AD-HSEs. Such improved AD-HSEs can be used to screen new compounds 
designed for the treatment of AD, as well as to discover new points for intervention in this 
skin disease. Thereby, these AD-HSEs may contribute to the development of novel treatments 
for AD, which prevent the progression of AD into secondary diseases and have less adverse 
effects. In doing so, these AD-HSEs might contribute to (partly) relieve the heavy burden of 
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De huid is het grootste orgaan van het menselijk lichaam en heeft een belangrijke beschermende 
functie. Het zorgt voor een barrière tegen invloeden van buitenaf, zoals bijvoorbeeld allergene 
stoffen. 
De huid bestaat uit 2 lagen; de lederhuid (dermis) en de opperhuid (epidermis). De dermis is de 
onderste laag van de huid en  bestaat uit fibroblasten en bindweefsel. Fibroblasten produceren 
verschillende eiwitten die zorgen voor ondersteuning van de epidermis, zoals collageen en 
elastines1;2. De epidermis is de bovenste laag en  bestaat voornamelijk uit keratinocyten die 
een differentiatieproces ondergaan waardoor er vier lagen ontstaan. Deze vier lagen zijn van 
binnen naar buiten; het stratum basale (SB), stratum spinosum (SP), stratum granulosum 
(SG) en het stratum corneum (SC). De keratinocyten delen in het SB. Zodra ze na deling 
ontsnappen uit het SB beginnen de cellen te differentiëren. Tijdens dit differentiatieproces 
migreren de cellen via het SP richting het SG om uiteindelijk het SC te vormen3;4. Tijdens 
dit proces veranderen de cellen van vorm en worden er op specifieke momenten eiwitten tot 
expressie gebracht die kenmerkend zijn voor een bepaalde status van de differentiatie. Zo is 
bijvoorbeeld de expressie van keratine 10 kenmerkend voor vroege differentiatie, terwijl de 
expressie van filaggrine en loricrine kenmerkend is voor late differentiatie. Het SC bestaat 
uit terminaal gedifferentieerde keratinocyten (corneocyten) die omringt zijn door lipiden. 
De samenstelling van deze lipiden in het SC is uitzonderlijk. De belangrijkste lipidenklassen 
zijn ceramiden, vrije vetzuren en cholesterol die georganiseerd zijn in lagen met een hoge 
dichtheid5-8. 
Wanneer processen in de huid ernstig verstoord worden kunnen er huidaandoeningen 
ontstaan. Een van de meest voorkomende huidaandoening is constitutioneel eczeem, ook 
wel atopisch eczeem (AE) genoemd. De niet aangedane huid van patiënten ziet er normaal 
uit, maar is gevoeliger voor het ontstaan van ontstekingen in vergelijking met de huid van 
gezonde personen. Aangedane huid wordt veelal gekenmerkt door droge, rode en vooral 
jeukende plekken9;10. Naast het ontstaan van huidproblemen ontwikkelen patiënten andere 
allergische aandoeningen zoals astma en hooikoorts11. 
Bij het ontstaan van AE spelen zowel genetische als omgevingsfactoren een belangrijke rol. Een 
van de kenmerken van AE is een verminderde barrièrefunctie van de huid. Deze verminderde 
barrièrefunctie zorgt ervoor dat allergenen en andere stoffen uit de omgeving makkelijker de 
huid kunnen binnendringen en een ontsteking kunnen veroorzaken. Daarnaast kan water 
makkelijker door de huid dringen en verdampen aan het oppervlakte, waardoor het SC 
uitdroogt. Een verminderde barrière functie is aanwezig in zowel de aangedane als de niet-




afwijkingen vertonen zoals de aanwezigheid van T-cellen in de huid. Dit kan op een sterke 
immuunreactie op de binnendringende stoffen tot gevolg hebben. 
De huidbarrière (als fysieke barrière) en het immuunsysteem (als verdedigingssysteem tegen 
lichaamsvreemde stoffen) werden altijd beschouwd als twee onafhankelijke mechanismen. 
Echter, recent onderzoek heeft aangetoond dat de huidbarrière en het immuunsysteem elkaar 
beinvloeden. Dit maakt het heel lastig om de oorzaak van de ziekte vast te stellen en daar een 
nieuwe therapie voor te ontwikkelen12-14.
Gedurende de laatste decennia is het aantal patiënten met AE enorm toegenomen. Samen met 
het verhoogde risico van deze patiënten om astma en hooikoorts te ontwikkelen, wordt deze 
aandoening een steeds groter sociaal economisch probleem en zijn nieuwe behandelingen 
dringend nodig9;11. Tot nu toe worden patiënten vaak behandelt met corticosteroïden, 
ontstekingsremmers, barrière herstellende crèmes, hydraterende crèmes en antimicrobiële 
therapieën. Corticosteroïden en ontstekingsremmers worden vooral gebruikt omdat deze het 
grootste probleem, de ontstekingen, kunnen remmen. Echter, deze behandelingsmethoden 
hebben een nadelig effect op de huid en/of ze vergroten de kans op bacteriële infecties. Om 
de droge huid te behandelen, worden veelal (vettige) zalven gebruikt die het vochtgehalte in 
het SC verhogen15. Omdat AE patiënten ook vaak bacteriële infecties hebben op de aangedane 
plekken, met name veroorzaakt door Staphylococcus aureus, wordt soms ook een antimicrobiële 
behandeling toegepast16;17. De huidige behandelingen hebben veel bijwerkingen en zijn over 
het algemeen symptoom bestrijding, maar leiden niet tot genezing. Er is daarom behoefte aan 
nieuwe behandelingen. 
Veel wetenschappelijke kennis betreffende AE is verkregen met behulp van in vivo studies 
waarin proefdieren, vaak muizen, zijn gebruikt18;19. Echter, de huid van muizen vertoont grote 
verschillen met humane huid. Zo is de structuur van muizenhuid verschillend met die van 
humane huid. Deze verschillen maken muizen minder geschikt als “gereedschap” om nieuwe 
therapieën en behandelingen te testen die uiteindelijk geschikt moeten zijn voor de behandeling 
van patiënten20;21. Een alternatief voor dit soort studies is een humaan huidmodel, ook wel 
humane huidequivalenten genoemd. Deze in vitro modellen vertonen grote gelijkenissen 
met de natieve menselijke huid en zijn makkelijker hanteerbaar. Het onderzoek dat in dit 
proefschrift wordt beschreven richt zich op het ontwikkelen en nabootsen van AE kenmerken 
in een huidmodel. 
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De rol van filaggrine in atopisch eczeem
De ontdekking dat mutaties in het filaggrine gen (FLG) een risicofactor zijn voor het 
ontwikkelen van AE was een belangrijke doorbraak in het onderzoek naar deze huidaandoening 
en heeft geleid tot een verschuiving van de focus in dit onderzoeksgebied22-24. Het filaggrine 
gen codeert voor een eiwit dat betrokken is bij verschillende processen in de epidermis en 
in het SC. Zo zorgt het filaggrine eiwit voor een stevige structuur in de corneocyten en zijn 
de afbraakproducten van filaggrine betrokken bij de regulatie van de vochtbalans in het SC. 
Vanwege zijn belangrijke aandeel in AE wordt filaggrine ook als belangrijk target gezien voor 
nieuwe behandelingen. 
De exacte rol van filaggrine in de verminderde huidbarrière van AE patiënten is op dit 
moment nog onduidelijk. Om de rol van filaggrine in de huidbarrière te onderzoeken zijn 
humane huidmodellen een buitengewoon aantrekkelijk hulpmiddel, omdat deze beter de 
eigenschappen van de natieve humane huid nabootsen dan de eerder genoemde diermodellen. 
In het onderzoek wat beschreven wordt in dit proefschrift proberen we de volgende 
onderzoeksvragen te beantwoorden:
•	 Leidt een verminderde filaggrine expressie in the epidermis tot een verslechterde 
huidbarrière?
•	 Wat is het effect van een verminderde filaggrine expressie op bacteriële kolonisatie?
•	 Is het mogelijk om van biopten van AE patiënten met en zonder een filaggrine mutatie 
een huidmodel maken?
•	 Is het mogelijk om door toevoegen van ontstekingsfactoren aan het kweekmedium de 




Het maken van een reproduceerbaar huidmodel met behulp van een cellijn
Huidmodellen worden veelal gemaakt met behulp van primaire cellen die geïsoleerd worden 
uit restmateriaal wat verkregen wordt bij cosmetische ingrepen. Deze huidmodellen lijken 
in veel aspecten op de humane huid. Zo is de structuur (de morfologie) en de expressie van 
een aantal belangrijke differentiatie eiwitten vergelijkbaar met die van de humane huid25. 
Het gebruik van primaire cellen heeft ook nadelen, zoals een beperkte levensduur na isolatie 
en, beperkte beschikbaarheid van restmateriaal. Daarnaast zijn er ook verschillen tussen de 
donoren wat de interpretatie van resultaten soms lastig maakt. 
Als alternatief voor deze primaire cellen kunnen cellijnen gebruikt worden. Deze hebben 
als eigenschap dat ze blijven delen en daardoor een homogene voorraad kunnen zijn voor 
het maken van huidmodellen. Echter cellijnen moeten wel eigenschappen hebben waarmee 
een representatief huidmodel gevormd kan worden. Cellijnen kunnen spontaan ontstaan 
door een samenloop van verschillende mutaties. Een voorbeeld hiervan is de veelgebruikte 
cellijn HaCaT. Wanneer deze gebruikt wordt voor het maken van een huidmodel resulteert 
dit over het algemeen in een verstoorde huidstructuur met slechte barrière eigenschappen. 
Daarnaast kunnen cellijnen ook gemaakt worden door genetische modificatie. Een voorbeeld 
van zo’n gemaakte cellijn is de N/TERT cellijn. In hoofdstuk 2 staat een studie beschreven 
waarin een huidmodel met deze cellijn is gemaakt  en vervolgens is gekarakteriseerd voor 
de epidermale kenmerken en barrière eigenschappen. Deze N/TERT huidmodellen vertonen 
een normale huidstructuur en barrière eigenschappen, zoals de expressie van filaggrine, de 
lipidenorganisatie in het SC en de SC permeabiliteit. Echter de lipidensamenstelling wijkt 
in sommige opzichten af van de conventionele huidmodellen. Uit deze resultaten blijkt dat 
het N/TERT huidmodel een aantrekkelijke kandidaat is voor het onderzoeken van allerlei 
huidziekten.
Het maken van een reproduceerbaar huidmodel voor atopisch eczeem  door middel van 
filaggrine “knockdown”
Het gebruik van een cellijn heeft nog een ander voordeel. Deze cellen zijn bijzonder 
goed geschikt voor het gebruik bij transfectie studies. Hierbij kan met behulp van een 
transfectiemethode cellen genetisch worden gemodificeerd zodat bijvoorbeeld genetische 
afwijkingen van ziekten kunnen worden nagebootst. In hoofdstuk 3 staat een huidmodel 
beschreven waarin de filaggrine mutaties, een belangrijke factor in AE26, zijn nagebootst door 
middel van filaggrine “knockdown”. Om deze knockdown te verwezenlijken, is met behulp 
van een transfectie een zogenaamd “short-hairpin RNA” (shRNA) in de cellen gebracht om 
te voorkomen dat het filaggrine eiwit geproduceerd kon worden. Deze methode resulteerde 
in een verlaagde eiwit expressie van filaggrine in huidmodellen. Daarnaast vertoonden ze, 
naast een verlaagde expressie voor filaggrine, geen veranderingen in de huidstructuur en in 
expressie van andere differentiatie eiwitten. Uit de analyse van de barrière eigenschappen 
bleek dat de lipidenorganisatie, de lipidensamenstelling en de permeabiliteit van het SC niet 
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beïnvloed worden door de verlaagde filaggrine expressie. Uit deze studie is gebleken dat een 
verminderde filaggrine expressie niet voldoende is om een verslechtering in de SC barrière 
eigenschappen te veroorzaken.
Het gebruiken van een biopt voor het maken van een huidmodel voor atopisch eczeem 
Naast het gebruik van geïsoleerde primaire cellen voor het maken van een huidmodel, kunnen 
deze ook gemaakt worden met behulp van een biopt uit gezonde huid. Het plaatsen van zo’n 
biopt, op een collageen matrix, zorgt ervoor dat keratinocyten kunnen uitgroeien, waardoor 
een huidmodel kan worden gemaakt. Dit heeft het grote voordeel dat er veel meer materiaal 
beschikbaar komt voor analyses. Uiteraard moet de uitgegroeide huid dan wel dezelfde 
eigenschappen hebben als het originele biopt. 
In hoofdstuk 4 is deze methode uitgebreid. Nadat de keratinocyten van het biopt waren 
uitgegroeid, werd een stukje van deze uitgroei vervolgens op een tweede collageen matrix 
met fibroblasten geplaatst om zo een “tweede generatie” huidmodel te construeren. Deze 
methode kon zelfs nogmaals herhaald worden om zo ook een “derde generatie” huidmodel 
te verwezenlijken. Deze drie generaties huidmodellen vertonen allen dezelfde expressie van 
differentiatie eiwitten, wat inhoudt dat de ontwikkeling van de drie verschillende generaties 
vergelijkbaar waren. Nog interessanter was dat de tweede en derde generatie huidmodellen 
veel SC eigenschappen vertonen die vergelijkbaar zijn met die van de eerste generatie 
huidmodellen. Met name de aanwezigheid van de drie lipidenklassen en de lamellaire 
lipidenorganisatie waren vergelijkbaar. De dichtheid waarin de lipiden georganiseerd waren 
verminderde bij een volgende generatie. In vergelijking met normale huid waren de SC lipiden 
eigenschappen wel drastisch veranderd. Ook kon een derde generatie huidmodel niet altijd 
gegenereerd worden. Dit bleek af te hangen van de donor-eigenschappen en van de kwaliteit 
van het primaire biopt.
Naast het gebruik van gezonde biopten, was één van de onderzoeksvragen of zulke 
huidmodellen ook gemaakt konden worden met biopten van niet-aangedane huid van AE 
patiënten en of filaggrine mutaties invloed hebben op de epidermale ontwikkeling. Deze 
huidmodellen staan beschreven in hoofdstuk 5. De huidmodellen die gereconstrueerd zijn 
met biopten van patiënten met en zonder filaggrine mutaties hadden een morfologie die 
vergelijkbaar was met die van de natieve huid. De biopten die filaggrine mutaties hadden 
vertoonden bijna geen filaggrine expressie, net zoals de originele biopten. De aanwezigheid 
van deze mutaties had geen invloed op de expressie van de meeste differentiatie gerelateerde 
eiwitten, maar zorgde wel voor een verlaagde loricrine expressie in zowel het originele biopt 
als in de huidmodellen gemaakt met deze biopten. Uit deze studie blijkt dat deze aanpak 
resulteert in huidmodellen die een vergelijkbaar eiwit profiel vertonen als hun originele biopt, 
ongeacht de aanwezigheid van filaggrine mutaties. Daarnaast bleek dat de verlaagde filaggrine 




eiwitten. Deze aanpak lijkt daardoor een uitstekend alternatief voor het maken van een 
huidmodel met eigenschappen van niet aangedane AE huid. Daarnaast zou dit een goed 
model kunnen zijn voor het testen van nieuwe therapieën die erop gericht zijn om filaggrine 
expressie te herstellen.
Verminderde filaggrine expressie als risico factor voor kolonisatie met Staphylococcus 
aureus
Zoals eerder beschreven kunnen externe factoren een belangrijk aandeel hebben in de 
ontwikkeling van AE. Met name de bacterie Staphylococcus aureus heeft een belangrijke rol in 
het ontstaan en in de instandhouding van deze huidaandoening. Bijna alle patiënten vertonen 
een verhoogde en een voortdurende kolonisatie van deze bacterie. Naast dat deze bacterie 
verschillende toxines produceert die de aandoening verergeren, vormt deze ook zogenaamde 
biofilms, een beschermende slijmachtige laag wat de behandeling van deze bacteriën lastig 
maakt17;27-29. 
Het is al bekend dat de afbraakproducten van filaggrine de groei van S. aureus kan remmen30. 
Om te onderzoeken of filaggrine een rol speelt in de bacteriële kolonisatie, is een epidermaal 
huidmodel ontwikkeld. Dit huidmodel was wederom gemaakt met behulp van filaggrine 
knockdown, of in de aanwezigheid van een ontsteking gerelateerd eiwit (cytokine, interleukine 
31 (IL-31). IL-31 is een belangrijke cytokine voor AE en het is bekent dat IL-31 de filaggrine 
expressie in de huid kan beïnvloeden31. Zoals beschreven in hoofdstuk 6, resulteert filaggrine 
knockdown en de aanwezigheid van IL-31 tot een verlaagde filaggrine expressie in het 
epidermale huidmodel. Beide benaderingen leidden tot een verhoogde bacteriële kolonisatie, 
wat er op duidt dat filaggrine een rol speelt in de bescherming tegen S. aureus. Daarnaast bleek 
uit deze studie dat de immuunreactie van het huidmodel, de productie van cytokine IL-8 en 
de expressie van antimicrobiële peptiden, niet werd beïnvloed door filaggrine knockdown. 
Echter door de aanwezigheid van IL-31 werd de immuunreactie verstoord. Zo werd de IL-8 
productie verhoogd en de expressie van antimicrobiële peptiden verhinderd. Daarnaast bleek 
uit deze studie dat zowel de bacterie als IL-31 de expressie van enzymen die betrokken zijn bij 
het vormen van de lipiden in het SC beïnvloedt.
Het gebruik van cytokines om de aangedane huid van atopisch eczeem na te bootsten
Naast de aanwezigheid van filaggrine mutaties is ook een verstoorde immuunreactie een 
kenmerk voor AE. Deze wordt gekenmerkt door de aanwezigheid van diverse cytokines in 
de huid. Door het toevoegen van cytokines aan het kweekmedium van de huidmodellen 
is getracht de  immuun reactie in vitro na te bootsen. In hoofdstuk 7 wordt een methode 
beschreven waarin met het toevoegen van een combinatie van cytokines de ontstekingsreactie 
in het huidmodel wordt nagebootst. 
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Dit resulteerde in verschillende veranderingen in de epidermis; een toegenomen epidermale 
dikte, een verstoorde differentiatie en een verandering in expressie van enzymen die betrokken 
zijn bij het desquamatie proces en bij lipidensynthese. Daarnaast leidde het toevoegen van 
deze combinatie ook tot een verandering in de organisatie van de lipiden in het SC. Veel van 
deze veranderingen waren ook aanwezig in de aangedane huid van patiënten. Deze methode 
lijkt dus te resulteren in epidermale kenmerken van de aangedane huid van AE patiënten.
Samenvattend
Het nabootsten van een multifactoriële huidaandoening in een huidmodel blijft een 
uitdaging. De huidmodellen die beschreven zijn in dit proefschrift bootsen allen een aantal 
AE kenmerken na, zoals bijvoorbeeld een verminderde filaggrine expressie en verhoogde 
bacteriële kolonisatie. Deze AE huidmodellen zijn nu beschikbaar voor verder onderzoek 
naar AE. Echter, omdat dit een eerste aanzet was tot het maken van zulke AE huidmodellen, 




Discussie en verdere ontwikkeling van huidmodellen voor atopisch 
eczeem 
Onderzoek naar de rol van filaggrine in atopisch eczeem 
Het gebruik van huidmodellen maakt het mogelijk om de rol van filaggrine mutaties in de 
ontwikkeling van AE te onderzoeken. Uit het onderzoek dat beschreven is in dit proefschrift 
blijkt dat filaggrine knockdown (hoofdstuk 3) of de aanwezigheid van filaggrine mutaties 
(hoofdstuk 5) geen effect heeft op verschillende epidermale kenmerken. De epidermale 
structuur en de expressie van een aantal eiwitten in de epidermis waren niet aangetast. 
Daarnaast had filaggrine knockdown geen effect op de barrière eigenschappen, een observatie 
die ook was gedaan in een studie met AE patiënten32. Echter, gekweekte huidmodellen vertonen 
een aantal verschillen in SC eigenschappen in vergelijking met normale huid. Daarom is de 
optimalisatie van deze eigenschappen waarschijnlijk noodzakelijk om de rol van filaggrine in 
de huidbarrière nauwkeuriger te kunnen bestuderen.
Het gevolg van een verminderde filaggrine expressie is verminderde filaggrine 
afbraakproducten. Deze afbraakproducten beïnvloeden bacteriële kolonisatie (hoofdstuk 6) 
en beschermen tegen UV straling33. Daaruit blijkt dat niet zozeer het filaggrine eiwit zelf, 
maar met name de filaggrine afbraakproducten een belangrijke rol spelen in de huidbarrière. 
Daarom zijn filaggrine deficiënte huidmodellen waarschijnlijk meer bruikbaar voor het 
onderzoek naar de afbraakproducten in plaats van naar de rol van het filaggrine eiwit in 
de barrière. Echter moet rekening gehouden worden met het feit dat de hoeveelheid van 
filaggrine afbraakproducten wordt beïnvloed door de omgevingsluchtvochtigheid en dat deze 
anders is voor huidmodellen34. 
De ontdekking dat een verminderde filaggrine expressie leidt tot een verhoogde bacteriële 
kolonisatie, beantwoordt waarschijnlijk de vraag waarom filaggrine mutaties zo belangrijk zijn 
voor de ontwikkeling van AE. De aanwezigheid van jeuk wordt gedeeltelijk veroorzaakt door 
toxines van de toegenomen hoeveelheid bacteriën en leidt tot krabben wat een fysieke barrière 
breuk veroorzaakt. De grote hoeveelheid bacterie veroorzaakt in zo’n situatie sneller een 
infectie wat het begin zou kunnen zijn van de vicieuze cirkel van barrière breuk – ontsteking – 
het verergeren van de barrièrefunctie zoals die vaak gezien wordt bij AE patiënten. Daarnaast 
kunnen de verschillende cytokines die vrijkomen bij de ontsteking die veroorzaakt wordt 
door een infectie de barrièrefunctie op verschillende niveaus verslechteren, waaronder het 
veranderen van de lipidensamenstelling in het SC13;35;36.
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Het nabootsen van de ontstekingsverschijnselen in vitro
Op dit moment is het toevoegen van ontstekingsfactoren (cytokines) aan het kweekmedium 
de meest succesvolle benadering om kenmerken van de aangedane huid van AE in het 
huidmodel na te bootsen. Op deze manier zou ook de rol van nieuw ontdekte cytokines in 
AE onderzocht kunnen worden. Zoals bijvoorbeeld IL-17 en IL-22, waarvan op basis van gen 
expressie is gebleken dat ze mogelijk betrokken zijn bij het herstel van de huid in AE37. Ook 
al is deze aanpak succesvol voor functioneel onderzoek, er zitten ook een aantal nadelen aan. 
Met name voor het testen van nieuwe ontstekingsremmers is deze aanpak niet zo geschikt. 
De concentratie van cytokines wordt min of meer willekeurig gekozen, omdat deze in de 
aangedane huid niet meetbaar is. Daarnaast is deze ook afhankelijke van veel factoren, onder 
andere door de ernst van de aandoening en de behandeling die de patiënt heeft gekregen. 
Daardoor zijn de resultaten die op deze manier worden verkregen moeilijk te vertalen naar 
de patiënten. 
Als alternatief zouden immuun cellen in het huidmodel geïntroduceerd kunnen worden. Er 
zijn een groot aantal verschillende immuuncellen, maar in aangedane huid van AE zijn met 
name de T-cellen, eosinofielen, dendritische cellen en de mest cellen aanwezig. 
T-cellen zijn gespecialiseerde immuuncellen die relatief makkelijk te verkrijgen zijn van 
gezonde mensen of van patiënten . Deze cellen kunnen in het lab worden opgekweekt en zo 
nodig (genetisch) worden gemodificeerd. Eerdere pogingen om T-cellen in huidmodellen te 
introduceren om AE na te bootsen waren tot nu toe niet succesvol38. Een verbetering van deze 
aanpak zou zijn het gebruiken van T-cellen die zijn verkregen uit AE patiënten. 
Eosinofielen zijn immuuncellen die een grote hoeveelheid ontstekingsfactoren produceren. 
Normaal gesproken zijn deze cellen niet aanwezig in de huid maar wel in aangedane huid 
van AE.39 Over de bijdrage van deze cellen in AE is niet veel bekend, maar ze zijn hoogst 
waarschijnlijk betrokken bij de overgang van een acute naar een chronische huidaandoening39. 
Introductie van deze cellen in het huidmodel zou meer inzicht geven over de interactie 
tussen deze immuuncellen, de fibroblasten en de keratinocyten. Dit zou misschien nieuwe 
aanknopingspunten kunnen opleveren voor nieuwe therapieën. 
Mestcellen zijn met name aanwezig in chronische laesies en zijn verantwoordelijk voor het 
vrijlaten van histamine39. Eerder is aangetoond dat het huidmodel gebruikt kan worden voor 
onderzoek naar de effecten van histamine op de epidermis40. Het introduceren van (actieve) 
mestcellen in het huidmodel zou daarom zeer bruikbaar zijn voor het screenen van anti-
histamine therapieën. 
Dendritische cellen zijn belangrijke cellen in het signaleren van lichaamsvreemde eiwitten 




dendritische cel een lichaamsvreemd eiwit tegenkomt, migreert het naar de dichtstbijzijnde 
lymfknoop om daar het immuunsysteem te activeren. In een eerdere studie is dit celtype al met 
succes in het huidmodel geïntroduceerd41. Door deze cellen in het huidmodel te introduceren 
zouden (nieuwe) initiërende factoren onderzocht kunnen worden, maar ook hun bijdrage in 
bijvoorbeeld kolonisatie met S. aureus en in reactie op deze bacterie.
Het bestuderen van de bacteriële omgeving in atopisch eczeem 
De verhoogde aanwezigheid van S. aureus op filaggrine knockdown huidmodellen biedt 
nieuwe mogelijkheden voor het bestuderen van de rol van deze bacterie in AE. Daarnaast 
kan de rol van filaggrine in de kolonisatie van andere bacteriën bestudeerd worden met dit 
huidmodel. Eventueel  kan met behulp van een dergelijk huidmodel de rol van filaggrine 
in de veranderingen in het zogenaamde huid microbiome, het geheel aan goede en slechte 
bacteriën op de huid, zoals die gevonden zijn in AE onderzocht worden42.
De biofilm die S. aureus vormt zorgt ervoor dat deze bacterie lastig te behandelen is28. Een 
“goede” bacterie die op de huid aanwezig is, Staphyloccoccus Epidermidis, produceert een 
enzym Esp dat de biofilm kan afbreken43. Een filaggrine deficiënt epidermaal huidmodel zoals 
beschreven is in hoofdstuk 6 zou kunnen bijdragen aan het onderzoek naar de efficiëntie 
van dit enzym in de bestrijding van S aureus in AE. Op dit moment wordt dit huidmodel al 
gebruikt voor het testen van een antimicrobieel eiwit in de behandeling van S. aureus in AE. 
Naast het testen van nieuwe antibacteriële behandelingen voor AE, bleek S. aureus in staat om 
de expressie van enzymen die betrokken zijn bij de lipide synthese te veranderen. Daarom lijkt 
het erop dat S. aureus bijdraagt aan de verslechterde barrièrefunctie in AE. Vervolg studies 
die het effect van S. aureus op de lipiden samenstelling in het SC van (filaggine deficiënte) 
huidmodellen moeten uitwijzen wat de daadwerkelijke effecten van S. aureus op deze barrière 
eigenschappen zijn. 
De rol van fibroblasten in atopisch eczeem 
Veel van het huidige onderzoek voor AE richt zich op de keratinocyten, de epidermis en 
het SC. Weinig onderzoek richt zich op de rol van de fibroblasten. Deze cellen zouden een 
belangrijke rol kunnen spelen in AE. In andere huidaandoeningen is al aangetoond dat 
fibroblasten een belangrijke  rol spelen. In de blaarziekte Recessieve Epidermolysis Bullosa 
Simplex (REBS) zijn de fibroblasten betrokken bij het reproduceren van karakteristieken van 
deze huidaandoening in een huidmodel44. Ook in plaveiselcel carcinoom spelen de fibroblasten 
een belangrijke rol bij de ontwikkeling van deze vorm van huidkanker45. Fibroblasten zijn 
ook belangrijk voor het regelen van de reactie van keratinocyten op bijvoorbeeld S. aureus, 
doordat zij noodzakelijk zijn voor de productie van bepaalde ontstekingsfactoren. Daarnaast 
zijn fibroblasten waarschijnlijk betrokken bij veranderingen in het SC zoals gesuggereerd 
wordt in het onderzoek van hoofdstuk 7. In een eerste studie blijkt dat fibroblasten van 
AE patiënten de epidermale huidstructuur van huidmodellen kunnen beïnvloeden.46 Het 
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is daarom interessant om fibroblasten van AE patiënten in het huidmodel te introduceren 
om zo de interactie tussen fibroblasten en keratinocyten te onderzoeken. Daarnaast kan zo 
de invloed van deze fibroblasten op het SC onderzocht worden. Tevens kan met behulp van 
een huidmodel onderzocht kunnen worden hoe fibroblasten van AE patiënten reageren op 
ontstekingsfactoren in een driedimensionele omgeving en of AE fibroblasten anders reageren 
op zulke factoren dan fibroblasten van gezonde individuen.
Concluderend
In dit proefschrift is onderzoek gepresenteerd dat een aantal nieuwe huidmodellen voor AE 
beschrijft. Deze huidmodellen hebben verschillende kenmerken van AE en zijn gebruikt om 
verschillende aspecten van deze huidaandoening te onderzoeken. Uit dit onderzoek blijkt 
dat filaggrine een meer indirecte rol heeft in deze aandoening, door de betrokkenheid van de 
afbraakproducten bij bacteriële kolonisatie. Echter de exacte rol van filaggrine in AE blijft nog 
steeds een interessant onderwerp voor vervolg studies. 
Zoals bij de meeste onderzoeksmodellen, hebben ook huidmodellen een aantal beperkingen. 
Onder andere het gebrek aan systemische aspecten zoals vascularisatie (bloedvaten) en 
de aanwezigheid van zenuwen voor onderzoek naar jeuk. Daarom is, althans voorlopig, 
onderzoek dat zich richt op deze aspecten, zoals bijvoorbeeld het testen van anti-jeuk 
therapieën, nog steeds afhankelijk van muismodellen.
De huidmodellen die in dit proefschrift zijn beschreven hebben hun toepasbaarheid 
aangetoond, maar behoren tot een eerste generatie van huidmodellen voor AE. Na 
verbeteringen, zoals bijvoorbeeld voorgesteld in het laatste gedeelte van dit proefschrift, 
kunnen zulke huidmodellen bijdragen aan de ontwikkeling en het testen van nieuwe 
behandelingen voor AE. Dit onderzoek is gedaan in de hoop dat deze huidmodellen voor AE 
(gedeeltelijk) kunnen bijdragen aan de ontwikkeling van nieuwe behandelingen en daarmee 
bijdragen aan een verlichting van de zware last die deze huidaandoening met zich meebrengt 
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